<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type="text/xsl" href="/global/feed/rss.xslt" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:googleplay="http://www.google.com/schemas/play-podcasts/1.0" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:media="http://search.yahoo.com/mrss/" xmlns:podaccess="https://access.acast.com/schema/1.0/" xmlns:acast="https://schema.acast.com/1.0/">
    <channel>
		<ttl>60</ttl>
		<generator>acast.com</generator>
		<title>NPP BrainPod</title>
		<link>http://www.nature.com/npp/podcast/index.html</link>
		<atom:link href="https://feeds.acast.com/public/shows/1b454f3a-002e-540e-82a0-3e5bcb0b5da9" rel="self" type="application/rss+xml"/>
		<language>en</language>
		<copyright>American College of Neuropsychopharmacology</copyright>
		<itunes:keywords/>
		<itunes:author>Springer Nature</itunes:author>
		<itunes:subtitle>Neuropsychopharmacology Podcast</itunes:subtitle>
		<itunes:summary><![CDATA[BrainPod is the podcast from the journal Neuropsychopharmacology, produced in association with Nature Publishing Group. Join us as we delve into the latest basic and clinical research that advance our understanding of the brain and behavior, featuring highlighted content from a top journal in fields of neuroscience, psychiatry, and pharmacology. For complete access to the original papers and reviews featured in this podcast, subscribe to Neuropsychopharmacology.<hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		<description><![CDATA[BrainPod is the podcast from the journal Neuropsychopharmacology, produced in association with Nature Publishing Group. Join us as we delve into the latest basic and clinical research that advance our understanding of the brain and behavior, featuring highlighted content from a top journal in fields of neuroscience, psychiatry, and pharmacology. For complete access to the original papers and reviews featured in this podcast, subscribe to Neuropsychopharmacology.<hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
		<itunes:explicit>false</itunes:explicit>
		<itunes:owner>
			<itunes:name>Marina Ostankovitch</itunes:name>
			<itunes:email>info+1b454f3a-002e-540e-82a0-3e5bcb0b5da9@mg-eu.acast.com</itunes:email>
		</itunes:owner>
		<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
		<acast:showUrl>neuropsychopharmacologypodcast</acast:showUrl>
		<acast:signature key="EXAMPLE" algorithm="aes-256-cbc"><![CDATA[wbG1Z7+6h9QOi+CR1Dv0uQ==]]></acast:signature>
		<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmU13c0otUap75NIyVufnZVBoBcFwz3Y0zGA/pFjpP70+3oZt3+5O3uX8mfQZWzV35Kby8OfdHfDJlQAYxij1gc0J63rxgoMm4loq58gBzd9i]]></acast:settings>
        <acast:network id="aa57431d-fb50-013d-6504-05d371df58a9" slug="macmillan-publishers-ltd-receivables-springer-nature-ltd"><![CDATA[Macmillan Publishers Ltd Receivables/Springer Nature Ltd]]></acast:network>
		<acast:importedFeed>https://rss.acast.com/neuropsychopharmacologypodcast</acast:importedFeed>
		<itunes:type>episodic</itunes:type>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<image>
				<url>https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg</url>
				<link>http://www.nature.com/npp/podcast/index.html</link>
				<title>NPP BrainPod</title>
			</image>
			<itunes:new-feed-url>https://feeds.acast.com/public/shows/1b454f3a-002e-540e-82a0-3e5bcb0b5da9</itunes:new-feed-url>
		<item>
			<title>Oxytocin neurons in the anterior and posterior paraventricular nucleus have distinct behavioral functions and electrophysiological profiles</title>
			<itunes:title>Oxytocin neurons in the anterior and posterior paraventricular nucleus have distinct behavioral functions and electrophysiological profiles</itunes:title>
			<pubDate>Mon, 23 Feb 2026 21:04:06 GMT</pubDate>
			<itunes:duration>9:44</itunes:duration>
			<enclosure url="https://sphinx.acast.com/p/acast/s/neuropsychopharmacologypodcast/e/699cc0c6e58ea9113841a9eb/media.mp3" length="9423352" type="audio/mpeg"/>
			<guid isPermaLink="false">699cc0c6e58ea9113841a9eb</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://shows.acast.com/neuropsychopharmacologypodcast/episodes/oxytocin-neurons-in-the-anterior-and-posterior-paraventricul</link>
			<acast:episodeId>699cc0c6e58ea9113841a9eb</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>oxytocin-neurons-in-the-anterior-and-posterior-paraventricul</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCc620DlX1lkW5m5qDNj/Oy1kVuioy+OOmYp5PexZk4ZltXx1xidKroIDVgnzq4yOGZlGWZpML+7PrRi20xiwCbdUKZnPvvhgXTJytOGB9vHAI5ROILD1iH+IR/5KbQSrp5IuULJTTGDHwMW3INCNmZ2qxZYA1A7ggKJNbZtIspIDpL176N6ulBcj5/U7h3dJE0a5QnihgY1ECfQ+MJrcQ/4]]></acast:settings>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[<p>Oxytocin has become known for having anti-anxiety and affiliative behavioral effects. That’s why clinicians and researchers are excited about using oxytocin as a potential therapeutic.&nbsp;</p><br><p>Brian Trainor is a professor at UC Davis, and his lab has been studying this complexity for the past decade. For an animal model, they work with a territorial, aggressive, monogamous rodent species called California mice. If the male is removed and the female is forced to defend their nest, she will experience what’s known as social defeat, and she will exhibit what’s called inhibited affiliative behavior, the type that can be affected by oxytocin — and this effect can be studied in a mouse’s brain.</p><br><p>Read the full study here: https://www.nature.com/articles/s41386-026-02352-y</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[<p>Oxytocin has become known for having anti-anxiety and affiliative behavioral effects. That’s why clinicians and researchers are excited about using oxytocin as a potential therapeutic.&nbsp;</p><br><p>Brian Trainor is a professor at UC Davis, and his lab has been studying this complexity for the past decade. For an animal model, they work with a territorial, aggressive, monogamous rodent species called California mice. If the male is removed and the female is forced to defend their nest, she will experience what’s known as social defeat, and she will exhibit what’s called inhibited affiliative behavior, the type that can be affected by oxytocin — and this effect can be studied in a mouse’s brain.</p><br><p>Read the full study here: https://www.nature.com/articles/s41386-026-02352-y</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>The genetics of cannabis lifetime use</title>
			<itunes:title>The genetics of cannabis lifetime use</itunes:title>
			<pubDate>Wed, 07 Jan 2026 20:02:10 GMT</pubDate>
			<itunes:duration>9:53</itunes:duration>
			<enclosure url="https://sphinx.acast.com/p/acast/s/neuropsychopharmacologypodcast/e/695ebbc2313b808065d746a3/media.mp3" length="9566294" type="audio/mpeg"/>
			<guid isPermaLink="false">695ebbc2313b808065d746a3</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://shows.acast.com/neuropsychopharmacologypodcast/episodes/the-genetics-of-cannabis-lifetime-use</link>
			<acast:episodeId>695ebbc2313b808065d746a3</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>the-genetics-of-cannabis-lifetime-use</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCeFyUK9odL8h1tYguWmfLK32Pd2ddF1PPlH5GjxJW/WNGy1WYaamcDhCfroT6EZNzVAHaFNWn4tCsMZ3l4dtT455fo6PlkzjYZLecC41UI9IgJxxCyGwJ+dTfZV5gRIAtW0zmX5tWyOlVj158t1U9H6MXszDAdZRzTn+xDELqc3n68T0ExFMLfu8JrZxhaVSqapqOkP81DgD5bhjl7W3b78]]></acast:settings>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[<p>Cannabis, which is increasingly legally available, both for therapeutic and recreational use, is now one of the most commonly used drugs worldwide.&nbsp;Of people who have ever used cannabis, studies vary, but they estimate that about 10-25 percent of people who use cannabis go on to develop cannabis use disorder.</p><br><p>Uri Bright is a postdoctoral associate at the Yale School of Medicine and is one of the authors of a recent study in the journal Neuropsychopharmacology on the genetics of cannabis lifetime use — which is anyone who has ever used cannabis even once. That’s a distinct population from people who have cannabis use disorder, as his colleagues had looked into in the previous study.</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[<p>Cannabis, which is increasingly legally available, both for therapeutic and recreational use, is now one of the most commonly used drugs worldwide.&nbsp;Of people who have ever used cannabis, studies vary, but they estimate that about 10-25 percent of people who use cannabis go on to develop cannabis use disorder.</p><br><p>Uri Bright is a postdoctoral associate at the Yale School of Medicine and is one of the authors of a recent study in the journal Neuropsychopharmacology on the genetics of cannabis lifetime use — which is anyone who has ever used cannabis even once. That’s a distinct population from people who have cannabis use disorder, as his colleagues had looked into in the previous study.</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Older and wiser? The neural correlates of worry induction and reappraisal in older adults</title>
			<itunes:title>Older and wiser? The neural correlates of worry induction and reappraisal in older adults</itunes:title>
			<pubDate>Mon, 27 Oct 2025 17:16:14 GMT</pubDate>
			<itunes:duration>9:30</itunes:duration>
			<enclosure url="https://sphinx.acast.com/p/acast/s/neuropsychopharmacologypodcast/e/68ffa8de4bfd27f82db16beb/media.mp3" length="9188041" type="audio/mpeg"/>
			<guid isPermaLink="false">68ffa8de4bfd27f82db16beb</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://shows.acast.com/neuropsychopharmacologypodcast/episodes/older-and-wiser-the-neural-correlates-of-worry-induction-and</link>
			<acast:episodeId>68ffa8de4bfd27f82db16beb</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>older-and-wiser-the-neural-correlates-of-worry-induction-and</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCfyzwENSAhSQIqeTiLYdcRWfcnpG7EPgpu/FcdMMyVcFtqPtO6nLpDnlovOUE3BqodJK//W7hVG5NDFQLNbMXU3Q6kUGUi9i/TpB73S0BGu1rx9uyRZBvHegTEuewfWwJ/FoziHqLWhFEuGMDnHLl08PXLrK+own+KYQ8snzvad7Gw5fvdeoOI2jY0xzrsL8w8Bnb/CH8Wb2pVq/Mz4MzEA]]></acast:settings>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[<p>Worry seems like something most people do from time to time, but for some people, severe worry can become an overwhelming sensation, and for older adults later in life, severe worry has been associated with an increased risk of stroke and coronary heart disease. Carmen Andreescu is a professor of psychiatry and bioengineering at the University of Pittsburgh School of Medicine. She says mild worry is useful evolutionarily, to help us make plans or adapt behavior.</p><br><p>Read the full study here: https://www.nature.com/articles/s41386-025-02193-1</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[<p>Worry seems like something most people do from time to time, but for some people, severe worry can become an overwhelming sensation, and for older adults later in life, severe worry has been associated with an increased risk of stroke and coronary heart disease. Carmen Andreescu is a professor of psychiatry and bioengineering at the University of Pittsburgh School of Medicine. She says mild worry is useful evolutionarily, to help us make plans or adapt behavior.</p><br><p>Read the full study here: https://www.nature.com/articles/s41386-025-02193-1</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title><![CDATA[Grey matter morphometry in young adult e-cigarette users, tobacco cigarette users & non-using controls]]></title>
			<itunes:title><![CDATA[Grey matter morphometry in young adult e-cigarette users, tobacco cigarette users & non-using controls]]></itunes:title>
			<pubDate>Tue, 29 Jul 2025 13:49:01 GMT</pubDate>
			<itunes:duration>8:45</itunes:duration>
			<enclosure url="https://sphinx.acast.com/p/acast/s/neuropsychopharmacologypodcast/e/6888d14d7a996a7baaa27b9f/media.mp3" length="8468733" type="audio/mpeg"/>
			<guid isPermaLink="false">6888d14d7a996a7baaa27b9f</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://shows.acast.com/neuropsychopharmacologypodcast/episodes/grey-matter-morphometry-in-young-adult-e-cigarette-users-tob</link>
			<acast:episodeId>6888d14d7a996a7baaa27b9f</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>grey-matter-morphometry-in-young-adult-e-cigarette-users-tob</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCe9HT2OVugTDyY8k23k5lNN4uNXXi7cF6HzYAQq3EvskNTz/tnqS9ppWHdx6oM5dAZD8XyCknVaLP6/GaeDAn8Z4Pb2hiufzZ8df5C0/yXyaHA37JpJytqHENmplTGYBknMzwcKidpmoL3aw3YdLqTPT31Sd74dG8ktc8ElgAOtdF/b5XiN5505KS95BgWFWdBSlRjyyFWRpXNTUJjW7CB2]]></acast:settings>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[<p>There’s been a fair amount of animal data suggesting that nicotine can affect the developing brain, but there hadn’t been the equivalent human studies done on people whose brains are still developing. And today there are two predominant forms of nicotine delivery - tobacco cigarettes, and e-cigarettes, or vaping.</p><br><p>Laurie Zawertailo is a senior scientist at the Center for Addiction and Mental Health in Toronto and an associate professor in the department of pharmacology and toxicology at the University of Toronto. Kanwar Boparai recently completed her PhD, working with Dr. Zawertailo, and is now a postdoc. For their new study, they and some colleagues recruited young adults age 18-25, and these people fell into three groups: one that had only smoked cigarettes, one that had only ever vaped, and a third that functioned as a control, that had never used either. They ended up with 26 smokers, 27 vapers, and 25 controls. This is the first human study to separate cigarette smokers and vapers into distinct groups.</p><br><p>Read the full study here: https://www.nature.com/articles/s41386-025-02086-3</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[<p>There’s been a fair amount of animal data suggesting that nicotine can affect the developing brain, but there hadn’t been the equivalent human studies done on people whose brains are still developing. And today there are two predominant forms of nicotine delivery - tobacco cigarettes, and e-cigarettes, or vaping.</p><br><p>Laurie Zawertailo is a senior scientist at the Center for Addiction and Mental Health in Toronto and an associate professor in the department of pharmacology and toxicology at the University of Toronto. Kanwar Boparai recently completed her PhD, working with Dr. Zawertailo, and is now a postdoc. For their new study, they and some colleagues recruited young adults age 18-25, and these people fell into three groups: one that had only smoked cigarettes, one that had only ever vaped, and a third that functioned as a control, that had never used either. They ended up with 26 smokers, 27 vapers, and 25 controls. This is the first human study to separate cigarette smokers and vapers into distinct groups.</p><br><p>Read the full study here: https://www.nature.com/articles/s41386-025-02086-3</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Validation of L-type calcium channel blocker amlodipine as a novel ADHD treatment through cross-species analysis, drug-target Mendelian randomization, and clinical evidence from medical records</title>
			<itunes:title>Validation of L-type calcium channel blocker amlodipine as a novel ADHD treatment through cross-species analysis, drug-target Mendelian randomization, and clinical evidence from medical records</itunes:title>
			<pubDate>Wed, 04 Jun 2025 13:58:33 GMT</pubDate>
			<itunes:duration>9:41</itunes:duration>
			<enclosure url="https://sphinx.acast.com/p/acast/s/neuropsychopharmacologypodcast/e/68405109c8835d385c206d3a/media.mp3" length="9369435" type="audio/mpeg"/>
			<guid isPermaLink="false">68405109c8835d385c206d3a</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://shows.acast.com/neuropsychopharmacologypodcast/episodes/validation-of-l-type-calcium-channel-blocker-amlodipine-as-a</link>
			<acast:episodeId>68405109c8835d385c206d3a</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>validation-of-l-type-calcium-channel-blocker-amlodipine-as-a</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCfyBaRSDB8Nzj4WxY0ZnUINcGu9nKRTdT+2s7c+4UGAINrPBdx8maLcWRx7dIfdcXBHamca+xmFLy60nNPvOcNXZeKnjsZYlRxoph2mJT8S+C0K3HVi0ReE4veOfH/3f7FGDsCRoC0dpgnebe6SHK1riRH457OH/hQyzWMtVhST3jPp674UWktHLmCK6aZV4HFD4KNR8v/z1A2XPKQ2JCJZ]]></acast:settings>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[<p>Attention deficit hyperactivity disorder, or ADHD, is a common condition that, for a lot of people, is difficult to treat. The drugs that exist have a number of adverse side effects, and about 25 percent of patients don’t respond to existing drugs. And so a team of researchers in Iceland, led by Karl Karlsson, professor of biomolecular engineering at Reykjavik University, undertook a number of different steps to narrow in on and then test what the team has determined to be a novel treatment for ADHD, using an existing drug, amlodipine.&nbsp;</p><br><p>Read the full study here: https://www.nature.com/articles/s41386-025-02062-x</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[<p>Attention deficit hyperactivity disorder, or ADHD, is a common condition that, for a lot of people, is difficult to treat. The drugs that exist have a number of adverse side effects, and about 25 percent of patients don’t respond to existing drugs. And so a team of researchers in Iceland, led by Karl Karlsson, professor of biomolecular engineering at Reykjavik University, undertook a number of different steps to narrow in on and then test what the team has determined to be a novel treatment for ADHD, using an existing drug, amlodipine.&nbsp;</p><br><p>Read the full study here: https://www.nature.com/articles/s41386-025-02062-x</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Rapid and sustained antidepressant effects of vaporized N,N-Dimethyltryptamine: A Phase 2a clinical trial in Treatment-Resistant Depression.</title>
			<itunes:title>Rapid and sustained antidepressant effects of vaporized N,N-Dimethyltryptamine: A Phase 2a clinical trial in Treatment-Resistant Depression.</itunes:title>
			<pubDate>Fri, 18 Apr 2025 18:22:49 GMT</pubDate>
			<itunes:duration>9:52</itunes:duration>
			<enclosure url="https://sphinx.acast.com/p/acast/s/neuropsychopharmacologypodcast/e/680298796aefdc1cfc0e8bb4/media.mp3" length="9537873" type="audio/mpeg"/>
			<guid isPermaLink="false">680298796aefdc1cfc0e8bb4</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://shows.acast.com/neuropsychopharmacologypodcast/episodes/rapid-and-sustained-antidepressant-effects-of-vaporized-nn-d</link>
			<acast:episodeId>680298796aefdc1cfc0e8bb4</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>rapid-and-sustained-antidepressant-effects-of-vaporized-nn-d</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCdGrOslhJekxd3bFxijYK7V/zkL3GA9DlZCGwit24aafQha1WlBiKWgIdb/1mVO5bBjXKcvZHRQncZYdt7cqd4TEUSpTFd/kZKAEy/MzZFe7h94yyXy4Yg1JQAmHDtjTwe9o7lJNZHKaXo/Jeb7CUYs3s9ZqVgKauOEjVs+QkJIvYIGPd9JivPLRlSPg3ugNVTGf2GIb65YseZ4Z4O140D2]]></acast:settings>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[<p>Draulio Araujo, professor at the Brain Institute in the University of Rio Grande Norte in Natal, Brazil, has been studying ayahuasca for more than 20 years. It’s a psychedelic plant used in rituals in South America that has also been researched for its potential to treat depression. The effects of ayahuasca can last for hours and also lead to side effects including vomiting and diarrhea. The active psychedelic drug in ayahuasca is DMT, and so Dr. Araujo and his colleagues decided to conduct the first test of DMT itself, which is also an endogenous chemical and has been demonstrated to be safe.</p><br><p>Read the full article here: https://www.nature.com/articles/s41386-025-02091-6</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[<p>Draulio Araujo, professor at the Brain Institute in the University of Rio Grande Norte in Natal, Brazil, has been studying ayahuasca for more than 20 years. It’s a psychedelic plant used in rituals in South America that has also been researched for its potential to treat depression. The effects of ayahuasca can last for hours and also lead to side effects including vomiting and diarrhea. The active psychedelic drug in ayahuasca is DMT, and so Dr. Araujo and his colleagues decided to conduct the first test of DMT itself, which is also an endogenous chemical and has been demonstrated to be safe.</p><br><p>Read the full article here: https://www.nature.com/articles/s41386-025-02091-6</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Endocannabinoid contributions to the perception of socially relevant, affective touch in humans</title>
			<itunes:title>Endocannabinoid contributions to the perception of socially relevant, affective touch in humans</itunes:title>
			<pubDate>Tue, 04 Mar 2025 15:37:15 GMT</pubDate>
			<itunes:duration>9:13</itunes:duration>
			<enclosure url="https://sphinx.acast.com/p/acast/s/neuropsychopharmacologypodcast/e/67c71e2bece4993ac7ce6e1f/media.mp3" length="8922637" type="audio/mpeg"/>
			<guid isPermaLink="false">67c71e2bece4993ac7ce6e1f</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://shows.acast.com/neuropsychopharmacologypodcast/episodes/endocannabinoid-contributions-to-the-perception-of-socially-</link>
			<acast:episodeId>67c71e2bece4993ac7ce6e1f</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>endocannabinoid-contributions-to-the-perception-of-socially-</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCf6a092uh8bZfu4qemIv1OuhQuf7DGMNwe6MtFDzQVvrVi/oyCwBtxZr2tdb0OJDb1g9kdf54aRkcl+a+GGHyhqwAvbIHsbtEURDpdmDbdBCklB61/7FFI+5ksrUz/6MMlPIOj0cdN/mRspXAfJCWYyJUD0dZN3+UaGBwTqRvac64IcYyNxGQt5YrRTN2OxumZ+c3pz9I//KdEK3p1oovGX]]></acast:settings>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[<p>New drugs that target the endocannabinoid system are being proposed for disorders that are usually characterized by the dysregulation of social processing, like social anxiety disorder and autism spectrum disorder. Researchers have been trying to understand the mechanisms for how these drugs work.&nbsp;</p><br><p>Leah Mayo is assistant professor at the University of Calgary, and she’s one of the authors of a new study in the journal Neuropsychopharmacology in which they examined two aspects of the system. One is the endocannabinoid system itself. And then there’s another aspect of social processing called the C tactile system.&nbsp;</p><br><p>Read the full study here: <a href="https://www.nature.com/articles/s41386-025-02053-y" rel="noopener noreferrer" target="_blank">Endocannabinoid contributions to the perception of socially relevant, affective touch in humans | Neuropsychopharmacology</a></p><br><p><br></p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[<p>New drugs that target the endocannabinoid system are being proposed for disorders that are usually characterized by the dysregulation of social processing, like social anxiety disorder and autism spectrum disorder. Researchers have been trying to understand the mechanisms for how these drugs work.&nbsp;</p><br><p>Leah Mayo is assistant professor at the University of Calgary, and she’s one of the authors of a new study in the journal Neuropsychopharmacology in which they examined two aspects of the system. One is the endocannabinoid system itself. And then there’s another aspect of social processing called the C tactile system.&nbsp;</p><br><p>Read the full study here: <a href="https://www.nature.com/articles/s41386-025-02053-y" rel="noopener noreferrer" target="_blank">Endocannabinoid contributions to the perception of socially relevant, affective touch in humans | Neuropsychopharmacology</a></p><br><p><br></p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Sex differences in sensitivity to dopamine receptor manipulations of risk-based decision making in rats</title>
			<itunes:title>Sex differences in sensitivity to dopamine receptor manipulations of risk-based decision making in rats</itunes:title>
			<pubDate>Wed, 15 Jan 2025 00:27:12 GMT</pubDate>
			<itunes:duration>9:46</itunes:duration>
			<enclosure url="https://sphinx.acast.com/p/acast/s/neuropsychopharmacologypodcast/e/67852f2278acadca63f3d8fd/media.mp3" length="9441742" type="audio/mpeg"/>
			<guid isPermaLink="false">67852f2278acadca63f3d8fd</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://shows.acast.com/neuropsychopharmacologypodcast/episodes/sex-differences-in-sensitivity-to-dopamine-receptor</link>
			<acast:episodeId>67852f2278acadca63f3d8fd</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>sex-differences-in-sensitivity-to-dopamine-receptor</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCdUto5LE/5Q0llSAwehpGAtcSKKQjdimiXkCfvrHBYFMVNeU2QJJbXjCt3CObN+xGngSqCN5EbrujNJWp+4S5+hP4OGYfFEz+ISusMtjcq2TazWgMWm0LhnYLwBodqskcECphNQBAG0PwzOYPeUku/EUdEXTnxIS3JaOwETz3ooiOflRuQBteEk3sv2MMutmu6WOpL0fF88f8fBMchEvKmX]]></acast:settings>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[<p>The scientific literature has shown that females demonstrate more aversion to risk-taking than males. Studies have also demonstrated that the basal lateral amygdala, or BLA, is a critical hub for processing risk and reward information. And yet further research has shown that activity in the amygdala differs between males and females, and that the expression of particular dopamine receptors called D2 receptors are greater in females than in males. The authors hypothesized that one mediating mechanism that leads to greater risk aversion in females is differential activity of dopamine in the basal lateral amygdala.&nbsp;</p><p>Caitlin Orsini is an assistant professor in the departments of psychology and neurology at UT Austin.&nbsp;</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[<p>The scientific literature has shown that females demonstrate more aversion to risk-taking than males. Studies have also demonstrated that the basal lateral amygdala, or BLA, is a critical hub for processing risk and reward information. And yet further research has shown that activity in the amygdala differs between males and females, and that the expression of particular dopamine receptors called D2 receptors are greater in females than in males. The authors hypothesized that one mediating mechanism that leads to greater risk aversion in females is differential activity of dopamine in the basal lateral amygdala.&nbsp;</p><p>Caitlin Orsini is an assistant professor in the departments of psychology and neurology at UT Austin.&nbsp;</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Biomarker development for menstrual Cycle affective change: the need for greater temporal, mechanistic, and phenotypic specificity.</title>
			<itunes:title>Biomarker development for menstrual Cycle affective change: the need for greater temporal, mechanistic, and phenotypic specificity.</itunes:title>
			<pubDate>Mon, 02 Dec 2024 23:05:00 GMT</pubDate>
			<itunes:duration>9:39</itunes:duration>
			<enclosure url="https://sphinx.acast.com/p/acast/s/neuropsychopharmacologypodcast/e/674e3cdb603b9bf59a0b6ca2/media.mp3" length="9345193" type="audio/mpeg"/>
			<guid isPermaLink="false">674e3cdb603b9bf59a0b6ca2</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://shows.acast.com/neuropsychopharmacologypodcast/episodes/biomarker-development-for-menstrual-cycle-affective-change-t</link>
			<acast:episodeId>674e3cdb603b9bf59a0b6ca2</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>biomarker-development-for-menstrual-cycle-affective-change-t</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCdVWck0mu0yF8tbMZQuofAchc9QkiGIV9h5kHJ0jowMpfW7V+gjNWL536OH7Zgah6H8L+HvN32rN99dR1XbKF/J0koqkK+K0AJPY6GHJLusD2aRivvOoa3yRV1rKm0DlLYn+j2DTsmCBvHaAuG6j1w1cj+4/RPDmajkS6jjvai98mTiJ0UnxbU9P+SBC1RXTx6UcaFLNltrFY76J8EOjaYY]]></acast:settings>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[<p>The menstrual cycle is known to affect things like mood and changes in pain. But there can also be symptoms that have a serious impact on a person’s function, ability to work, ability to maintain friendships and romantic relationships. This is a rare condition known as premenstrual dysphoric disorder. But it’s not the only psychiatric condition that can worsen with changes in the menstrual cycle. For instance, nearly 60 percent of menstruating patients with depression can experience cyclical worsening similar to PMDD. Conditions such as these are generally referred to as menstrual cycle affective change.&nbsp;Menstrual cycle affective change is more common in those with chronic psychiatric disorders. </p><p>&nbsp;</p><p>The authors are interested in reframing the conversation around menstrual cycle affective change to be something that is a more fundamental process that we can study across disorders, across categories, and identify biomarkers that might help us predict who's going to have those symptoms in more complex ways than we might be able to do with categories. This paper represents how can we take this dimensional way of thinking about menstrual cycle affective change and talk about the specific ways that we can be precise in looking at the time the time characteristics of that, the specific mechanisms, et cetera.</p><p>&nbsp;</p><p>Tory Eisenlohr-Moul is an associate professor of psychiatry at the University of Illinois at Chicago in the department of psychiatry, and she’s one of the authors. Jordan Barone is an MD/PhD candidate at the University of Illinois at Chicago, and she’s another author.&nbsp;</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[<p>The menstrual cycle is known to affect things like mood and changes in pain. But there can also be symptoms that have a serious impact on a person’s function, ability to work, ability to maintain friendships and romantic relationships. This is a rare condition known as premenstrual dysphoric disorder. But it’s not the only psychiatric condition that can worsen with changes in the menstrual cycle. For instance, nearly 60 percent of menstruating patients with depression can experience cyclical worsening similar to PMDD. Conditions such as these are generally referred to as menstrual cycle affective change.&nbsp;Menstrual cycle affective change is more common in those with chronic psychiatric disorders. </p><p>&nbsp;</p><p>The authors are interested in reframing the conversation around menstrual cycle affective change to be something that is a more fundamental process that we can study across disorders, across categories, and identify biomarkers that might help us predict who's going to have those symptoms in more complex ways than we might be able to do with categories. This paper represents how can we take this dimensional way of thinking about menstrual cycle affective change and talk about the specific ways that we can be precise in looking at the time the time characteristics of that, the specific mechanisms, et cetera.</p><p>&nbsp;</p><p>Tory Eisenlohr-Moul is an associate professor of psychiatry at the University of Illinois at Chicago in the department of psychiatry, and she’s one of the authors. Jordan Barone is an MD/PhD candidate at the University of Illinois at Chicago, and she’s another author.&nbsp;</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Genome-wide association studies of coffee intake in UK/US participants of European ancestry uncover cohort-specific genetic associations</title>
			<itunes:title>Genome-wide association studies of coffee intake in UK/US participants of European ancestry uncover cohort-specific genetic associations</itunes:title>
			<pubDate>Wed, 21 Aug 2024 15:18:42 GMT</pubDate>
			<itunes:duration>9:39</itunes:duration>
			<enclosure url="https://sphinx.acast.com/p/acast/s/neuropsychopharmacologypodcast/e/66c60552aba59aa5bb87fc4f/media.mp3" length="9343939" type="audio/mpeg"/>
			<guid isPermaLink="false">66c60552aba59aa5bb87fc4f</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://shows.acast.com/neuropsychopharmacologypodcast/episodes/genome-wide-association-studies-of-coffee-intake-in-ukus-par</link>
			<acast:episodeId>66c60552aba59aa5bb87fc4f</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>genome-wide-association-studies-of-coffee-intake-in-ukus-par</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCdxvjvLut3UeddqyQgN9ppddSzux8+EbAAAuJ+yR5bEr5k/7g2lfPUg6pwmuIfAMyfZFNtvKXawlJI9E4EcT75GvMBRipUZ4n8U4zUpkC2dAeqCk1eNLWB6Olegbjccz7Yd8dMo+KOsdB0kVMXWCX61Pwde3DKwRTx+fDBD5fLc+IXM1wbcs0cFX0xR9appeMvmBHQxeGLDGbFB8LFe38Jy]]></acast:settings>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[<p>Researchers are interested in understanding the biology of why some people are more likely to overconsume substances. Some substances are difficult to study—people might not admit to illegal substance abuse or to how much alcohol they drink. But Americans are more likely to accurately recall and share how much coffee they drink—which is related to how much caffeine they consume. And so a team of researchers paired up with the company 23 and Me to try to understand genetic differences among a large set of people, to try to tease out any genetic similarities that could be correlated with coffee consumption. Sandra Sanchez-Roige is an associate professor in the department of psychiatry at the University of California San Diego, and she’s one of the study’s authors.&nbsp;Abraham Palmer is a professor and vice chair of basic research in the department of psychiatry at UC San Diego, and he’s another of the study’s authors.&nbsp;</p><br><p>Read their full study here: https://www.nature.com/articles/s41386-024-01870-x</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[<p>Researchers are interested in understanding the biology of why some people are more likely to overconsume substances. Some substances are difficult to study—people might not admit to illegal substance abuse or to how much alcohol they drink. But Americans are more likely to accurately recall and share how much coffee they drink—which is related to how much caffeine they consume. And so a team of researchers paired up with the company 23 and Me to try to understand genetic differences among a large set of people, to try to tease out any genetic similarities that could be correlated with coffee consumption. Sandra Sanchez-Roige is an associate professor in the department of psychiatry at the University of California San Diego, and she’s one of the study’s authors.&nbsp;Abraham Palmer is a professor and vice chair of basic research in the department of psychiatry at UC San Diego, and he’s another of the study’s authors.&nbsp;</p><br><p>Read their full study here: https://www.nature.com/articles/s41386-024-01870-x</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>C-reactive protein moderates associations between racial discrimination and ventromedial prefrontal cortex activation during attention to threat in Black American women</title>
			<itunes:title>C-reactive protein moderates associations between racial discrimination and ventromedial prefrontal cortex activation during attention to threat in Black American women</itunes:title>
			<pubDate>Fri, 21 Jun 2024 14:11:46 GMT</pubDate>
			<itunes:duration>9:56</itunes:duration>
			<enclosure url="https://sphinx.acast.com/p/acast/s/neuropsychopharmacologypodcast/e/66758a22d93b3d0012c6f991/media.mp3" length="9602238" type="audio/mpeg"/>
			<guid isPermaLink="false">66758a22d93b3d0012c6f991</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://shows.acast.com/neuropsychopharmacologypodcast/episodes/c-reactive-protein-moderates-associations-between-racial-dis</link>
			<acast:episodeId>66758a22d93b3d0012c6f991</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>c-reactive-protein-moderates-associations-between-racial-dis</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCeyrSQL+P5913fJFhg5HjJawU1i1+AfEo/OiBlX1m40qBs4dgaHqAwmAXQp8XJa8Yz2v7bbvPyUv0tKojVYXEVjK+nSfT6kj3KgTMEWs9CBki0YyrOkvnRmkQ9oS8fN5qejYziluHw1VvDT/ac2evzCPo1Wy//XTeIiGkLPOtZbYsuthWZa6B85uHaMl+EeY7nGeTDiuwkrEAnCN9k/XSlL]]></acast:settings>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[<p>Scientists have been amassing an increasing amount of evidence about the impact of racial discrimination and racial trauma, including how it can have an impact on brain regions involved with threat vigilance and emotional regulation. At the same time, there’s evidence that increased engagement in those areas has been linked to increased risk of mental health problems like depression, and they also suspect it could be a vulnerability for brain health issues such as dementia and Alzheimer’s disease.&nbsp;</p><br><p>Negar Fani is an associate professor in the department of psychiatry and behavioral sciences at Emory University School of Medicine, and she worked with Aziz Elbasheir, a PhD candidate at Emory University in the neuroscience program, on the study. They knew that C-reactive proteins, or CRPs, are a marker of immune activation in the blood.</p><br><p>Read their full study here: https://www.nature.com/articles/s41386-023-01737-7</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[<p>Scientists have been amassing an increasing amount of evidence about the impact of racial discrimination and racial trauma, including how it can have an impact on brain regions involved with threat vigilance and emotional regulation. At the same time, there’s evidence that increased engagement in those areas has been linked to increased risk of mental health problems like depression, and they also suspect it could be a vulnerability for brain health issues such as dementia and Alzheimer’s disease.&nbsp;</p><br><p>Negar Fani is an associate professor in the department of psychiatry and behavioral sciences at Emory University School of Medicine, and she worked with Aziz Elbasheir, a PhD candidate at Emory University in the neuroscience program, on the study. They knew that C-reactive proteins, or CRPs, are a marker of immune activation in the blood.</p><br><p>Read their full study here: https://www.nature.com/articles/s41386-023-01737-7</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Ghrelin decreases sensitivity to negative feedback and increases prediction-error related caudate activity in humans, a randomized controlled trial</title>
			<itunes:title>Ghrelin decreases sensitivity to negative feedback and increases prediction-error related caudate activity in humans, a randomized controlled trial</itunes:title>
			<pubDate>Mon, 06 May 2024 16:55:36 GMT</pubDate>
			<itunes:duration>9:06</itunes:duration>
			<enclosure url="https://sphinx.acast.com/p/acast/s/neuropsychopharmacologypodcast/e/66390b88793d40001322591a/media.mp3" length="8810206" type="audio/mpeg"/>
			<guid isPermaLink="false">66390b88793d40001322591a</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://shows.acast.com/neuropsychopharmacologypodcast/episodes/ghrelin-decreases-sensitivity-to-negative-feedback-and-incre</link>
			<acast:episodeId>66390b88793d40001322591a</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>ghrelin-decreases-sensitivity-to-negative-feedback-and-incre</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCflXCvB4Gl+QXZOiV77zv+ogfb82oDh9EXNzCa8eLv68TSE3mnjKv2i4q02kXkM5mS7MJRw2HCZz6Q2yHJrvmwbwPcm37K//R+fUy6NpsT7N7K09EOTMV5jVIURFh5QiPSRY868DhUwjmlXeD/Z4RKptAog8BF+h+izDk3KE2P4AIirJYCmvsyFAPZCT2OHtJph1i0J0bkIFVOOVxH3o3Hn]]></acast:settings>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[<p>There’s a hormone called ghrelin that’s secreted in the stomach, and when someone is hungry it contributes to that feeling of hunger and the need to search for food. But neurological studies have suggested that ghrelin might also play a role in compulsivity and impulsivity, and it might be related to substance use disorders.</p><br><p>Rebecca Boeme is an assistant professor at Linkoping University in Sweden. She and her colleagues decided to use human subjects to investigate how ghrelin affects reinforcement learning, basically how ghrelin influences decision making when subjects receive positive and negative feedback —and also how it might actually be affecting the brain.&nbsp;</p><br><p>Read the full study <a href="https://www.nature.com/articles/s41386-024-01821-6" rel="noopener noreferrer" target="_blank">here</a>: https://www.nature.com/articles/s41386-024-01821-6</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[<p>There’s a hormone called ghrelin that’s secreted in the stomach, and when someone is hungry it contributes to that feeling of hunger and the need to search for food. But neurological studies have suggested that ghrelin might also play a role in compulsivity and impulsivity, and it might be related to substance use disorders.</p><br><p>Rebecca Boeme is an assistant professor at Linkoping University in Sweden. She and her colleagues decided to use human subjects to investigate how ghrelin affects reinforcement learning, basically how ghrelin influences decision making when subjects receive positive and negative feedback —and also how it might actually be affecting the brain.&nbsp;</p><br><p>Read the full study <a href="https://www.nature.com/articles/s41386-024-01821-6" rel="noopener noreferrer" target="_blank">here</a>: https://www.nature.com/articles/s41386-024-01821-6</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Spotlighting SHAPERS: Sex hormones associated with psychological and endocrine roles</title>
			<itunes:title>Spotlighting SHAPERS: Sex hormones associated with psychological and endocrine roles</itunes:title>
			<pubDate>Tue, 05 Mar 2024 14:19:35 GMT</pubDate>
			<itunes:duration>9:08</itunes:duration>
			<enclosure url="https://sphinx.acast.com/p/acast/s/neuropsychopharmacologypodcast/e/65e72952ccd9aa0015a57034/media.mp3" length="8844478" type="audio/mpeg"/>
			<guid isPermaLink="false">65e72952ccd9aa0015a57034</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://shows.acast.com/neuropsychopharmacologypodcast/episodes/spotlighting-shapers-ex-hormones-associated-with-psychologic</link>
			<acast:episodeId>65e72952ccd9aa0015a57034</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>spotlighting-shapers-ex-hormones-associated-with-psychologic</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCcFAe0fnxBJy/1ju4Qxy1fh8gO4DvlGA40yms2g0/hOkcrfHIopjTygHFqGwwOPKFIai4SuTvs86Lx3UYCyl6Zsma6ZjxY1sbH02l3rfpxRZ0hgV1GLY0rz46oVazru1zuMpk8U5Da69GEiS/Rn/Ns4IWbIXQT3pWUxe+i+RPnQMz9GNKgD3OCTEU+JjKfLxG+hyVD6yfqrcZ3n9yENqB7A]]></acast:settings>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[<p>Dr. Nicole Petersen is an assistant professor in the department of psychiatry and behavioral sciences at UCLA. Her commentary is a new paper in the journal Neuropsychopharmacology, called “Spotlighting SHAPERS: sex hormones associated with psychological and endocrine roles.” Dr. Petersen starts the paper describing an unnamed signaling molecule that can affect the physical structure of the brain and that seems to be related to a wide number of psychological and neurological conditions. Then she reveals that this is estradiol.&nbsp;The point she makes in the paper is that estrogen isn’t the only neuroactive substance that affects the brain in ways that we just don’t understand.</p><br><p>Read the&nbsp;<a href="https://www.nature.com/articles/s41386-024-01819-0" rel="noopener noreferrer" target="_blank">full study here</a>: https://www.nature.com/articles/s41386-024-01819-0</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[<p>Dr. Nicole Petersen is an assistant professor in the department of psychiatry and behavioral sciences at UCLA. Her commentary is a new paper in the journal Neuropsychopharmacology, called “Spotlighting SHAPERS: sex hormones associated with psychological and endocrine roles.” Dr. Petersen starts the paper describing an unnamed signaling molecule that can affect the physical structure of the brain and that seems to be related to a wide number of psychological and neurological conditions. Then she reveals that this is estradiol.&nbsp;The point she makes in the paper is that estrogen isn’t the only neuroactive substance that affects the brain in ways that we just don’t understand.</p><br><p>Read the&nbsp;<a href="https://www.nature.com/articles/s41386-024-01819-0" rel="noopener noreferrer" target="_blank">full study here</a>: https://www.nature.com/articles/s41386-024-01819-0</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Comparable roles for serotonin in rats and humans for computations underlying flexible decision-making</title>
			<itunes:title>Comparable roles for serotonin in rats and humans for computations underlying flexible decision-making</itunes:title>
			<pubDate>Thu, 04 Jan 2024 16:42:08 GMT</pubDate>
			<itunes:duration>9:33</itunes:duration>
			<enclosure url="https://sphinx.acast.com/p/acast/s/neuropsychopharmacologypodcast/e/6596dfe085908f0016e5e5d3/media.mp3" length="9248645" type="audio/mpeg"/>
			<guid isPermaLink="false">6596dfe085908f0016e5e5d3</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://shows.acast.com/neuropsychopharmacologypodcast/episodes/httpswwwnaturecomarticless41386-023-01762-6</link>
			<acast:episodeId>6596dfe085908f0016e5e5d3</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>httpswwwnaturecomarticless41386-023-01762-6</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCcFAe0fnxBJy/1ju4Qxy1fh8gO4DvlGA40yms2g0/hOkcrfHIopjTygHFqGwwOPKFIai4SuTvs86Lx3UYCyl6Zsma6ZjxY1sbH02l3rfpxRZ0hgV1GLY0rz46oVazru1zuvybO8oXx+gaVIdQrQSgJVQjIsu28n1Gz1/SJwcDVeErevW5sSVLoUHStx0I1e2ahC1GnTnxhjvqZ6Sbvwbv8p]]></acast:settings>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[<p>Serotonin is a critical chemical when it comes to a number of psychiatric conditions, such as OCD, where it seems to play a particular role in cognitive flexibility. That is, serotonin levels are related to the fact that someone is perseverating on intrusive thoughts or compulsions and isn’t able to be as flexible as otherwise would be necessary.</p><br><p>Trevor Robbins, professor of cognitive neuroscience at the University of Cambridge, is one of the authors of a recent study titled <em>Comparable roles for serotonin in rats and humans for computations underlying flexible decision-making</em>, and he says such cognitive flexibility also plays a role in depression and schizophrenia<em>. </em></p><br><p>Read the full study <a href="https://www.nature.com/articles/s41386-023-01762-6" rel="noopener noreferrer" target="_blank">here</a>: https://www.nature.com/articles/s41386-023-01762-6</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[<p>Serotonin is a critical chemical when it comes to a number of psychiatric conditions, such as OCD, where it seems to play a particular role in cognitive flexibility. That is, serotonin levels are related to the fact that someone is perseverating on intrusive thoughts or compulsions and isn’t able to be as flexible as otherwise would be necessary.</p><br><p>Trevor Robbins, professor of cognitive neuroscience at the University of Cambridge, is one of the authors of a recent study titled <em>Comparable roles for serotonin in rats and humans for computations underlying flexible decision-making</em>, and he says such cognitive flexibility also plays a role in depression and schizophrenia<em>. </em></p><br><p>Read the full study <a href="https://www.nature.com/articles/s41386-023-01762-6" rel="noopener noreferrer" target="_blank">here</a>: https://www.nature.com/articles/s41386-023-01762-6</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Integrating public health and translational basic science to address challenges of xylazine adulteration of fentanyl</title>
			<itunes:title>Integrating public health and translational basic science to address challenges of xylazine adulteration of fentanyl</itunes:title>
			<pubDate>Mon, 16 Oct 2023 15:22:16 GMT</pubDate>
			<itunes:duration>9:58</itunes:duration>
			<enclosure url="https://sphinx.acast.com/p/acast/s/neuropsychopharmacologypodcast/e/652d5528d40c970012646735/media.mp3" length="9641108" type="audio/mpeg"/>
			<guid isPermaLink="false">652d5528d40c970012646735</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://shows.acast.com/neuropsychopharmacologypodcast/episodes/integrating-public-health-and-translational-basic-science-to</link>
			<acast:episodeId>652d5528d40c970012646735</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>integrating-public-health-and-translational-basic-science-to</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCclqSRINUn9rMdYa6Mqxi6/OyA1tKMrdmUdpQbeCmuQxyPOl3ibR8gCuQmv46Gk7GZDASQkMfGBhfjrqMEcTsEd80QhqoIF2n31F0kqsjuFB8rLvKGs39TIwbyKOEhqTy61smWi8OIloYkYvZivOjSEmoP7pfwcXAsMAYmiiny8LtAuPR0d2GU69XGJ3bf//O4=]]></acast:settings>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[<p>The drug naloxone, otherwise known as Narcan, is a critical tool in reversing fentanyl overdoses and reducing mortality. But now fentanyl is appearing on the streets adulterated with a drug called xylazine.&nbsp;</p><br><p>Justin Strickland, assistant professor at Johns Hopkins University School of Medicine, and Cassandra Gipson-Reichardt, associate professor in the department of pharmacology nutritional sciences at the University of Kentucky, are the coauthors of a new paper in the journal Neuropsychopharmacology about the importance of integrating public health and translational science to address the challenges of xylazine adulteration of fentanyl.&nbsp;</p><br><p>Read the <a href="https://www.nature.com/articles/s41386-023-01680-7" rel="noopener noreferrer" target="_blank">full study here</a>: https://www.nature.com/articles/s41386-023-01680-7</p><br><p><br></p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[<p>The drug naloxone, otherwise known as Narcan, is a critical tool in reversing fentanyl overdoses and reducing mortality. But now fentanyl is appearing on the streets adulterated with a drug called xylazine.&nbsp;</p><br><p>Justin Strickland, assistant professor at Johns Hopkins University School of Medicine, and Cassandra Gipson-Reichardt, associate professor in the department of pharmacology nutritional sciences at the University of Kentucky, are the coauthors of a new paper in the journal Neuropsychopharmacology about the importance of integrating public health and translational science to address the challenges of xylazine adulteration of fentanyl.&nbsp;</p><br><p>Read the <a href="https://www.nature.com/articles/s41386-023-01680-7" rel="noopener noreferrer" target="_blank">full study here</a>: https://www.nature.com/articles/s41386-023-01680-7</p><br><p><br></p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>The why, when, where, how, and so what of so-called rapidly acting antidepressants</title>
			<itunes:title>The why, when, where, how, and so what of so-called rapidly acting antidepressants</itunes:title>
			<pubDate>Wed, 06 Sep 2023 14:03:54 GMT</pubDate>
			<itunes:duration>8:29</itunes:duration>
			<enclosure url="https://sphinx.acast.com/p/acast/s/neuropsychopharmacologypodcast/e/64f886cbb20f810011c58e21/media.mp3" length="8209598" type="audio/mpeg"/>
			<guid isPermaLink="false">64f886cbb20f810011c58e21</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://shows.acast.com/neuropsychopharmacologypodcast/episodes/the-why-when-where-how-and-so-what-of-so-called-rapidly-acti</link>
			<acast:episodeId>64f886cbb20f810011c58e21</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>the-why-when-where-how-and-so-what-of-so-called-rapidly-acti</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCdpebpRogwTSk2UnoJYIhB+TOxJaDcxcdHp8f2GDBxreglcaRN8xaClsPdd3fsr7X4hxVvsRNwzJV6O6QOr1JAtIIYXCF6F3YfPeGfpKsw/NU6HvYyTfW7IoS1HgsqHYiXIhgbmfo7U/uJUoWbFNX0K2jWM5mqnnXIjHls2SFT8fj6SZ7RrobG3MEgKWuB777LI427mK5XL70SKu94Hxfm5]]></acast:settings>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[<p>Sanjay Mathew is a professor and vice chair for research at Baylor College of Medicine and director of the Mood and Anxiety Disorders Program. He’s one of the two authors of a recent review paper in the journal Neuropsychopharmacology, “The why, when, where, how, and so what of so-called rapidly acting antidepressants.” </p><br><p>With his colleague Alan Schatzberg, professor of psychiatry and behavioral sciences and director of the Mood Disorders Center at Stanford University, they explore both the drugs that have been studied as rapidly-acting anti-depressants to date, and they also review the challenges and opportunities in how such research is conducted. They say that a version of ketamine has changed the field.</p><br><p>Read the full study <a href="https://www.nature.com/articles/s41386-023-01647-8" rel="noopener noreferrer" target="_blank">here</a>: https://www.nature.com/articles/s41386-023-01647-8</p><br><p><br></p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[<p>Sanjay Mathew is a professor and vice chair for research at Baylor College of Medicine and director of the Mood and Anxiety Disorders Program. He’s one of the two authors of a recent review paper in the journal Neuropsychopharmacology, “The why, when, where, how, and so what of so-called rapidly acting antidepressants.” </p><br><p>With his colleague Alan Schatzberg, professor of psychiatry and behavioral sciences and director of the Mood Disorders Center at Stanford University, they explore both the drugs that have been studied as rapidly-acting anti-depressants to date, and they also review the challenges and opportunities in how such research is conducted. They say that a version of ketamine has changed the field.</p><br><p>Read the full study <a href="https://www.nature.com/articles/s41386-023-01647-8" rel="noopener noreferrer" target="_blank">here</a>: https://www.nature.com/articles/s41386-023-01647-8</p><br><p><br></p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>AI-based analysis of social media language predicts addiction treatment dropout at 90 days</title>
			<itunes:title>AI-based analysis of social media language predicts addiction treatment dropout at 90 days</itunes:title>
			<pubDate>Fri, 23 Jun 2023 19:09:49 GMT</pubDate>
			<itunes:duration>9:09</itunes:duration>
			<enclosure url="https://sphinx.acast.com/p/acast/s/neuropsychopharmacologypodcast/e/6495edfd66f8a20011923151/media.mp3" length="8851584" type="audio/mpeg"/>
			<guid isPermaLink="false">6495edfd66f8a20011923151</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://shows.acast.com/neuropsychopharmacologypodcast/episodes/ai-based-analysis-of-social-media-language-predicts-addictio</link>
			<acast:episodeId>6495edfd66f8a20011923151</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>ai-based-analysis-of-social-media-language-predicts-addictio</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCd68OyIUH2Lr8TnA2Qd8PekFyr8P05LmC6pMpsCwJYsYJI3ikwGfMM8CCPeI1cyT0WzHMsBomK2UT/dG5BfXyx6MLGxh3E0r7kH/aztkWV7L4PhjyzY9yn8zWqsvmSf+rMBHQBp1IBq2486+QMAloLppdLj6Fmszg8LDpYmPk/0WlUG5qPQFmudupIMzax3Yn+/AcaIPWEK3OyeiH9ZK9Jt]]></acast:settings>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[<p>In-person treatment for substance use disorders is an incredibly important tool, but there’s a high failure rate — more than 50 percent of people who enter drop out within the first month. There hasn’t been a highly accurate method of identifying who might leave and who might succeed, and knowing this could help centers allocate resources to give the right type of assistance to the right people at the right time. One tool available is called the Addiction Severity Index, which is used to help identify the severity of the addiction and thus customize treatment, but it wasn’t developed to gauge whether a patient might drop out entirely. So a team of researchers decided to mine something known as a digital phenotype.&nbsp;</p><br><p>Dr. Brenda Curtis is a clinical researcher at the National Institute on Drug Abuse Intramural Research Program, and she’s one of the paper’s authors.</p><br><p>Read the <a href="https://www.nature.com/articles/s41386-023-01585-5" rel="noopener noreferrer" target="_blank">full study here</a>: https://www.nature.com/articles/s41386-023-01585-5</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[<p>In-person treatment for substance use disorders is an incredibly important tool, but there’s a high failure rate — more than 50 percent of people who enter drop out within the first month. There hasn’t been a highly accurate method of identifying who might leave and who might succeed, and knowing this could help centers allocate resources to give the right type of assistance to the right people at the right time. One tool available is called the Addiction Severity Index, which is used to help identify the severity of the addiction and thus customize treatment, but it wasn’t developed to gauge whether a patient might drop out entirely. So a team of researchers decided to mine something known as a digital phenotype.&nbsp;</p><br><p>Dr. Brenda Curtis is a clinical researcher at the National Institute on Drug Abuse Intramural Research Program, and she’s one of the paper’s authors.</p><br><p>Read the <a href="https://www.nature.com/articles/s41386-023-01585-5" rel="noopener noreferrer" target="_blank">full study here</a>: https://www.nature.com/articles/s41386-023-01585-5</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Oxytocin effects on amygdala reactivity to angry faces in males and females with ASPD</title>
			<itunes:title>Oxytocin effects on amygdala reactivity to angry faces in males and females with ASPD</itunes:title>
			<pubDate>Fri, 21 Apr 2023 18:46:20 GMT</pubDate>
			<itunes:duration>9:27</itunes:duration>
			<enclosure url="https://sphinx.acast.com/p/acast/s/neuropsychopharmacologypodcast/e/6442d9fc8aa57e0011650b0b/media.mp3" length="9147499" type="audio/mpeg"/>
			<guid isPermaLink="false">6442d9fc8aa57e0011650b0b</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://shows.acast.com/neuropsychopharmacologypodcast/episodes/oxytocin-effects-on-amygdala-reactivity-to-angry-faces-in-ma</link>
			<acast:episodeId>6442d9fc8aa57e0011650b0b</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>oxytocin-effects-on-amygdala-reactivity-to-angry-faces-in-ma</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCexoL40v2qLzes0Sa+wYZpSxipbBQK0piUBNIg+4trINx5SCCaflhXvUgATAvHZ5QZMFGic9jfueIM4zXXKRgJ3EdNK5BOdNyxs8qHa13hilORR8fpRUsHMra1dfkxSeD6xbd+Iz7RclzK2zdia2wbLAtKER1O/Ww/S6+U0AH6UQJJKkRSboto8wl7FG+YcKRjksUeO1fKzNlkHRG2dX85k]]></acast:settings>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[<p>Antisocial personality disorder, or ASPD, is a difficult disorder to study. There have been studies on psychopathic individuals, and on youth with psychopathic traits, but most studies on ASPD to date have been on incarcerated adults. A team of researchers at Heidelberg University wanted to study individuals who are not incarcerated and see what these findings could elucidate about the brains, in particular the amygdalas, of individuals with ASPD.</p><br><p>Haang Jeung-Maarse is a medical doctor at Bielfeld University in Germany and is one of the authors of the paper in the journal Neuropsychopharmacology, on the effects of oxytocin on amygdala reactivity to angry faces in males and females with antisocial personality disorder.</p><br><p>Read the full study <a href="https://www.nature.com/articles/s41386-023-01549-9" rel="noopener noreferrer" target="_blank">here</a>: https://www.nature.com/articles/s41386-023-01549-9</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[<p>Antisocial personality disorder, or ASPD, is a difficult disorder to study. There have been studies on psychopathic individuals, and on youth with psychopathic traits, but most studies on ASPD to date have been on incarcerated adults. A team of researchers at Heidelberg University wanted to study individuals who are not incarcerated and see what these findings could elucidate about the brains, in particular the amygdalas, of individuals with ASPD.</p><br><p>Haang Jeung-Maarse is a medical doctor at Bielfeld University in Germany and is one of the authors of the paper in the journal Neuropsychopharmacology, on the effects of oxytocin on amygdala reactivity to angry faces in males and females with antisocial personality disorder.</p><br><p>Read the full study <a href="https://www.nature.com/articles/s41386-023-01549-9" rel="noopener noreferrer" target="_blank">here</a>: https://www.nature.com/articles/s41386-023-01549-9</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>To dismantle structural racism in science, scientists need to learn how it works</title>
			<itunes:title>To dismantle structural racism in science, scientists need to learn how it works</itunes:title>
			<pubDate>Wed, 22 Feb 2023 15:24:21 GMT</pubDate>
			<itunes:duration>9:54</itunes:duration>
			<enclosure url="https://sphinx.acast.com/p/acast/s/neuropsychopharmacologypodcast/e/63f633a5aa5a9a0011ab1356/media.mp3" length="9577997" type="audio/mpeg"/>
			<guid isPermaLink="false">63f633a5aa5a9a0011ab1356</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://shows.acast.com/neuropsychopharmacologypodcast/episodes/to-dismantle-structural-racism-in-science-scientists-need-to</link>
			<acast:episodeId>63f633a5aa5a9a0011ab1356</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>to-dismantle-structural-racism-in-science-scientists-need-to</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCf2ce6JCo+QHgH/4apSrGotliVGUvysbCZd3ynpZitzJdMayIzPLMjUdA5Ot9E2BH70R2ByJn7MKr+kMH7asQFpM1KN/zv+0uN6W4e8M0M7doMYk27NcZYSAZ9wXEEt7DqHfwtJuQRhUDJvtBfPE8REkPcisHZYCayKFfdlcS4UJ+Zm2L3S16dTzZuR2yYusKr4YB1pUPUFTsObpeinFRoU]]></acast:settings>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[<p>It’s clear there are diversity issues in science, both in terms of who does or doesn’t receive research grants, as well as who is or isn’t represented at the highest levels of scientific research. When Caleb Weinreb and Daphne Sun began their PhD program at Harvard University Medical School in systems biology, they took this on as an issue. They learned from others in their department, and they eventually created a course on the topic for incoming first year PhD students. </p><p>&nbsp;</p><p>As they worked on improving their course over the years, they saw that in science there was a focus on narrowing racial gaps by correcting for implicit bias. For example, there had been a well-known study in which resumes with stereotypically African-American names weren’t considered as seriously as those with stereotypically white names. But the two PhD students realized that efforts to overcome such implicit bias weren’t moving the needle. They recently published a perspective paper in the journal Neuropsychopharmacology called “To dismantle structural racism in science, scientists need to learn how it works.” Caleb Weinreb is now a post-doc in the neuroscience department at Harvard Medical School.</p><br><p>Read the full paper <a href="https://www.nature.com/articles/s41386-023-01534-2" rel="noopener noreferrer" target="_blank">here</a>: https://www.nature.com/articles/s41386-023-01534-2</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[<p>It’s clear there are diversity issues in science, both in terms of who does or doesn’t receive research grants, as well as who is or isn’t represented at the highest levels of scientific research. When Caleb Weinreb and Daphne Sun began their PhD program at Harvard University Medical School in systems biology, they took this on as an issue. They learned from others in their department, and they eventually created a course on the topic for incoming first year PhD students. </p><p>&nbsp;</p><p>As they worked on improving their course over the years, they saw that in science there was a focus on narrowing racial gaps by correcting for implicit bias. For example, there had been a well-known study in which resumes with stereotypically African-American names weren’t considered as seriously as those with stereotypically white names. But the two PhD students realized that efforts to overcome such implicit bias weren’t moving the needle. They recently published a perspective paper in the journal Neuropsychopharmacology called “To dismantle structural racism in science, scientists need to learn how it works.” Caleb Weinreb is now a post-doc in the neuroscience department at Harvard Medical School.</p><br><p>Read the full paper <a href="https://www.nature.com/articles/s41386-023-01534-2" rel="noopener noreferrer" target="_blank">here</a>: https://www.nature.com/articles/s41386-023-01534-2</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity</title>
			<itunes:title>Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity</itunes:title>
			<pubDate>Thu, 22 Dec 2022 18:37:29 GMT</pubDate>
			<itunes:duration>9:59</itunes:duration>
			<enclosure url="https://sphinx.acast.com/p/acast/s/neuropsychopharmacologypodcast/e/63a4a3e92a786e00109bff4b/media.mp3" length="9658245" type="audio/mpeg"/>
			<guid isPermaLink="false">63a4a3e92a786e00109bff4b</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://shows.acast.com/neuropsychopharmacologypodcast/episodes/low-doses-of-lysergic-acid-diethylamide-lsd-increase-reward-</link>
			<acast:episodeId>63a4a3e92a786e00109bff4b</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>low-doses-of-lysergic-acid-diethylamide-lsd-increase-reward-</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCfmyj5OOJ6mlI1pNyMS2ys111IUxYUAEdvVIr68iD6urNZWITx77x6xKORp5NBRFeGxTMZlOH78w898ImdvUHCCF1MXjjs9wTa6qp4qwygm049P5ThTl0AcI0rSeF1J9jjSjfHCPUQsboEURiYP5up27/IU/qLgY302dd5zGRHzzGBLhHgXZwTUjtupRnl8ldEwu+T656NYVDS+2doCCDk2]]></acast:settings>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[<p>Psychedelic drugs have received attention recently for their potential use as treatments for psychiatric disorders. Single, high doses of LSD have shown promise for treating depressive disorders. But there’s another way in which people have been using LSD, and it’s what’s known as micro-dosing, taking LSD at below noticeable levels, where it doesn’t seem to have a psychedelic impact—but users say it does in fact have an impact on their overall sense of well-being. </p><br><p>This is just what Harriet de Wit, University of Chicago professor in the department of psychiatry and behavioral neuroscience, wanted to study.&nbsp;Dr. de Wit partnered with James Glazer, a postdoc in psychiatry at Northwestern University.</p><br><p>Read their full study <a href="https://www.nature.com/articles/s41386-022-01479-y" rel="noopener noreferrer" target="_blank">here</a>: <a href="https://www.nature.com/articles/s41386-022-01479-y" rel="noopener noreferrer" target="_blank" style="background-color: rgb(255, 255, 255);">Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity | Neuropsychopharmacology (nature.com)</a></p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[<p>Psychedelic drugs have received attention recently for their potential use as treatments for psychiatric disorders. Single, high doses of LSD have shown promise for treating depressive disorders. But there’s another way in which people have been using LSD, and it’s what’s known as micro-dosing, taking LSD at below noticeable levels, where it doesn’t seem to have a psychedelic impact—but users say it does in fact have an impact on their overall sense of well-being. </p><br><p>This is just what Harriet de Wit, University of Chicago professor in the department of psychiatry and behavioral neuroscience, wanted to study.&nbsp;Dr. de Wit partnered with James Glazer, a postdoc in psychiatry at Northwestern University.</p><br><p>Read their full study <a href="https://www.nature.com/articles/s41386-022-01479-y" rel="noopener noreferrer" target="_blank">here</a>: <a href="https://www.nature.com/articles/s41386-022-01479-y" rel="noopener noreferrer" target="_blank" style="background-color: rgb(255, 255, 255);">Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity | Neuropsychopharmacology (nature.com)</a></p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Sex-dependent risk factors for PTSD: a prospective structural MRI study</title>
			<itunes:title>Sex-dependent risk factors for PTSD: a prospective structural MRI study</itunes:title>
			<pubDate>Tue, 01 Nov 2022 14:09:50 GMT</pubDate>
			<itunes:duration>9:29</itunes:duration>
			<enclosure url="https://sphinx.acast.com/p/acast/s/neuropsychopharmacologypodcast/e/636128ae0759420012e3cbe6/media.mp3" length="9178428" type="audio/mpeg"/>
			<guid isPermaLink="false">636128ae0759420012e3cbe6</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://shows.acast.com/neuropsychopharmacologypodcast/episodes/sex-dependent-risk-factors-for-ptsd-a-prospective-structural</link>
			<acast:episodeId>636128ae0759420012e3cbe6</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>sex-dependent-risk-factors-for-ptsd-a-prospective-structural</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCeZQlmvPJm6M4l39vlB66gFniNtdWWx8T3Wamjd7CmllseLe87b0GISuBZ7kMUYe17Myq9ebVI3jP5ugBuY2K5kKu/DcIVR4AOyt9EWi8TsRFQt9aCc5qfL9ozCCMQTa+iDViigfGwNVsc8kYOBEY1MPJjeElok7JmZoLy7Egre0dCHEhnyk8pHPr9UHcY8PEQtFFivvBoy470nqasngNDv]]></acast:settings>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[<p>After a traumatic event, women are more likely to be diagnosed with post-traumatic stress disorder, or PTSD. Research has been conducted on what might be causing this higher rate of diagnoses; for instance, perhaps women had more cumulative trauma in their lives than the men in question. But scientists say that even taking prior childhood trauma into account, women are still diagnosed at a higher rate than men.&nbsp;</p><br><p>Alyssa Roeckner is a neuroscience PhD candidate at Emory University, she’s in the lab of Dr. Jennifer Stevens, assistant professor in the department of Psychiatry and Behavioral Sciences at Emory University. They are two of the authors of a recent study in NPP titled “Sex-dependent risk factors for PTSD: a prospective structural MRI study.”</p><br><p>Read the full study here: <a href="https://www.nature.com/articles/s41386-022-01452-9" rel="noopener noreferrer" target="_blank">Sex-dependent risk factors for PTSD: a prospective structural MRI study | Neuropsychopharmacology (nature.com)</a></p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[<p>After a traumatic event, women are more likely to be diagnosed with post-traumatic stress disorder, or PTSD. Research has been conducted on what might be causing this higher rate of diagnoses; for instance, perhaps women had more cumulative trauma in their lives than the men in question. But scientists say that even taking prior childhood trauma into account, women are still diagnosed at a higher rate than men.&nbsp;</p><br><p>Alyssa Roeckner is a neuroscience PhD candidate at Emory University, she’s in the lab of Dr. Jennifer Stevens, assistant professor in the department of Psychiatry and Behavioral Sciences at Emory University. They are two of the authors of a recent study in NPP titled “Sex-dependent risk factors for PTSD: a prospective structural MRI study.”</p><br><p>Read the full study here: <a href="https://www.nature.com/articles/s41386-022-01452-9" rel="noopener noreferrer" target="_blank">Sex-dependent risk factors for PTSD: a prospective structural MRI study | Neuropsychopharmacology (nature.com)</a></p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Sex differences in appetitive and reactive aggression</title>
			<itunes:title>Sex differences in appetitive and reactive aggression</itunes:title>
			<pubDate>Tue, 06 Sep 2022 18:10:54 GMT</pubDate>
			<itunes:duration>9:47</itunes:duration>
			<enclosure url="https://sphinx.acast.com/p/acast/s/neuropsychopharmacologypodcast/e/63178d2eaba23d001218bb8d/media.mp3" length="9466401" type="audio/mpeg"/>
			<guid isPermaLink="false">63178d2eaba23d001218bb8d</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://shows.acast.com/neuropsychopharmacologypodcast/episodes/sex-differences-in-appetitive-and-reactive-aggression</link>
			<acast:episodeId>63178d2eaba23d001218bb8d</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>sex-differences-in-appetitive-and-reactive-aggression</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCdzHRV1rssiQYUx665UuXK8uXhgug9L46xqd9rNg3IPDihOw0HJ30oGwPPiEAwHqqqTrrIgysdf5tV13yNiVCK8SiYw6nn5vAE8rGn6tTwC/0yyfeZCTqBqjoXReYM7PtvCkJ/y3mvWO6Nc87HaHMGG2kJtZUHe4EgS+ONct0ppDXXvZoSvukgFikNjOy0nTTw4A5mJGHmUVLLLRQFmSGJw]]></acast:settings>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[<p>Maladaptive aggression, while not a diagnosable neuropsychiatric disorder on its own, often presents as an important comorbid condition with other neuropsychiatric disorders. But while both men and women can and do display aggression, there’s been a bias to thinking of aggression, in both its adaptive and maladaptive forms, as a male behavior.&nbsp;</p><br><p>Sam Golden is an assistant professor at the University of Washington in the department of biological structure and also has an appointment in the Center for Excellence in the Neurobiology of Addiction, Pain, and Emotion. He’s one of the authors of a recent study on aggression in the journal Neuropsychopharmacology.&nbsp;</p><br><p>Read the full study <a href="https://www.nature.com/articles/s41386-022-01375-5" rel="noopener noreferrer" target="_blank">here</a>: <a href="https://www.nature.com/articles/s41386-022-01375-5" rel="noopener noreferrer" target="_blank">Sex differences in appetitive and reactive aggression | Neuropsychopharmacology (nature.com)</a></p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[<p>Maladaptive aggression, while not a diagnosable neuropsychiatric disorder on its own, often presents as an important comorbid condition with other neuropsychiatric disorders. But while both men and women can and do display aggression, there’s been a bias to thinking of aggression, in both its adaptive and maladaptive forms, as a male behavior.&nbsp;</p><br><p>Sam Golden is an assistant professor at the University of Washington in the department of biological structure and also has an appointment in the Center for Excellence in the Neurobiology of Addiction, Pain, and Emotion. He’s one of the authors of a recent study on aggression in the journal Neuropsychopharmacology.&nbsp;</p><br><p>Read the full study <a href="https://www.nature.com/articles/s41386-022-01375-5" rel="noopener noreferrer" target="_blank">here</a>: <a href="https://www.nature.com/articles/s41386-022-01375-5" rel="noopener noreferrer" target="_blank">Sex differences in appetitive and reactive aggression | Neuropsychopharmacology (nature.com)</a></p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>What’s wrong with my experiment?: The impact of hidden variables on neuropsychopharmacology research</title>
			<itunes:title>What’s wrong with my experiment?: The impact of hidden variables on neuropsychopharmacology research</itunes:title>
			<pubDate>Thu, 16 Jun 2022 17:39:55 GMT</pubDate>
			<itunes:duration>9:34</itunes:duration>
			<enclosure url="https://sphinx.acast.com/p/acast/s/neuropsychopharmacologypodcast/e/62ab6aeb444baf0013779c94/media.mp3" length="9262437" type="audio/mpeg"/>
			<guid isPermaLink="false">62ab6aeb444baf0013779c94</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://www.nature.com/articles/s41386-022-01309-1</link>
			<acast:episodeId>62ab6aeb444baf0013779c94</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>whats-wrong-with-my-experiment-the-impact-of-hidden-variable</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCcXTKVl8HST/qvuwbWHGzwBONU4AnRtLAhap2SX6g6nWbkOVwS4ts0YpcYPEfmzM4TEPRVHJI+1OPTeibemtAGdWghYkxrOqO1VerE1uOaXXkqrKfRlMypT7TBAM+c3AV0xjPzw3vvSs7Bor9aI/YQI9oJYjIPvAOAcM04c6izM02J9UjeY1ldjBquR2MjCUU3kGgHfSGHKHkJacwkxSBQC]]></acast:settings>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[<p>Sometimes, when researchers are conducting an experiment, the results are confusing. Maybe the control group of animals doesn’t behave the way a control should in theory be behaving. Maybe a researcher repeats a study and sees results that are unusually different from the first time around. The answers to these issues might lie in something called ‘hidden variables,’ according to a new study titled, “What’s wrong with my research? The impact of hidden variables on neuropsychopharmacology research.”</p><p>&nbsp;</p><p>Brian Trainor is a professor of psychology at the University of California Davis, and he’s one of three authors of the study. His co-authors are Amanda Kentner, professor at the Massachusetts College of Pharmacy and Health Sciences, and Hannah Butler-Struben, a graduate student in the animal behavior group at UC Davis. They say that many of the articles in the review are from journals about animal behavior that wouldn’t typically come across the desk of those working in the field of neuroscience.</p><br><p>Read the full article here: <a href="https://www.nature.com/articles/s41386-022-01309-1" rel="noopener noreferrer" target="_blank">What’s wrong with my experiment?: The impact of hidden variables on neuropsychopharmacology research</a></p><p><br></p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[<p>Sometimes, when researchers are conducting an experiment, the results are confusing. Maybe the control group of animals doesn’t behave the way a control should in theory be behaving. Maybe a researcher repeats a study and sees results that are unusually different from the first time around. The answers to these issues might lie in something called ‘hidden variables,’ according to a new study titled, “What’s wrong with my research? The impact of hidden variables on neuropsychopharmacology research.”</p><p>&nbsp;</p><p>Brian Trainor is a professor of psychology at the University of California Davis, and he’s one of three authors of the study. His co-authors are Amanda Kentner, professor at the Massachusetts College of Pharmacy and Health Sciences, and Hannah Butler-Struben, a graduate student in the animal behavior group at UC Davis. They say that many of the articles in the review are from journals about animal behavior that wouldn’t typically come across the desk of those working in the field of neuroscience.</p><br><p>Read the full article here: <a href="https://www.nature.com/articles/s41386-022-01309-1" rel="noopener noreferrer" target="_blank">What’s wrong with my experiment?: The impact of hidden variables on neuropsychopharmacology research</a></p><p><br></p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>A scientific approach to navigating the academic job market</title>
			<itunes:title>A scientific approach to navigating the academic job market</itunes:title>
			<pubDate>Mon, 09 May 2022 18:34:27 GMT</pubDate>
			<itunes:duration>7:04</itunes:duration>
			<enclosure url="https://sphinx.acast.com/p/acast/s/neuropsychopharmacologypodcast/e/62795eb3fcc96b001542d755/media.mp3" length="6854993" type="audio/mpeg"/>
			<guid isPermaLink="false">62795eb3fcc96b001542d755</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://www.nature.com/articles/s41386-021-01225-w</link>
			<acast:episodeId>62795eb3fcc96b001542d755</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>a-scientific-approach-to-navigating-the-academic-job-market</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCfBdR613ydE8VWM+BZSK1+PZls6F/L0Ugn4ONuV5CC6TPKA70y/24k80y7TX+idEcfvCLUgecA3u3xuqq74x/FYjvRpZORRt7Kb/5kvbW2HRXJjggyxgWyQPZezq47AWUhT7VZOqSyIOP7lemI2xvzH/U9i/OlB721qJL02Ie4U81IRqvekU90SkDlDpchOJi3Xg2f/pka+h6vzNd8tZcjD]]></acast:settings>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[<p>Kirstie Cummings and Sofia Beas are both new assistant professors in the department of neurobiology at the University of Alabama, Birmingham. When they met, they discussed the job application process, their support network, and their own personal processes, and they decided to write an article that could serve as a resource for candidates from different backgrounds, many of whom might not have the same resources that Dr. Cummings and Dr. Beas did. The result was their paper, “A Scientific Approach to Navigating the Academic Job Market,” published in the journal <em>Neuropsychopharmacology</em>.</p><br><p>Read the full article here: <a href="https://www.nature.com/articles/s41386-021-01225-w" rel="noopener noreferrer" target="_blank">A scientific approach to navigating the academic job market | Neuropsychopharmacology (nature.com)</a></p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[<p>Kirstie Cummings and Sofia Beas are both new assistant professors in the department of neurobiology at the University of Alabama, Birmingham. When they met, they discussed the job application process, their support network, and their own personal processes, and they decided to write an article that could serve as a resource for candidates from different backgrounds, many of whom might not have the same resources that Dr. Cummings and Dr. Beas did. The result was their paper, “A Scientific Approach to Navigating the Academic Job Market,” published in the journal <em>Neuropsychopharmacology</em>.</p><br><p>Read the full article here: <a href="https://www.nature.com/articles/s41386-021-01225-w" rel="noopener noreferrer" target="_blank">A scientific approach to navigating the academic job market | Neuropsychopharmacology (nature.com)</a></p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Identification of THC impairment using functional brain imaging</title>
			<itunes:title>Identification of THC impairment using functional brain imaging</itunes:title>
			<pubDate>Wed, 23 Feb 2022 17:27:57 GMT</pubDate>
			<itunes:duration>9:17</itunes:duration>
			<enclosure url="https://sphinx.acast.com/p/acast/s/neuropsychopharmacologypodcast/e/62166e9dcdf63200131cfb7c/media.mp3" length="8988256" type="audio/mpeg"/>
			<guid isPermaLink="false">62166e9dcdf63200131cfb7c</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://www.nature.com/npp/podcast</link>
			<acast:episodeId>62166e9dcdf63200131cfb7c</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>identification-of-thc-impairment-using-functional-brain-imag</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmfwL2jaMW9OfVjpl1A481t14TmPPNBt/QBdFV0cjQSq6O95gGg1G5VX1qUALnMwOy84DIRWdD816dQkEuoT9tdbrGOMq1iUO7eB5544ZTUzEM/A3hOHvZ1yebforOpWFE59xiUxB/LGcHaob2U13MMaSwKx9f2w8LR7BW5/imUttqDYUBCa2xmDMEQxQFMdjrQku6TtCviU7MyZZKoeagFAKn2Q2F2W0xDXaUNKsX9imF5ljkBZ7rEwUfflOS3DVsfGwG0e4s0tXVYw2wOuqZrCP2VDlt93knN6ts1r2nuqV]]></acast:settings>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[<p>Driving while under the influence of THC, known as drugged driving, is becoming more of an issue as more states legalize cannabis for both medical and recreational use around the country. THC is known to impair cognitive and psychomotor performance and thus impair driving. Jodi Gilman is a neuroscientist and an associate professor of psychiatry at Mass General Hospital and Harvard Medical School, and she’s one of the authors of a new study in the journal Neuropsychopharmacology. She says that impairment and exposure are easier to correlate with alcohol. But tolerance to THC is so vastly different among different people, and the amounts that people use whether for pain or to get high are also so vastly different, that people can have detectible amounts of THC in their system, but it does not necessarily correlate with whether or not that person is too impaired to drive. Listen in to hear what she and her team did to try to detect brain impairment under the influence of THC.</p><br><p>Read the full article here: https://www.nature.com/articles/s41386-021-01259-0 </p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[<p>Driving while under the influence of THC, known as drugged driving, is becoming more of an issue as more states legalize cannabis for both medical and recreational use around the country. THC is known to impair cognitive and psychomotor performance and thus impair driving. Jodi Gilman is a neuroscientist and an associate professor of psychiatry at Mass General Hospital and Harvard Medical School, and she’s one of the authors of a new study in the journal Neuropsychopharmacology. She says that impairment and exposure are easier to correlate with alcohol. But tolerance to THC is so vastly different among different people, and the amounts that people use whether for pain or to get high are also so vastly different, that people can have detectible amounts of THC in their system, but it does not necessarily correlate with whether or not that person is too impaired to drive. Listen in to hear what she and her team did to try to detect brain impairment under the influence of THC.</p><br><p>Read the full article here: https://www.nature.com/articles/s41386-021-01259-0 </p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Evolution of prefrontal cortex </title>
			<itunes:title>Evolution of prefrontal cortex </itunes:title>
			<pubDate>Mon, 31 Jan 2022 15:42:33 GMT</pubDate>
			<itunes:duration>9:22</itunes:duration>
			<enclosure url="https://sphinx.acast.com/p/acast/s/neuropsychopharmacologypodcast/e/61f803696bb2bb0014767c02/media.mp3" length="13562402" type="audio/mpeg"/>
			<guid isPermaLink="false">61f803696bb2bb0014767c02</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://shows.acast.com/neuropsychopharmacologypodcast/episodes/evolution-of-prefrontal-cortex</link>
			<acast:episodeId>61f803696bb2bb0014767c02</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>evolution-of-prefrontal-cortex</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmfwL2jaMW9OfVjpl1A481t14TmPPNBt/QBdFV0cjQSq6O95gGg1G5VX1qUALnMwOy84DIRWdD816dQkEuoT9tdb6UmeNCcD3nvZs06QIqps9TekQMFWuP8Pd2vNj4wE/+YuVbIq3b2LcO+o27GvBqQnh4V82rodA1YQIOvlsryYXVyQF6zZ6cz3rTGy24r1KQCsrMCMzKYovSwm2mJQDKaLSjmrjfuxh7LWi3a1Xc+LvduvwjbJtvWq2VpNqw01r54ixUzW92/nZh2AC1kwHPFUxXxp47uwlrAXprmVqldJk]]></acast:settings>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[In the past, there had been a school of thought that looked at evolution linearly — that is, you could in theory draw a line among mammals as they evolved, and so, say, rodent brains would basically be less evolved primate brains. That turns out not to be true; evolution is much more like a branching tree, and each branch then goes on to develop independently, sometimes in parallel. Some groups of animals such as primates can evolve features of their brains that other groups simply don’t have. And now, with advanced DNA sequencing, scientists have been able to determine which groups of mammals are more closely related than others, and so they’ve figured out that, for instance, tree shrews and flying lemurs are more closely related to primates than rodents are. Here, we speak with Dr. Todd M. Preuss, professor of pathology at Emory University and an associate research professor at the Yerkes National Primate Research Center. Dr. Preuss is&nbsp;co-author with Steven Wise of a review article in&nbsp;<em>Neuropsychopharmacology</em>&nbsp;called “<a href="https://www.nature.com/articles/s41386-021-01076-5" rel="noopener noreferrer" target="_blank">Evolution of prefrontal cortex</a>.”&nbsp;&nbsp;Listen in!<hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[In the past, there had been a school of thought that looked at evolution linearly — that is, you could in theory draw a line among mammals as they evolved, and so, say, rodent brains would basically be less evolved primate brains. That turns out not to be true; evolution is much more like a branching tree, and each branch then goes on to develop independently, sometimes in parallel. Some groups of animals such as primates can evolve features of their brains that other groups simply don’t have. And now, with advanced DNA sequencing, scientists have been able to determine which groups of mammals are more closely related than others, and so they’ve figured out that, for instance, tree shrews and flying lemurs are more closely related to primates than rodents are. Here, we speak with Dr. Todd M. Preuss, professor of pathology at Emory University and an associate research professor at the Yerkes National Primate Research Center. Dr. Preuss is&nbsp;co-author with Steven Wise of a review article in&nbsp;<em>Neuropsychopharmacology</em>&nbsp;called “<a href="https://www.nature.com/articles/s41386-021-01076-5" rel="noopener noreferrer" target="_blank">Evolution of prefrontal cortex</a>.”&nbsp;&nbsp;Listen in!<hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Astrocyte-neuron signaling in the mesolimbic dopamine system: the hidden stars of dopamine signaling</title>
			<itunes:title>Astrocyte-neuron signaling in the mesolimbic dopamine system: the hidden stars of dopamine signaling</itunes:title>
			<pubDate>Mon, 01 Nov 2021 19:03:00 GMT</pubDate>
			<itunes:duration>9:43</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/astrocyte-neuronsignalinginthemesolimbicdopaminesystem-thehiddenstarsofdopaminesignaling/media.mp3" length="5839442" type="audio/mpeg"/>
			<guid isPermaLink="false">2dad42c7-5be5-48d9-b575-25a870d9da5b</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/astrocyte-neuronsignalinginthemesolimbicdopaminesystem-thehiddenstarsofdopaminesignaling</link>
			<acast:episodeId>2dad42c7-5be5-48d9-b575-25a870d9da5b</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>astrocyte-neuronsignalinginthemesolimbicdopaminesystem-thehiddenstarsofdopaminesignaling</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCTjSB0k789TphnkClkZ7qeQCFLayOvz5NN8fsHGSQvY2hI2/jurKveHs9UiiG8CzQ3ExZtDo2ndutmHGMPJPa9Lm09tpXB2sHGt/QzGfNBS3O0MIo+OiGUaxj6BoNeobhwVH6Xii1tkVJ5Z5y7EgwWWGZ85KueRiTlR4N7PUCdIaQBIRemdWi9HQvdPxHXyJTur57GOgt6f1q9R3NCl05tA8lxBcSMBpdbg9JWazwVrw=]]></acast:settings>
			<itunes:subtitle>Star-shaped cells called astrocytes are the most abundant cells to be found in the human brain. In the past, they’d been thought to play a supporting role to neurons, such as providing metabolic support, but recently they’re also emerging as stars of i...</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[Star-shaped cells called astrocytes are the most abundant cells to be found in the human brain. In the past, they’d been thought to play a supporting role to neurons, such as providing metabolic support, but recently they’re also emerging as stars of information processing. They can respond to neurotransmitters and release neuroactive substances that then affect synaptic transmission and plasticity. Michelle Corkrum is a child neurology resident at Columbia University and is one of the authors of a recent review paper on the links between astrocytes and dopamine signalling. The review looks back at the history of research in this field, going back decades. Listen in to learn more!&nbsp;<hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[Star-shaped cells called astrocytes are the most abundant cells to be found in the human brain. In the past, they’d been thought to play a supporting role to neurons, such as providing metabolic support, but recently they’re also emerging as stars of information processing. They can respond to neurotransmitters and release neuroactive substances that then affect synaptic transmission and plasticity. Michelle Corkrum is a child neurology resident at Columbia University and is one of the authors of a recent review paper on the links between astrocytes and dopamine signalling. The review looks back at the history of research in this field, going back decades. Listen in to learn more!&nbsp;<hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Neurobiology of loneliness: a systematic review</title>
			<itunes:title>Neurobiology of loneliness: a systematic review</itunes:title>
			<pubDate>Mon, 13 Sep 2021 19:11:12 GMT</pubDate>
			<itunes:duration>8:11</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/neurobiologyofloneliness-asystematicreview/media.mp3" length="5900674" type="audio/mpeg"/>
			<guid isPermaLink="false">87e3c26b-1b6b-4843-a32f-336e33dd15d4</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/neurobiologyofloneliness-asystematicreview</link>
			<acast:episodeId>87e3c26b-1b6b-4843-a32f-336e33dd15d4</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>neurobiologyofloneliness-asystematicreview</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzC+ZR5AoFFZEd1y6FmPl+I5RolPm8MqQrbVNVE+mzOl/lUcFYiA6z4jlC93HuxsKpM5V+Qd7Z+8Oqb415SnpQK2CBJgqnzowS0asvKbOUqUmqFv8zusxMAROpFcQRQ4zG5562EaIPuomsvTvbCbZ2O6swVCGwlX1XBJJAJlORGhn06HAb5XgIDkbnmxQobLsU09BjZPtzaABM59TadgxpGXEHNnTfVbLMakZOrY2BAPVg=]]></acast:settings>
			<itunes:subtitle>Loneliness is a subjective experience, but neuroscientists define it as a distress that arrives from a discrepancy between perceived and desired social relationships. There may be an evolutionary benefit to the feeling of loneliness; we’re a social spe...</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[<p>Loneliness is a subjective experience, but neuroscientists define it as a distress that arrives from a discrepancy between perceived and desired social relationships. There may be an evolutionary benefit to the feeling of loneliness; we’re a social species, and feeling lonely might have sent us to seek out other humans, which has been very important for survival. Moreover, if gone unaddressed and isolation worsens, health effects of loneliness have been shown to double mortality rates. It's linked to cardiovascular disease, metabolic disease, cognitive decline, higher rates of dementia, and poor mental health outcomes (i.e. depression and anxiety).</p><br><p>With loneliness implicated in so many cognitive impacts, Dr. Lee and her colleagues wanted to understand what is known to date about the impact of loneliness on the brain. They conducted a systematic review of the published research that examines loneliness and resulting neurobiological assessments, such as imaging studies, EEG studies, and pathological studies.&nbsp;Listen in and read to learn more!</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[<p>Loneliness is a subjective experience, but neuroscientists define it as a distress that arrives from a discrepancy between perceived and desired social relationships. There may be an evolutionary benefit to the feeling of loneliness; we’re a social species, and feeling lonely might have sent us to seek out other humans, which has been very important for survival. Moreover, if gone unaddressed and isolation worsens, health effects of loneliness have been shown to double mortality rates. It's linked to cardiovascular disease, metabolic disease, cognitive decline, higher rates of dementia, and poor mental health outcomes (i.e. depression and anxiety).</p><br><p>With loneliness implicated in so many cognitive impacts, Dr. Lee and her colleagues wanted to understand what is known to date about the impact of loneliness on the brain. They conducted a systematic review of the published research that examines loneliness and resulting neurobiological assessments, such as imaging studies, EEG studies, and pathological studies.&nbsp;Listen in and read to learn more!</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Medial orbitofrontal cortex dopamine D1/D2 receptors differentially modulate distinct forms of probabilistic decision-making</title>
			<itunes:title>Medial orbitofrontal cortex dopamine D1/D2 receptors differentially modulate distinct forms of probabilistic decision-making</itunes:title>
			<pubDate>Tue, 20 Jul 2021 15:06:05 GMT</pubDate>
			<itunes:duration>8:58</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/medialorbitofrontalcortexdopamined1-d2receptorsdifferentiallymodulatedistinctformsofprobabilisticdecision-making/media.mp3" length="6458971" type="audio/mpeg"/>
			<guid isPermaLink="false">5248b0fe-f590-4437-a585-3ebe66bf57c6</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/medialorbitofrontalcortexdopamined1-d2receptorsdifferentiallymodulatedistinctformsofprobabilisticdecision-making</link>
			<acast:episodeId>5248b0fe-f590-4437-a585-3ebe66bf57c6</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>medialorbitofrontalcortexdopamined1-d2receptorsdifferentiallymodulatedistinctformsofprobabilisticdecision-making</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCxiSHBeZcdbKLQ3NKjPppxf+dHnhWcedjKVll5p6rAbDg3VxbaQ425emKazGrV7q4VRMTpKc+nMJiQwdyofIN1coFWaS3xLRegm3dBiQ9XQnmCb+OAq+gMwh1QCJJXoZUdsu1Y+c0JZ5uQA6xXZlGsEAIwPOilRQFFZ1DvNF2OXIyOs2tK8nJzBPIDECAFsuXTYT4ZlKwu9hfny8XjWjuhzFqwXGj+jajiUI7dkfShHE=]]></acast:settings>
			<itunes:subtitle>It’s known that dopamine transmission in the brain, particularly in the frontal lobes, can affect decision-making and can regulate choices when it comes to actions and rewards. But the effect of dopamine transition in the medial orbital frontal cortex ...</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[It’s known that dopamine transmission in the brain, particularly in the frontal lobes, can affect decision-making and can regulate choices when it comes to actions and rewards. But the effect of dopamine transition in the medial orbital frontal cortex hasn’t yet been studied, and dysfunction in that region has been implicated in a variety of mental illnesses, including obsessive compulsive disorder, certain kinds of depression, and even schizophrenia. And so a team of researchers led by Stan Floresco, professor of psychology at the University of British Columbia, used a rat model to study the effects of dopamine on two receptors in the region, D1 and D2. To do so, they trained the rats on two games that involved decision-making, and then they infused drugs, one an agonist and one an antagonist, to the brain region. Have a listen!<hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[It’s known that dopamine transmission in the brain, particularly in the frontal lobes, can affect decision-making and can regulate choices when it comes to actions and rewards. But the effect of dopamine transition in the medial orbital frontal cortex hasn’t yet been studied, and dysfunction in that region has been implicated in a variety of mental illnesses, including obsessive compulsive disorder, certain kinds of depression, and even schizophrenia. And so a team of researchers led by Stan Floresco, professor of psychology at the University of British Columbia, used a rat model to study the effects of dopamine on two receptors in the region, D1 and D2. To do so, they trained the rats on two games that involved decision-making, and then they infused drugs, one an agonist and one an antagonist, to the brain region. Have a listen!<hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Addiction as a brain disease revised: why it still matters, and the need for consilience</title>
			<itunes:title>Addiction as a brain disease revised: why it still matters, and the need for consilience</itunes:title>
			<pubDate>Fri, 21 May 2021 04:00:00 GMT</pubDate>
			<itunes:duration>9:54</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/addictionasabraindiseaserevised-whyitstillmatters-andtheneedforconsilience/media.mp3" length="7132926" type="audio/mpeg"/>
			<guid isPermaLink="false">880dfd6b-044a-4608-9477-2ba97d983448</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/addictionasabraindiseaserevised-whyitstillmatters-andtheneedforconsilience</link>
			<acast:episodeId>880dfd6b-044a-4608-9477-2ba97d983448</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>addictionasabraindiseaserevised-whyitstillmatters-andtheneedforconsilience</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCcxMg1JMj6XZptM1ySP4BccNzAVHT8BO86mfjCYxxROEXcx1fOV9Z8UM39Mz5bdYxctKv2YEAlSrY2MhqLsCMT1PNK8M9XlWuf/+YXk1MCKUdJ83QTHx26Ze//FTzZv5J63h+enfNf73Sn+lSh7oc5l5Wq/gFEht9yGH+IZYzTw5rslMtrJO/rHh8uSMluzaj8xEMRAKx7BRGS2cIHeTWyAyGqE8thunKyNzna1b+psk=]]></acast:settings>
			<itunes:subtitle>Nearly 25 years ago, a paper was published about addiction that transformed the field. The director of the US National Institute on Drug Abuse at the time called addiction a “brain disease,” and he wrote a paper articulating this position and the agend...</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[Nearly 25 years ago, a paper was published about addiction that transformed the field. The director of the US National Institute on Drug Abuse at the time called addiction a “brain disease,” and he wrote a paper articulating this position and the agenda that it implied. It led to a focus on researching the brain to understand the mechanisms behind addiction, which could lead to novel treatments. And it meant that the country began to treat addiction as a disease, thus treating it within the medical system and removing the victim-blaming stigma. Over the years, there has been a pushback against the view of addiction as a brain disease, even within the scientific community. In part, this occurred because research in neuroscience didn’t lead to effective treatments as quickly as the field hoped or promised. And in part, says Markus Heilig, it’s because other researchers felt that funding into the neuroscience of addition meant that other relevant mechanisms, such as social and psychological factors, were perhaps being somewhat neglected. Dr. Heilig and his colleagues recently published a review addressing these and other concerns. Listen in to learn more!<hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[Nearly 25 years ago, a paper was published about addiction that transformed the field. The director of the US National Institute on Drug Abuse at the time called addiction a “brain disease,” and he wrote a paper articulating this position and the agenda that it implied. It led to a focus on researching the brain to understand the mechanisms behind addiction, which could lead to novel treatments. And it meant that the country began to treat addiction as a disease, thus treating it within the medical system and removing the victim-blaming stigma. Over the years, there has been a pushback against the view of addiction as a brain disease, even within the scientific community. In part, this occurred because research in neuroscience didn’t lead to effective treatments as quickly as the field hoped or promised. And in part, says Markus Heilig, it’s because other researchers felt that funding into the neuroscience of addition meant that other relevant mechanisms, such as social and psychological factors, were perhaps being somewhat neglected. Dr. Heilig and his colleagues recently published a review addressing these and other concerns. Listen in to learn more!<hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Big data in psychiatry: multiomics, neuroimaging, computational modeling, and digital phenotyping</title>
			<itunes:title>Big data in psychiatry: multiomics, neuroimaging, computational modeling, and digital phenotyping</itunes:title>
			<pubDate>Fri, 19 Mar 2021 04:00:00 GMT</pubDate>
			<itunes:duration>9:51</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/bigdatainpsychiatry-multiomics-neuroimaging-computationalmodeling-anddigitalphenotyping/media.mp3" length="7102204" type="audio/mpeg"/>
			<guid isPermaLink="false">3831eac9-4fe6-4b67-9167-2129099bb83c</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/bigdatainpsychiatry-multiomics-neuroimaging-computationalmodeling-anddigitalphenotyping</link>
			<acast:episodeId>3831eac9-4fe6-4b67-9167-2129099bb83c</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>bigdatainpsychiatry-multiomics-neuroimaging-computationalmodeling-anddigitalphenotyping</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCdC1EP71CIdvYaDwZpCoGF1AcbfyhI3Nq1tEUyz39Ai8+G0++y76Kx+NcueEUKmCYODIeDKeOyaCCNCf6/tLcivf5NlRBkTgavimN6lLetfep7WhTggdrYc1+syhupbSWFeE9pT6sHXEETrPa/E/TNyi2pI1eY2tm/XxnLnKQ8ll8qz4AK9MTwylx/hsCG2bKs4O/B3ma26DhiDe7dO4bX9rLa68FVGXVLnTr0wvhA88=]]></acast:settings>
			<itunes:subtitle>The world of medicine has been changing rapidly due to the increasing use of ‘big data.’ And there’s been a major revolution in this approach in neuroscience and psychiatry as well: computing power, sample sizes, neuroimaging technologies, digital appr...</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[The world of medicine has been changing rapidly due to the increasing use of ‘big data.’ And there’s been a major revolution in this approach in neuroscience and psychiatry as well: computing power, sample sizes, neuroimaging technologies, digital approaches to phenotyping, and computational modeling all are already starting to unleash dramatic new understandings of the brain, as well as new approaches to treatment. And so the journal <em>Neuropsychopharmacology</em> recently published a Reviews issue on the topic of Big Data. Kerry Ressler, chief scientific officer at McLean hospital and professor of psychiatry at Harvard medical school, is one of the editors.<hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[The world of medicine has been changing rapidly due to the increasing use of ‘big data.’ And there’s been a major revolution in this approach in neuroscience and psychiatry as well: computing power, sample sizes, neuroimaging technologies, digital approaches to phenotyping, and computational modeling all are already starting to unleash dramatic new understandings of the brain, as well as new approaches to treatment. And so the journal <em>Neuropsychopharmacology</em> recently published a Reviews issue on the topic of Big Data. Kerry Ressler, chief scientific officer at McLean hospital and professor of psychiatry at Harvard medical school, is one of the editors.<hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects</title>
			<itunes:title>Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects</itunes:title>
			<pubDate>Tue, 19 Jan 2021 19:20:56 GMT</pubDate>
			<itunes:duration>9:44</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/acutedose-dependenteffectsoflysergicaciddiethylamideinadouble-blindplacebo-controlledstudyinhealthysubjects/media.mp3" length="7010990" type="audio/mpeg"/>
			<guid isPermaLink="false">1ae96b21-a327-4e5f-9373-a2954cfd2c2c</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/acutedose-dependenteffectsoflysergicaciddiethylamideinadouble-blindplacebo-controlledstudyinhealthysubjects</link>
			<acast:episodeId>1ae96b21-a327-4e5f-9373-a2954cfd2c2c</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>acutedose-dependenteffectsoflysergicaciddiethylamideinadouble-blindplacebo-controlledstudyinhealthysubjects</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCOfZJW7fEx1TeovfBd78bQHo18GOchaAAN72NNhATTAisUCIo5mKZyOeB8k4CoI/eZYt5RPUSxwWicEuqo0gTDrUu73/b4Ww8xTaYDiPNdPr/JRpH7CyXBW03h/lPmqLifmpTOM65qgZT/QIp+8RqgXuKa7EQHkpAZyFrRKy5t51lCAsAXB4RrZPBXEJN09CJ3F49tgRPFHWDSeT8Q/fd6Gg6mFTpufTb1u8vMgk2zS8=]]></acast:settings>
			<itunes:subtitle>Interest is growing in the use of the psychedelic drug LSD for psychiatric research and even potentially for treatment. But placebo-controlled studies conducted to date have used just one dose of the drug—none have investigated the impacts of a variety...</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[Interest is growing in the use of the psychedelic drug LSD for psychiatric research and even potentially for treatment. But placebo-controlled studies conducted to date have used just one dose of the drug—none have investigated the impacts of a variety of dosages within the same subjects. In addition, past studies did not use pharmaceutically-defined dosages of LSD, which has made verifying the effects of a particular dose difficult. To address this gap, Matthias Liechti, professor in the department of clinical pharmacology and toxicology at the University of Basel in Switzerland, and his colleagues conducted a study.<hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[Interest is growing in the use of the psychedelic drug LSD for psychiatric research and even potentially for treatment. But placebo-controlled studies conducted to date have used just one dose of the drug—none have investigated the impacts of a variety of dosages within the same subjects. In addition, past studies did not use pharmaceutically-defined dosages of LSD, which has made verifying the effects of a particular dose difficult. To address this gap, Matthias Liechti, professor in the department of clinical pharmacology and toxicology at the University of Basel in Switzerland, and his colleagues conducted a study.<hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Big behavior: challenges and opportunities in a new era of deep behavior profiling</title>
			<itunes:title>Big behavior: challenges and opportunities in a new era of deep behavior profiling</itunes:title>
			<pubDate>Wed, 04 Nov 2020 05:00:00 GMT</pubDate>
			<itunes:duration>9:31</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/bigbehavior-challengesandopportunitiesinaneweraofdeepbehaviorprofiling/media.mp3" length="6860211" type="audio/mpeg"/>
			<guid isPermaLink="false">7636df7f-6c8d-49ec-ab8c-911ac571e659</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/bigbehavior-challengesandopportunitiesinaneweraofdeepbehaviorprofiling</link>
			<acast:episodeId>7636df7f-6c8d-49ec-ab8c-911ac571e659</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>bigbehavior-challengesandopportunitiesinaneweraofdeepbehaviorprofiling</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCeJVd8UVYKZpG5bAx7bn4KQ0OU4RFIDL0csg8lEMhztQOenvE7aWWrs5Rtm2iEwFmw5i/CR09agS1+QxfVQP+zKUpNq5Qw7ihD79KJEzfnScqbS1ZSNWCEwZW5myzPGFJENziSa0NESdJ8AOBvCCopqbVvg7Nkbq3qRqPublLc5IDASmXQogiurcok7ugiZFjI=]]></acast:settings>
			<itunes:subtitle>Scientists who study neuropsychiatric conditions and treatments often use rodent models to do so. From depression to anxiety to memory impairment and impulsivity, there are certain rodent behaviors that are used to represent these types of conditions i...</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[Scientists who study neuropsychiatric conditions and treatments often use rodent models to do so. From depression to anxiety to memory impairment and impulsivity, there are certain rodent behaviors that are used to represent these types of conditions in humans. And to use these models, researchers have had to watch the animals live or on video and jot down every instance of, say, exploratory behavior. As the process is labor intensive and results vary slightly from researcher to researcher, Dr. Bohacheck and his colleagues created a new system based on machine learning, and they published the results of their study in the journal <em>Neuropsychopharmacology</em>, along with a review of the field.&nbsp;<hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[Scientists who study neuropsychiatric conditions and treatments often use rodent models to do so. From depression to anxiety to memory impairment and impulsivity, there are certain rodent behaviors that are used to represent these types of conditions in humans. And to use these models, researchers have had to watch the animals live or on video and jot down every instance of, say, exploratory behavior. As the process is labor intensive and results vary slightly from researcher to researcher, Dr. Bohacheck and his colleagues created a new system based on machine learning, and they published the results of their study in the journal <em>Neuropsychopharmacology</em>, along with a review of the field.&nbsp;<hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Leveraging large genomic datasets to illuminate the pathobiology of autism spectrum disorders</title>
			<itunes:title>Leveraging large genomic datasets to illuminate the pathobiology of autism spectrum disorders</itunes:title>
			<pubDate>Wed, 23 Sep 2020 04:00:00 GMT</pubDate>
			<itunes:duration>9:49</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/leveraginglargegenomicdatasetstoilluminatethepathobiologyofautismspectrumdisorders/media.mp3" length="7074308" type="audio/mpeg"/>
			<guid isPermaLink="false">1306cb79-f2ac-47e2-a216-52dd170788e6</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/leveraginglargegenomicdatasetstoilluminatethepathobiologyofautismspectrumdisorders</link>
			<acast:episodeId>1306cb79-f2ac-47e2-a216-52dd170788e6</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>leveraginglargegenomicdatasetstoilluminatethepathobiologyofautismspectrumdisorders</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCcmHsLCf3FrPtdNbXohBwcPTKsmP/ViDC8IJDRw+W3mapG4LvF+RNAx/CKhG1nl6OyDGQ2eTB/WYoCw1zMlQCOdATScgO8ZTSZrQB0wYpOd3LL2ipPf7ZYP4AXXn0k2R+5H6olYquWO4epsVodDcP2bCMZNur379Xq9/g5/APnqsMHrRF3o+QLB+ZPqSufKB/k=]]></acast:settings>
			<itunes:subtitle>The application of the study of genetics and the use of big data to identify patterns of inheritance as well as de novo mutations has had a dramatic impact on the field of Autism Spectrum Disorder research, and it offers pathways to a greater understan...</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[The application of the study of genetics and the use of big data to identify patterns of inheritance as well as de novo mutations has had a dramatic impact on the field of Autism Spectrum Disorder research, and it offers pathways to a greater understanding of biological mechanisms, even potentially treatments. Matthew State, chair of the department of psychiatry at University of California San Francisco, and his colleagues wrote a review paper in the journal <em>Neuropsychopharmacology</em>, called “Leveraging large genomic datasets to illuminate the pathobiology of autism spectrum disorders.” Have a listen to learn more!<hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[The application of the study of genetics and the use of big data to identify patterns of inheritance as well as de novo mutations has had a dramatic impact on the field of Autism Spectrum Disorder research, and it offers pathways to a greater understanding of biological mechanisms, even potentially treatments. Matthew State, chair of the department of psychiatry at University of California San Francisco, and his colleagues wrote a review paper in the journal <em>Neuropsychopharmacology</em>, called “Leveraging large genomic datasets to illuminate the pathobiology of autism spectrum disorders.” Have a listen to learn more!<hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Pubertal adversity alters chromatin dynamics and stress circuitry in the pregnant brain</title>
			<itunes:title>Pubertal adversity alters chromatin dynamics and stress circuitry in the pregnant brain</itunes:title>
			<pubDate>Fri, 10 Jul 2020 14:15:40 GMT</pubDate>
			<itunes:duration>9:28</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/pubertaladversityalterschromatindynamicsandstresscircuitryinthepregnantbrain/media.mp3" length="6821334" type="audio/mpeg"/>
			<guid isPermaLink="false">2bb2fe09-2517-4bc1-95ab-82ae080b199f</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/pubertaladversityalterschromatindynamicsandstresscircuitryinthepregnantbrain</link>
			<acast:episodeId>2bb2fe09-2517-4bc1-95ab-82ae080b199f</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>pubertaladversityalterschromatindynamicsandstresscircuitryinthepregnantbrain</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCgwwC4xwJj0JiJS5/H5lolRZfwt+W1iFgh7BUWAdgtLKL0Vb2MubMQi1Je5kzZP9SMiikGM2bfk8wmI1TU0+LhxbeZ7Fw5sg5neLACLEcMdC3zCvX+i0V28IDYfMfCo/V11BNuBLSPE1JpHCEw4G+ecrW1YTHx4UCz+cDGpybqD8kYpnAC8SdYVqat+5oMg9Y34dZDrtewSxWsJNhPMc08bRcWl44ksl1biFuUSd5m6U=]]></acast:settings>
			<itunes:subtitle>It’s understood in epidemiological research that women who experience trauma during puberty are at significantly higher risk for affective disorders such as depression and anxiety when they become pregnant. And so Tracy Bale, a professor in the departm...</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[It’s understood in epidemiological research that women who experience trauma during puberty are at significantly higher risk for affective disorders such as depression and anxiety when they become pregnant. And so Tracy Bale, a professor in the departments of psychology and psychiatry at the University of Maryland in Baltimore, has done several studies using mice to try to model and understand this effect. In her latest paper in the journal&nbsp;<em>Neuropsychopharmacology</em>, she and her colleagues set out to study just what was happening to make the mouse brain so vulnerable to stress and trauma during puberty, and how this was activated during the hormonal onslaught of pregnancy.<hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[It’s understood in epidemiological research that women who experience trauma during puberty are at significantly higher risk for affective disorders such as depression and anxiety when they become pregnant. And so Tracy Bale, a professor in the departments of psychology and psychiatry at the University of Maryland in Baltimore, has done several studies using mice to try to model and understand this effect. In her latest paper in the journal&nbsp;<em>Neuropsychopharmacology</em>, she and her colleagues set out to study just what was happening to make the mouse brain so vulnerable to stress and trauma during puberty, and how this was activated during the hormonal onslaught of pregnancy.<hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Social networking and mental health: looking beyond frequency of use and towards mechanisms of action</title>
			<itunes:title>Social networking and mental health: looking beyond frequency of use and towards mechanisms of action</itunes:title>
			<pubDate>Fri, 15 May 2020 04:00:00 GMT</pubDate>
			<itunes:duration>9:32</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/socialnetworkingandmentalhealth-lookingbeyondfrequencyofuseandtowardsmechanismsofaction/media.mp3" length="6868980" type="audio/mpeg"/>
			<guid isPermaLink="false">02f9f9e9-192a-4848-9309-7970b5d01b0b</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/socialnetworkingandmentalhealth-lookingbeyondfrequencyofuseandtowardsmechanismsofaction</link>
			<acast:episodeId>02f9f9e9-192a-4848-9309-7970b5d01b0b</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>socialnetworkingandmentalhealth-lookingbeyondfrequencyofuseandtowardsmechanismsofaction</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCfqh+gEzZiB25jOGoiQYldopINaP2i6Aw3CL2YlZYnBw8DoASAQ4YEnUa1sBYOlO4CybGoU3qa82ckXyXLLWwf9nfyhBAzwXfpwrrOpnQMGX1BRzjtLtMxVtaWD94NBE/J0B3M92lBqToTPaEv/9szducqiHrgB042NlMULTYYynNJoIg2dILnhDNwzvDDgDnY=]]></acast:settings>
			<itunes:subtitle>Over the past decades, there’s clearly been a dramatic increase in the amount of time people spend online using social networking sites. For instance, Facebook and Instagram have literally billions of users. At the same time, there’s been a rise in men...</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[Over the past decades, there’s clearly been a dramatic increase in the amount of time people spend online using social networking sites. For instance, Facebook and Instagram have literally billions of users. At the same time, there’s been a rise in mental health issues for young people from teens through their mid 20s. The rise in these issues has been seen particularly for Millennials and the I generation, both of which grew up with increased access to and use of social networking sites. As a result, some have drawn the conclusion that perhaps the two are linked, and the rise in mental health issues is linked causally to the increase in time spent online, and so treatment should involve reducing social networking use. Dr. Kiara Timpano, associate professor at the University of Miami department of psychology, and Dr. Courtney Beard, co-director of the clinical research program in behavioral health at McLean Hospital and associate professor of psychiatry at Harvard Medical School, reviewed the literature.<hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[Over the past decades, there’s clearly been a dramatic increase in the amount of time people spend online using social networking sites. For instance, Facebook and Instagram have literally billions of users. At the same time, there’s been a rise in mental health issues for young people from teens through their mid 20s. The rise in these issues has been seen particularly for Millennials and the I generation, both of which grew up with increased access to and use of social networking sites. As a result, some have drawn the conclusion that perhaps the two are linked, and the rise in mental health issues is linked causally to the increase in time spent online, and so treatment should involve reducing social networking use. Dr. Kiara Timpano, associate professor at the University of Miami department of psychology, and Dr. Courtney Beard, co-director of the clinical research program in behavioral health at McLean Hospital and associate professor of psychiatry at Harvard Medical School, reviewed the literature.<hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects</title>
			<itunes:title>Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects</itunes:title>
			<pubDate>Fri, 06 Mar 2020 21:47:35 GMT</pubDate>
			<itunes:duration>9:07</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/distinctacuteeffectsoflsd-mdma-andd-amphetamineinhealthysubjects/media.mp3" length="6567738" type="audio/mpeg"/>
			<guid isPermaLink="false">ccf20439-bc26-4bf2-8f0a-9717f653029b</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/distinctacuteeffectsoflsd-mdma-andd-amphetamineinhealthysubjects</link>
			<acast:episodeId>ccf20439-bc26-4bf2-8f0a-9717f653029b</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>distinctacuteeffectsoflsd-mdma-andd-amphetamineinhealthysubjects</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCUOee3soQoX1BH3fBboxj1XeEubH9I4x4WwJFnUsgjPvNRgB6LmyjjDqKJZPyzFuaQ5Y7y6R/i8U87rfQMiuJV50gZkep96cQsGrVA7URYH8/pl8vWOpxg2ZarjPjyBT7r9+dATmnrf/9qHizGyEZGlBobcH2kmjvb+T/GfgvQrTOHy6WEkPC8hLZddSK7fPTwfcQb4IY31pWTH38Ua7EMgblP7ROBZOHaKDN/oNWIjE=]]></acast:settings>
			<itunes:subtitle>A number of drugs that are used recreationally are now being studied for their use in psychopharmacology. But while the ways in which these drugs are similar or different has been described anecdotally by recreational users, they haven’t been studied i...</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[A number of drugs that are used recreationally are now being studied for their use in psychopharmacology. But while the ways in which these drugs are similar or different has been described anecdotally by recreational users, they haven’t been studied in comparison to one another.&nbsp;Dr. Matthias Liechti&nbsp;and his team of researchers recently published a study in the journal <em>Neuropsychopharmacology</em>, in which 28 healthy subjects, men and women, take doses of LSD, MDMA, amphetamines, and a placebo over four different sessions. Dr. Liechti says this blinding is important; in other studies, participants either have taken a drug or a placebo and can tell when they’re taking the drug. But in this case they don’t know which drug they’re taking, which allows the effects of the drugs to be compared against each other. Take a listen to find out more!<hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[A number of drugs that are used recreationally are now being studied for their use in psychopharmacology. But while the ways in which these drugs are similar or different has been described anecdotally by recreational users, they haven’t been studied in comparison to one another.&nbsp;Dr. Matthias Liechti&nbsp;and his team of researchers recently published a study in the journal <em>Neuropsychopharmacology</em>, in which 28 healthy subjects, men and women, take doses of LSD, MDMA, amphetamines, and a placebo over four different sessions. Dr. Liechti says this blinding is important; in other studies, participants either have taken a drug or a placebo and can tell when they’re taking the drug. But in this case they don’t know which drug they’re taking, which allows the effects of the drugs to be compared against each other. Take a listen to find out more!<hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Chronic opioid pretreatment potentiates the sensitization of fear learning by trauma</title>
			<itunes:title>Chronic opioid pretreatment potentiates the sensitization of fear learning by trauma</itunes:title>
			<pubDate>Fri, 17 Jan 2020 15:25:51 GMT</pubDate>
			<itunes:duration>9:18</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/chronicopioidpretreatmentpotentiatesthesensitizationoffearlearningbytrauma/media.mp3" length="6700020" type="audio/mpeg"/>
			<guid isPermaLink="false">8886961d-de1c-4fe7-909f-7395bdf64e09</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/chronicopioidpretreatmentpotentiatesthesensitizationoffearlearningbytrauma</link>
			<acast:episodeId>8886961d-de1c-4fe7-909f-7395bdf64e09</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>chronicopioidpretreatmentpotentiatesthesensitizationoffearlearningbytrauma</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCedoszhrsfA5SCzkfKkdmrUp4tKSxrpd3a9RPc5dPkYC/z5H5poly9GbglpEvSCFH3RRmWA62L6qfpQbWcnwQAR0kr1KmSdnXS6RH8LDPbKaiTO6w/yeabaAxAPdR43p1z+pN4SrpijZnmAh3xa9jso2gog4bL85+wBEhTWsWsaOW1v3vr/QiflcLv5+BpEkL4=]]></acast:settings>
			<itunes:subtitle>It’s known that there’s a relationship between post-traumatic stress disorder, or PTSD, and a higher rate of opioid abuse. What isn’t understood, though, is what that relationship is. Does PTSD cause people to turn to opioids in particular among all th...</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[<p>It’s known that there’s a relationship between post-traumatic stress disorder, or PTSD, and a higher rate of opioid abuse. What isn’t understood, though, is what that relationship is. Does PTSD cause people to turn to opioids in particular among all the potential drugs of abuse, or is there something about opioid use that makes users particularly sensitive to trauma?</p><br><p>This is just what Michael Fanselow, professor in the psychology and psychiatry departments at UCLA, and his colleagues investigated for a recent study in the journal <em>Neuropsychopharmacology.</em></p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[<p>It’s known that there’s a relationship between post-traumatic stress disorder, or PTSD, and a higher rate of opioid abuse. What isn’t understood, though, is what that relationship is. Does PTSD cause people to turn to opioids in particular among all the potential drugs of abuse, or is there something about opioid use that makes users particularly sensitive to trauma?</p><br><p>This is just what Michael Fanselow, professor in the psychology and psychiatry departments at UCLA, and his colleagues investigated for a recent study in the journal <em>Neuropsychopharmacology.</em></p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Effects of MDMA on attention to positive social cues and pleasantness of affective touch.</title>
			<itunes:title>Effects of MDMA on attention to positive social cues and pleasantness of affective touch.</itunes:title>
			<pubDate>Thu, 19 Sep 2019 14:47:36 GMT</pubDate>
			<itunes:duration>9:34</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/effectsofmdmaonattentiontopositivesocialcuesandpleasantnessofaffectivetouch-/media.mp3" length="13785373" type="audio/mpeg"/>
			<guid isPermaLink="false">ABD59A5B-86F2-479D-BA1A-B8454E4D4F0F</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/effectsofmdmaonattentiontopositivesocialcuesandpleasantnessofaffectivetouch-</link>
			<acast:episodeId>c4ae3fcc-e5fc-49f4-8cd1-6f77d13cc464</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>effectsofmdmaonattentiontopositivesocialcuesandpleasantnessofaffectivetouch-</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCcYzJKsr3XnzLE1lNZV04EabAfb5giydZdqI6utpVB6nEhsXbybJVCeObu6kdSsUV2g68ymzthd6s+mEbFCuMoU3Kg2j1qtibj6HvB/uBKToX7fubrqcV662ZB8IA33lBhoevNv2YuA26ON8kfWlIHbmBgoVyVfFm5lDSuRD9SW/yrORdGFGOWWdygdv7LMRng=]]></acast:settings>
			<itunes:subtitle>Effects of MDMA on attention to positive social cues and pleasantness of affective touch.</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[The recreational drug MDMA, also known as Ecstasy or Molly, is particularly popular in social settings and raves, in large part because of how socially connected it makes the users feel. It's being studied for use in psychotherapy — there's a phase III clinical trial for the use of MDMA to treat PTSD. What's clear is that the drug affects how users experience social interactions. But there are questions: Does the drug make positive social interactions feel better, or reduce the negative feelings associated with negative social interactions?<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/Ca9pUqvutC8" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[The recreational drug MDMA, also known as Ecstasy or Molly, is particularly popular in social settings and raves, in large part because of how socially connected it makes the users feel. It's being studied for use in psychotherapy — there's a phase III clinical trial for the use of MDMA to treat PTSD. What's clear is that the drug affects how users experience social interactions. But there are questions: Does the drug make positive social interactions feel better, or reduce the negative feelings associated with negative social interactions?<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/Ca9pUqvutC8" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Superolateral medial forebrain bundle deep brain stimulation in major depression: a gateway trial.</title>
			<itunes:title>Superolateral medial forebrain bundle deep brain stimulation in major depression: a gateway trial.</itunes:title>
			<pubDate>Tue, 16 Jul 2019 14:47:36 GMT</pubDate>
			<itunes:duration>9:34</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/superolateralmedialforebrainbundledeepbrainstimulationinmajordepression-agatewaytrial-/media.mp3" length="13785373" type="audio/mpeg"/>
			<guid isPermaLink="false">GGD59A5B-86F2-479D-BA1A-B8454E4D4F0F</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/superolateralmedialforebrainbundledeepbrainstimulationinmajordepression-agatewaytrial-</link>
			<acast:episodeId>ea444dab-ac0a-4285-be8d-a630df999c0a</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>superolateralmedialforebrainbundledeepbrainstimulationinmajordepression-agatewaytrial-</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCbqpJE2IcE1FrchVLaFyfy9OR8u09dUAmYm31A5Y1Ztdw5R39+j0PWyuH68gOfSwr4S8SEi3Ita6MCSTp7s/Swm2WiHPg6vv4YU43ZWe8a7WgZfNhbDnh+CUbLIMTuxIWnoZZETzdL1GKRWUWRZLeLWGsCJOcBQYL21+JdwyBl1FpwP+uVicJdAnmTmnpqNLfw+NsRmFQKexNP2kvRoN67bmcqBCPplBNyplW8FdK1WE=]]></acast:settings>
			<itunes:subtitle>Superolateral medial forebrain bundle deep brain stimulation in major depression: a gateway trial.</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[Depression is an incredibly important disorder—according to Thomas Schlaepfer, head of the department of interventional biological psychiatry at the University of Freiburg, at least 20 percent of people have a depressive episode at least once in their lives. And while most patients' symptoms improve with a combination of psychotherapy and medicine, up to 20 percent of depressed patients do not improve from existing treatments. Dr. Schlaepfer and his colleagues have been conducting research on deep brain stimulation, in which implanted electrodes automatically deliver electrical impulses to a particular region of the brain. Have a listen to learn more!<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/zimJE92fb60" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[Depression is an incredibly important disorder—according to Thomas Schlaepfer, head of the department of interventional biological psychiatry at the University of Freiburg, at least 20 percent of people have a depressive episode at least once in their lives. And while most patients' symptoms improve with a combination of psychotherapy and medicine, up to 20 percent of depressed patients do not improve from existing treatments. Dr. Schlaepfer and his colleagues have been conducting research on deep brain stimulation, in which implanted electrodes automatically deliver electrical impulses to a particular region of the brain. Have a listen to learn more!<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/zimJE92fb60" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Cues play a critical role in estrous cycle-dependent enhancement of cocaine reinforcement</title>
			<itunes:title>Cues play a critical role in estrous cycle-dependent enhancement of cocaine reinforcement</itunes:title>
			<pubDate>Fri, 17 May 2019 14:47:36 GMT</pubDate>
			<itunes:duration>9:34</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/cuesplayacriticalroleinestrouscycle-dependentenhancementofcocainereinforcement/media.mp3" length="13785373" type="audio/mpeg"/>
			<guid isPermaLink="false">FFD59A5B-86F2-479D-BA1A-B8454E4D4F0F</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/cuesplayacriticalroleinestrouscycle-dependentenhancementofcocainereinforcement</link>
			<acast:episodeId>9703c19b-147f-463d-a451-263b7309e02d</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>cuesplayacriticalroleinestrouscycle-dependentenhancementofcocainereinforcement</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCcYzJKsr3XnzLE1lNZV04EabAfb5giydZdqI6utpVB6nEhsXbybJVCeObu6kdSsUV2g68ymzthd6s+mEbFCuMoU3Kg2j1qtibj6HvB/uBKToX7fubrqcV662ZB8IA33lBhoevNv2YuA26ON8kfWlIHbo92okJk6sIuoXzDLB1qZvFYegd5ZiY9oSIQqCLwOENQ=]]></acast:settings>
			<itunes:subtitle>Cues play a critical role in estrous cycle-dependent enhancement of cocaine reinforcement</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[Research has demonstrated that, overall, women are more vulnerable to drug addiction than men are. They become addicted more quickly after first using, they have a harder time staying off drugs, and they relapse at higher rates. But most studies have focused on men, and models that have been developed nearly entirely focus on male subjects. Now, two things are changing the situation: scientists are realizing that women's experience and women's brains are different when it comes to addiction, and the NIH has mandated that tests involve female subjects as well. Erin Calipari is assistant professor of pharmacology at the Vanderbilt University School of Medicine, and she's one of the authors of a new paper in the journal Neuropsychopharmacology. In it, she and her colleagues create a new model for examining the differences between female and male rodents when it comes to drug addiction.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/upC1ycVa2Go" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[Research has demonstrated that, overall, women are more vulnerable to drug addiction than men are. They become addicted more quickly after first using, they have a harder time staying off drugs, and they relapse at higher rates. But most studies have focused on men, and models that have been developed nearly entirely focus on male subjects. Now, two things are changing the situation: scientists are realizing that women's experience and women's brains are different when it comes to addiction, and the NIH has mandated that tests involve female subjects as well. Erin Calipari is assistant professor of pharmacology at the Vanderbilt University School of Medicine, and she's one of the authors of a new paper in the journal Neuropsychopharmacology. In it, she and her colleagues create a new model for examining the differences between female and male rodents when it comes to drug addiction.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/upC1ycVa2Go" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Food Addiction: A Valid Concept?</title>
			<itunes:title>Food Addiction: A Valid Concept?</itunes:title>
			<pubDate>Fri, 08 Mar 2019 14:47:36 GMT</pubDate>
			<itunes:duration>9:34</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/foodaddiction-avalidconcept-/media.mp3" length="13785373" type="audio/mpeg"/>
			<guid isPermaLink="false">EED59A5B-86F2-479D-BA1A-B8454E4D4F0F</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/foodaddiction-avalidconcept-</link>
			<acast:episodeId>9d2ee34a-8828-4659-98dc-ca8e836ff6ea</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>foodaddiction-avalidconcept-</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCbqpJE2IcE1FrchVLaFyfy9OR8u09dUAmYm31A5Y1Ztdw5R39+j0PWyuH68gOfSwr4S8SEi3Ita6MCSTp7s/Swm2WiHPg6vv4YU43ZWe8a7WgZfNhbDnh+CUbLIMTuxIWnoZZETzdL1GKRWUWRZLeLWGsCJOcBQYL21+JdwyBl1FpwP+uVicJdAnmTmnpqNLfuizsqB5Hn+JI+w6okJeWva6Zj03pfsiawl8jwrtytl8=]]></acast:settings>
			<itunes:subtitle>Food Addiction: A Valid Concept?</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[Over the past decade, the use of the term 'food addiction' to describe an unhealthy approach to eating has grown. It refers to the idea that, for some people, their inability to control their food intake has similarities to that of a drug of abuse. Paul Kenny is the chair of the Department of Neuroscience at the Icahn School of Medicine in New York. He's one of two authors of a recent circumspective in the journal Neuropsychopharmacology. In the piece, Dr. Kenny and his colleague Dr. Paul Fletcher of the University of Cambridge take opposing viewpoints, Dr. Fletcher arguing against the use of the term food addiction, and Dr. Kenny in favor.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/KIYMSsAD3_Y" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[Over the past decade, the use of the term 'food addiction' to describe an unhealthy approach to eating has grown. It refers to the idea that, for some people, their inability to control their food intake has similarities to that of a drug of abuse. Paul Kenny is the chair of the Department of Neuroscience at the Icahn School of Medicine in New York. He's one of two authors of a recent circumspective in the journal Neuropsychopharmacology. In the piece, Dr. Kenny and his colleague Dr. Paul Fletcher of the University of Cambridge take opposing viewpoints, Dr. Fletcher arguing against the use of the term food addiction, and Dr. Kenny in favor.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/KIYMSsAD3_Y" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Sex Matters</title>
			<itunes:title>Sex Matters</itunes:title>
			<pubDate>Tue, 15 Jan 2019 14:47:36 GMT</pubDate>
			<itunes:duration>9:34</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/sexmatters/media.mp3" length="13785373" type="audio/mpeg"/>
			<guid isPermaLink="false">DDD59A5B-86F2-479D-BA1A-B8454E4D4F0F</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/sexmatters</link>
			<acast:episodeId>fcdc7d22-29fd-4a38-9c16-afcc245bb165</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>sexmatters</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCfX5iduofR7kFeVlXVrYwONGzh2fO6P5XgZFlEJyssb3qYaPLEUdTwsuduEK2diZvKgKdjj6/F/UAiT707XcyR8kO/kjrjPAczR+xbTOaA1jE//OYMZh5UMMG54NobSB4o7xzZsOXJhgVm6EQ2esT+UpTy6tyEN1gehmWVtHS/pXyl24wHuexYm4RZZJCnFdTM=]]></acast:settings>
			<itunes:subtitle>Sex Matters</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[As our environment becomes ever increasingly complex, understanding how sex differences impact disease risk and resilience will only become more critical. The 2019 , "Sex Matters," edited by Dr. Tracy L. Bale, highlights the causal and mechanistic value in cases where significant sex differences are found, as well as when they're not; where sex differences may arise at one period of life and disappear in another. Additionally, this podcast, as well as the special issue, reinforces the message that males are not the control, and females are not more variable. The value is in appreciating the difference. Sex matters.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/6gLWUJ9DeyU" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[As our environment becomes ever increasingly complex, understanding how sex differences impact disease risk and resilience will only become more critical. The 2019 , "Sex Matters," edited by Dr. Tracy L. Bale, highlights the causal and mechanistic value in cases where significant sex differences are found, as well as when they're not; where sex differences may arise at one period of life and disappear in another. Additionally, this podcast, as well as the special issue, reinforces the message that males are not the control, and females are not more variable. The value is in appreciating the difference. Sex matters.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/6gLWUJ9DeyU" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Recent advances in the study of aggression</title>
			<itunes:title>Recent advances in the study of aggression</itunes:title>
			<pubDate>Fri, 16 Nov 2018 14:47:36 GMT</pubDate>
			<itunes:duration>9:34</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/recentadvancesinthestudyofaggression/media.mp3" length="13785373" type="audio/mpeg"/>
			<guid isPermaLink="false">CCD59A5B-86F2-479D-BA1A-B8454E4D4F0F</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/recentadvancesinthestudyofaggression</link>
			<acast:episodeId>f95bf043-5faa-4df4-b22b-fd96acc9bfd4</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>recentadvancesinthestudyofaggression</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCbqpJE2IcE1FrchVLaFyfy9OR8u09dUAmYm31A5Y1Ztdw5R39+j0PWyuH68gOfSwr4S8SEi3Ita6MCSTp7s/Swm2WiHPg6vv4YU43ZWe8a7WgZfNhbDnh+CUbLIMTuxIWnoZZETzdL1GKRWUWRZLeLWGsCJOcBQYL21+JdwyBl1FpwP+uVicJdAnmTmnpqNLf4GzmVfDjZ8Bl0FW8sRXkdT7839UGmuC6zplxSVS509o=]]></acast:settings>
			<itunes:subtitle>Recent advances in the study of aggression</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[Aggression is an evolutionary behavior seen throughout the animal world. When it comes to humans, however, some forms of aggression can be seen as pathological, dangerous, and quite costly to society. And yet there's a dearth of approved, effective treatments for aggression. Meghan Flanigan is a graduate student at the Icahn School of Medicine at Mount Sinai and one of the authors of a new article in the journal Neuropsychopharmacology, titled "Recent advances in the study of aggression,"  in which she argues that there isn't much data about the causes of abnormal aggression in humans, and part of the problem has been that it hasn't been modeled well in animals.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/CLahGH7BGy4" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[Aggression is an evolutionary behavior seen throughout the animal world. When it comes to humans, however, some forms of aggression can be seen as pathological, dangerous, and quite costly to society. And yet there's a dearth of approved, effective treatments for aggression. Meghan Flanigan is a graduate student at the Icahn School of Medicine at Mount Sinai and one of the authors of a new article in the journal Neuropsychopharmacology, titled "Recent advances in the study of aggression,"  in which she argues that there isn't much data about the causes of abnormal aggression in humans, and part of the problem has been that it hasn't been modeled well in animals.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/CLahGH7BGy4" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Neurocognitive effects of umami: association with eating behavior and food choice</title>
			<itunes:title>Neurocognitive effects of umami: association with eating behavior and food choice</itunes:title>
			<pubDate>Fri, 14 Sep 2018 14:47:36 GMT</pubDate>
			<itunes:duration>9:34</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/neurocognitiveeffectsofumami-associationwitheatingbehaviorandfoodchoice/media.mp3" length="13785373" type="audio/mpeg"/>
			<guid isPermaLink="false">BBD59A5B-86F2-479D-BA1A-B8454E4D4F0F</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/neurocognitiveeffectsofumami-associationwitheatingbehaviorandfoodchoice</link>
			<acast:episodeId>159e18eb-c629-4a6e-972a-b1a6c9bdb301</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>neurocognitiveeffectsofumami-associationwitheatingbehaviorandfoodchoice</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCbqpJE2IcE1FrchVLaFyfy9OR8u09dUAmYm31A5Y1Ztdw5R39+j0PWyuH68gOfSwr4S8SEi3Ita6MCSTp7s/Swm2WiHPg6vv4YU43ZWe8a7WgZfNhbDnh+CUbLIMTuxIWnoZZETzdL1GKRWUWRZLeLWGsCJOcBQYL21+JdwyBl1FpwP+uVicJdAnmTmnpqNLf/eFFtYoVgLEIav+r/NYqJN3HkypFRDMCFZzDAMD0BTE=]]></acast:settings>
			<itunes:subtitle>Neurocognitive effects of umami: association with eating behavior and food choice</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[While the influence of sweet taste on neurocognitive function has been widely studied, umami or savory has received less of a research focus. Animal models and even some small human studies seem to show that umami given in a broth before a meal can influence appetite and food intake. And this inspired Dr. Miguel Alonso-Alonso, Assistant Professor and Director of the Laboratory of Bariatric and Nutritional Neuroscience at Beth Israel Deaconess Medical Center and Harvard Medical School. He and his colleagues decided to test the influence of glutamate on behavior and food choice, as well as the neurocognitive mechanisms that might be affecting such behavioral changes.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/BecabazRoe4" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[While the influence of sweet taste on neurocognitive function has been widely studied, umami or savory has received less of a research focus. Animal models and even some small human studies seem to show that umami given in a broth before a meal can influence appetite and food intake. And this inspired Dr. Miguel Alonso-Alonso, Assistant Professor and Director of the Laboratory of Bariatric and Nutritional Neuroscience at Beth Israel Deaconess Medical Center and Harvard Medical School. He and his colleagues decided to test the influence of glutamate on behavior and food choice, as well as the neurocognitive mechanisms that might be affecting such behavioral changes.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/BecabazRoe4" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Burst activation of dopamine neurons produces prolonged post-burst availability of actively released dopamine.</title>
			<itunes:title>Burst activation of dopamine neurons produces prolonged post-burst availability of actively released dopamine.</itunes:title>
			<pubDate>Fri, 13 Jul 2018 14:47:36 GMT</pubDate>
			<itunes:duration>9:34</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/burstactivationofdopamineneuronsproducesprolongedpost-burstavailabilityofactivelyreleaseddopamine-/media.mp3" length="13785373" type="audio/mpeg"/>
			<guid isPermaLink="false">AAD59A5B-86F2-479D-BA1A-B8454E4D4F0F</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/burstactivationofdopamineneuronsproducesprolongedpost-burstavailabilityofactivelyreleaseddopamine-</link>
			<acast:episodeId>00a52bb6-f721-4b59-865d-4518b0157f8b</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>burstactivationofdopamineneuronsproducesprolongedpost-burstavailabilityofactivelyreleaseddopamine-</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCcYzJKsr3XnzLE1lNZV04EabAfb5giydZdqI6utpVB6nEhsXbybJVCeObu6kdSsUV2g68ymzthd6s+mEbFCuMoU3Kg2j1qtibj6HvB/uBKToX7fubrqcV662ZB8IA33lBhoevNv2YuA26ON8kfWlIHb1wl/fCZUQNZO2bbfXoic/kftLi+F2O8Jwjp+kFGqcHs=]]></acast:settings>
			<itunes:subtitle>Burst activation of dopamine neurons produces prolonged post-burst availability of actively released dopamine</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[For years now, scientists have noticed a rather strange phenomenon in animal models: scientists would stimulate dopamine production in the brain, but once the stimulation was over, the dopamine would remain. Bita Moghaddam is chair and professor of behavioral neuroscience at Oregon Health and Science University. She says that when dopamine is released, dopamine transporters take the dopamine back up into cells so it can be synthesized and broken down. So scientists had assumed that the dopamine that remained for those twenty minutes was just leftover dopamine from the original activation. But in theory the dopamine transporters should be more efficient in taking up the dopamine.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/s0NhdCjbsHI" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[For years now, scientists have noticed a rather strange phenomenon in animal models: scientists would stimulate dopamine production in the brain, but once the stimulation was over, the dopamine would remain. Bita Moghaddam is chair and professor of behavioral neuroscience at Oregon Health and Science University. She says that when dopamine is released, dopamine transporters take the dopamine back up into cells so it can be synthesized and broken down. So scientists had assumed that the dopamine that remained for those twenty minutes was just leftover dopamine from the original activation. But in theory the dopamine transporters should be more efficient in taking up the dopamine.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/s0NhdCjbsHI" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Debating the Persistence of Neurogenesis in Humans</title>
			<itunes:title>Debating the Persistence of Neurogenesis in Humans</itunes:title>
			<pubDate>Thu, 24 May 2018 14:47:36 GMT</pubDate>
			<itunes:duration>9:34</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/debatingthepersistenceofneurogenesisinhumans/media.mp3" length="13785373" type="audio/mpeg"/>
			<guid isPermaLink="false">1ED59A5B-86F2-479D-BA1A-B8454E4D4F0F</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/debatingthepersistenceofneurogenesisinhumans</link>
			<acast:episodeId>5fa10f59-f4d7-440b-b343-2eee4ad19b30</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>debatingthepersistenceofneurogenesisinhumans</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCcYzJKsr3XnzLE1lNZV04EabAfb5giydZdqI6utpVB6nEhsXbybJVCeObu6kdSsUV2g68ymzthd6s+mEbFCuMoU3Kg2j1qtibj6HvB/uBKToX7fubrqcV662ZB8IA33lBhoevNv2YuA26ON8kfWlIHbXf8fMbq4DvMlZs68waveoo7dftL8ymWwSEr+9NBYOd4=]]></acast:settings>
			<itunes:subtitle>Debating the Persistence of Neurogenesis in Humans</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[The question of whether neurogenesis persists in humans and for how long -- that is, whether and where humans grow new neurons in their brains, and how long into our lives -- is one that has engaged neuroscientists for decades. Some papers showed that humans did retain neurogenesis into adulthood, but the issue has been debated. That debate was reignited just recently with the publication of two new studies. The first one, published in Nature, is titled "Human hippocampal neurogenesis drops sharply in children to undetectable levels in adults." Not long after, a second paper was published in Cell Stem Cell, titled, "Human hipoocampal neurogenesis persists throughout aging." To discuss the seemingly contradictory results of these two papers on Neuropsychopharmacology's BrainPod are Dr. Lisa Monteggia, professor of neuroscience at UT Southwestern Medical Center, and Dr. Christoph Anacker, assistant professor in clinical neurobiology at Columbia University.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/pf2cwFgaU10" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[The question of whether neurogenesis persists in humans and for how long -- that is, whether and where humans grow new neurons in their brains, and how long into our lives -- is one that has engaged neuroscientists for decades. Some papers showed that humans did retain neurogenesis into adulthood, but the issue has been debated. That debate was reignited just recently with the publication of two new studies. The first one, published in Nature, is titled "Human hippocampal neurogenesis drops sharply in children to undetectable levels in adults." Not long after, a second paper was published in Cell Stem Cell, titled, "Human hipoocampal neurogenesis persists throughout aging." To discuss the seemingly contradictory results of these two papers on Neuropsychopharmacology's BrainPod are Dr. Lisa Monteggia, professor of neuroscience at UT Southwestern Medical Center, and Dr. Christoph Anacker, assistant professor in clinical neurobiology at Columbia University.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/pf2cwFgaU10" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Considerations for the Use of DREADDs in Behavioral Neuroscience</title>
			<itunes:title>Considerations for the Use of DREADDs in Behavioral Neuroscience</itunes:title>
			<pubDate>Fri, 16 Mar 2018 13:27:23 GMT</pubDate>
			<itunes:duration>9:18</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/considerationsfortheuseofdreaddsinbehavioralneuroscience/media.mp3" length="7017829" type="audio/mpeg"/>
			<guid isPermaLink="false">7E69EE13-EE41-493C-829B-FE345D0A09A7</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/considerationsfortheuseofdreaddsinbehavioralneuroscience</link>
			<acast:episodeId>8f7859c6-dc93-445c-8b91-0fafccf332d9</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>considerationsfortheuseofdreaddsinbehavioralneuroscience</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCfLja391V4aNe5kP8HUl6AwiyNpitHYab3XVZUSNB488YQbIEmsKniso5woNWxNsVL7wgaDSuRao59hSUORBDVils3/Hko1ysr1EHh83Ag8j8zPNK1STh/+uP5/9VGH2764JSq//uYHJag7tyuKzJAqkEGu+zGsPzDf+jIUFBgsElU2dt4YKdQ8c9BIc/3ztzQHEAuEDRfdJVKM8R7BJjCOFK/eLSDi4XS7NoPwNWOs8=]]></acast:settings>
			<itunes:subtitle>Considerations for the Use of DREADDs in Behavioral Neuroscience</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[There's a technology that's proven to be increasingly useful in the past decade -- it's called DREADD, or "designer receptors exclusively activated by designer drugs." The current approach is to create a designer receptor that is unlocked by the drug, clozapine-n-oxide, or CNO. Researchers have used it to study the function of populations of neurons or of particular pathways in the brains in rodents, by using the DREADD technique to turn on and off these neurons or pathways. However, last year, a paper published in the journal Science called the use of DREADDs into question. Some people interpreted the paper as an overall indictment of the DREADD technology, though this wasn't the original intent of the authors. Listen to Neuropsychopharmacology's latest podcast to learn more!<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/wWxCaYYyXp4" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[There's a technology that's proven to be increasingly useful in the past decade -- it's called DREADD, or "designer receptors exclusively activated by designer drugs." The current approach is to create a designer receptor that is unlocked by the drug, clozapine-n-oxide, or CNO. Researchers have used it to study the function of populations of neurons or of particular pathways in the brains in rodents, by using the DREADD technique to turn on and off these neurons or pathways. However, last year, a paper published in the journal Science called the use of DREADDs into question. Some people interpreted the paper as an overall indictment of the DREADD technology, though this wasn't the original intent of the authors. Listen to Neuropsychopharmacology's latest podcast to learn more!<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/wWxCaYYyXp4" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Neuropsychopharmacology Reviews: Cannabis and Cannabinoids: From Synapse to Society</title>
			<itunes:title>Neuropsychopharmacology Reviews: Cannabis and Cannabinoids: From Synapse to Society</itunes:title>
			<pubDate>Fri, 12 Jan 2018 14:55:56 GMT</pubDate>
			<itunes:duration>9:39</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/neuropsychopharmacologyreviews-cannabisandcannabinoids-fromsynapsetosociety/media.mp3" length="7259504" type="audio/mpeg"/>
			<guid isPermaLink="false">108E3429-8D21-4E53-84A4-564C19C8BA88</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/neuropsychopharmacologyreviews-cannabisandcannabinoids-fromsynapsetosociety</link>
			<acast:episodeId>743409d2-0f8e-43dc-b4c3-51316419f001</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>neuropsychopharmacologyreviews-cannabisandcannabinoids-fromsynapsetosociety</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCcPrGKC6yxvG/evL05bCre4n22Caacq5ZOHTs7+Yw7TQTJMf9Ovq/6LQ5s8FLwNz//AV+oxmPCgRKAF2vSc8WwvmcWhaz+A9pz0qEPOPemwXvryXG7bDPJVa1trBw/R8X/HTaEA7Xuo9gQBePABlgZhnzrSE6Q8HF1RBrT8dBl3fQaPaena9e0ch3y1AayV3V/Wf/CxNr8rHeDjIBWcmD60]]></acast:settings>
			<itunes:subtitle>Neuropsychopharmacology Reviews: Cannabis and Cannabinoids: From Synapse to Society</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[The 2018 issue of Neuropsychopharmacology Reviews, "Cannabis and Cannabinoids: From Synapse to Society," showcases the remarkable advances in the biology of cannabinoids and cannabis in the past two decades, ranging from their impact at the synaptic level through to public health.Edited by Margaret Haney and Matthew N Hill, this issue represents current findings across several major research areas, contributing novel insights into psychiatric illness treatment and a data-driven perspective relevant to public policy changes occurring worldwide.Neuropsychopharmacology Reviews: http://www.nature.com/nppr/index.html<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/iBZrKcKHf-I" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[The 2018 issue of Neuropsychopharmacology Reviews, "Cannabis and Cannabinoids: From Synapse to Society," showcases the remarkable advances in the biology of cannabinoids and cannabis in the past two decades, ranging from their impact at the synaptic level through to public health.Edited by Margaret Haney and Matthew N Hill, this issue represents current findings across several major research areas, contributing novel insights into psychiatric illness treatment and a data-driven perspective relevant to public policy changes occurring worldwide.Neuropsychopharmacology Reviews: http://www.nature.com/nppr/index.html<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/iBZrKcKHf-I" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Opioid Release after High-Intensity Interval Training in Healthy Human Subjects</title>
			<itunes:title>Opioid Release after High-Intensity Interval Training in Healthy Human Subjects</itunes:title>
			<pubDate>Fri, 10 Nov 2017 15:52:52 GMT</pubDate>
			<itunes:duration>6:15</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/opioidreleaseafterhigh-intensityintervaltraininginhealthyhumansubjects/media.mp3" length="4814450" type="audio/mpeg"/>
			<guid isPermaLink="false">74F8FBA1-25D6-4F9B-BDF3-DAB33498AF49</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/opioidreleaseafterhigh-intensityintervaltraininginhealthyhumansubjects</link>
			<acast:episodeId>7cea07d4-fd6d-43a3-82b8-3d65d7f2a0dc</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>opioidreleaseafterhigh-intensityintervaltraininginhealthyhumansubjects</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCf5U+HnTisC5kLI1f2k/DHQXBHR3pL44dg6kJsSw47pfd5MRjbjFOJ5ixhuNAQfSJNV6hylX4ePs3JWkopJ4V3V+WszGLFxcH15OKBxyrU8xC4eC7/WOKmukWS3mpcSOxD0bMFQwfX0szWss4W7nT4YzR6SfD1x/x8nxVluvM9vrVXUgri6hc+3sD/oWP0wYEg=]]></acast:settings>
			<itunes:subtitle>Opioid Release after High-Intensity Interval Training in Healthy Human Subjects</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[Many people who exercise regularly have experienced a so-called "runner's high," either a feeling of euphoria after exercise, or a feeling of happiness and well-being. Scientists have studied this and found that exercise does indeed improve mood and combat stress, for instance, but researchers at Finland's University of Turku wanted to know: Are endorphins being produced in and thus affecting the brain? To try to answer this question, the team labeled a drug that can bind to endorphin receptors in the brain and compete with endogenous endorphins. So if the study subjects were producing endorphins in the brain, the drug binding should be reduced. Listen to Neuropsychopharmacology's latest podcast to learn more!<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/mLCEIewJ8A0" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[Many people who exercise regularly have experienced a so-called "runner's high," either a feeling of euphoria after exercise, or a feeling of happiness and well-being. Scientists have studied this and found that exercise does indeed improve mood and combat stress, for instance, but researchers at Finland's University of Turku wanted to know: Are endorphins being produced in and thus affecting the brain? To try to answer this question, the team labeled a drug that can bind to endorphin receptors in the brain and compete with endogenous endorphins. So if the study subjects were producing endorphins in the brain, the drug binding should be reduced. Listen to Neuropsychopharmacology's latest podcast to learn more!<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/mLCEIewJ8A0" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Opioid Self-Administration is Attenuated by Early-Life Experience and Gene Therapy for Anti-Inflammatory IL-10 in the Nucleus Accumbens of Male Rats</title>
			<itunes:title>Opioid Self-Administration is Attenuated by Early-Life Experience and Gene Therapy for Anti-Inflammatory IL-10 in the Nucleus Accumbens of Male Rats</itunes:title>
			<pubDate>Wed, 13 Sep 2017 16:00:00 GMT</pubDate>
			<itunes:duration>8:18</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/opioidself-administrationisattenuatedbyearly-lifeexperienceandgenetherapyforanti-inflammatoryil-10inthenucleusaccumbensofmalerats/media.mp3" length="6297160" type="audio/mpeg"/>
			<guid isPermaLink="false">85719669-64C1-46BB-8FAC-0ADAA702BD40</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/opioidself-administrationisattenuatedbyearly-lifeexperienceandgenetherapyforanti-inflammatoryil-10inthenucleusaccumbensofmalerats</link>
			<acast:episodeId>625ced6a-de45-4f40-994f-3d8b8265c4fe</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>opioidself-administrationisattenuatedbyearly-lifeexperienceandgenetherapyforanti-inflammatoryil-10inthenucleusaccumbensofmalerats</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCC12eBErzSY+xUNryG+HSKYkyqISTo0WZ95sT4JeRO1anwnoLLuaJmAFKR4JV6SEOULbKQtjfLUSlBLwj3KOYaCwD9UyhpV3pKGAQTsqoj9Vnpn+qkehCrXhHe7YtdN2ynwF0oCTO9v9kL2caJ0BWVvn0nj5cNvBluQHZIUxa7/CuUxVNOCxHfUyA01OvQbaC6SCXIFNWirnlFFNTz3EDI4k32q5EnPVdKh+XA7QtkdM=]]></acast:settings>
			<itunes:subtitle>Opioid Self-Administration is Attenuated by Early-Life Experience and Gene Therapy for Anti-Inflammatory IL-10 in the Nucleus Accumbens of Male Rats</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[Studies have shown that stress and trauma early in life can lead to an increased risk for drug addiction later in life. In rat models developed to mimic and study this effect, some rats received normal maternal care, while others received enriched maternal care - extra grooming and attention from their mothers. Those with enriched maternal care have been shown to be less likely to return to a room in which the rats received a dose of morphine. But does that accurately represent drug use? They've also been shown to have neurological changes in the brain - but these changes have been correlational. A new study published in the journal Neuropsychopharmacology was set up to tease out a number of aspects of this research.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/nEhBeq01xxM" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[Studies have shown that stress and trauma early in life can lead to an increased risk for drug addiction later in life. In rat models developed to mimic and study this effect, some rats received normal maternal care, while others received enriched maternal care - extra grooming and attention from their mothers. Those with enriched maternal care have been shown to be less likely to return to a room in which the rats received a dose of morphine. But does that accurately represent drug use? They've also been shown to have neurological changes in the brain - but these changes have been correlational. A new study published in the journal Neuropsychopharmacology was set up to tease out a number of aspects of this research.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/nEhBeq01xxM" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Beta-Adrenoceptor Blockade in the Basolateral Amygdala, But Not the Medial Prefrontal Cortex, Rescues the Immediate Extinction Deficit</title>
			<itunes:title>Beta-Adrenoceptor Blockade in the Basolateral Amygdala, But Not the Medial Prefrontal Cortex, Rescues the Immediate Extinction Deficit</itunes:title>
			<pubDate>Thu, 13 Jul 2017 14:37:37 GMT</pubDate>
			<itunes:duration>8:47</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/beta-adrenoceptorblockadeinthebasolateralamygdala-butnotthemedialprefrontalcortex-rescuestheimmediateextinctiondeficit/media.mp3" length="6643864" type="audio/mpeg"/>
			<guid isPermaLink="false">FE796548-AB68-4E9B-B83C-51D683C28527</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/beta-adrenoceptorblockadeinthebasolateralamygdala-butnotthemedialprefrontalcortex-rescuestheimmediateextinctiondeficit</link>
			<acast:episodeId>abeb29b3-a0ca-4fa8-a515-2a792e07a310</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>beta-adrenoceptorblockadeinthebasolateralamygdala-butnotthemedialprefrontalcortex-rescuestheimmediateextinctiondeficit</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCdpqkTe6cM6dgUnLcPQtA+vA+jnWdQEVbomFTvRVnlcDYdObM37nRrLFaYinLB+pYAj9W2VXtCqW8NeObgEeBW3bLXYOH0Qd+AhdDa3hGV/WJA6nZOtI23R6ORZYsipRea8K0NZzkFb95SgHctjVEiTXZilg+ki5GTiqC2LQrW2o0Yjm1vSRk89qlnWC6MXDwc=]]></acast:settings>
			<itunes:subtitle>Beta-Adrenoceptor Blockade in the Basolateral Amygdala, But Not the Medial Prefrontal Cortex, Rescues the Immediate Extinction Deficit</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[One method of treating Post-traumatic stress disorder (PTSD) involves extinction therapy, but researchers have found that the timing of such therapy is extremely important, and that it often doesn't work if the therapy is conducted too soon after the initial trauma. Stress itself may be harming the efficacy of the treatment. A team of researchers at Texas A&M University conducted research to determine whether there was a way to dampen stress and make extinction therapy more effective by using pharmaceuticals. The results were published in a recent issue of the journal Neuropsychopharmacology. Listen to the latest podcast to hear about this study from researchers Stephen Maren and Tom Giustino!<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/JnKowyOCU2U" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[One method of treating Post-traumatic stress disorder (PTSD) involves extinction therapy, but researchers have found that the timing of such therapy is extremely important, and that it often doesn't work if the therapy is conducted too soon after the initial trauma. Stress itself may be harming the efficacy of the treatment. A team of researchers at Texas A&M University conducted research to determine whether there was a way to dampen stress and make extinction therapy more effective by using pharmaceuticals. The results were published in a recent issue of the journal Neuropsychopharmacology. Listen to the latest podcast to hear about this study from researchers Stephen Maren and Tom Giustino!<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/JnKowyOCU2U" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Arbaclofen in Children and Adolescents with Autism Spectrum Disorder</title>
			<itunes:title>Arbaclofen in Children and Adolescents with Autism Spectrum Disorder</itunes:title>
			<pubDate>Fri, 12 May 2017 13:31:02 GMT</pubDate>
			<itunes:duration>9:36</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/arbaclofeninchildrenandadolescentswithautismspectrumdisorder/media.mp3" length="7232651" type="audio/mpeg"/>
			<guid isPermaLink="false">BAC78FA1-DB8D-4C75-AF9D-F0A30565D125</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/arbaclofeninchildrenandadolescentswithautismspectrumdisorder</link>
			<acast:episodeId>5b898a37-550c-4048-85e4-403abbe3db10</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>arbaclofeninchildrenandadolescentswithautismspectrumdisorder</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCcMNoMy4Cuawp+lFU638QTG/ZoqzyL5y/RX6hUhyFqW0/H4zGvSSyGzLIUnAVl5OeZw7fU+jQ5rV6rJffsv6zzXhHiL5s48BhaPwEcqr3UM9t7zItT61w/1a3HV8ragiMj4mKm5zb/wcs1GMf94iDgRLbi9s+hlP3gksQAZyw63qGQ2jAv8V/MbfIj/5hplFS0=]]></acast:settings>
			<itunes:subtitle>Arbaclofen in Children and Adolescents with Autism Spectrum Disorder</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[Autism Spectrum Disorder is a disorder that has been defined by the medical community, but so far, none of the medications available for ASD treat the core symptoms of the disease, but rather secondary symptoms such as agitation or hyperactivity. Because ASD is genetically linked to Fragile X syndrome, researchers noticed that in a mouse model, the drug arbaclofen reduced what would be core symptoms of autism, such as combatting social avoidance and improving social function. A randomized placebo-controlled trial was conducted to test this idea and the results were recently published in Neuropsychopharmacology. Listen to the latest BrainPod to hear Dr. Jeremy Veenstra-VanderWeele discuss these results!<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/vlQn4lxBkKM" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[Autism Spectrum Disorder is a disorder that has been defined by the medical community, but so far, none of the medications available for ASD treat the core symptoms of the disease, but rather secondary symptoms such as agitation or hyperactivity. Because ASD is genetically linked to Fragile X syndrome, researchers noticed that in a mouse model, the drug arbaclofen reduced what would be core symptoms of autism, such as combatting social avoidance and improving social function. A randomized placebo-controlled trial was conducted to test this idea and the results were recently published in Neuropsychopharmacology. Listen to the latest BrainPod to hear Dr. Jeremy Veenstra-VanderWeele discuss these results!<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/vlQn4lxBkKM" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>The Gateway Hypothesis of Addiction</title>
			<itunes:title>The Gateway Hypothesis of Addiction</itunes:title>
			<pubDate>Wed, 15 Mar 2017 14:13:04 GMT</pubDate>
			<itunes:duration>8:47</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/thegatewayhypothesisofaddiction/media.mp3" length="6637903" type="audio/mpeg"/>
			<guid isPermaLink="false">A2376801-DF7F-4267-B889-C94E5CF97856</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/thegatewayhypothesisofaddiction</link>
			<acast:episodeId>340dc6b0-1196-4de3-8429-c422cff1f288</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>thegatewayhypothesisofaddiction</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzC1edeQ0Tu6pL3NmpjCXbaHqrUt28nSAk4fZOCQKvTCSzDy1Z+xc1zySSir99nUTCy9fDsOQq3GTRij8eDexnGOzTXFm0Al4KSz/KvCCjcMVHtkgRedIE2l2RBlQ0tsEkwdq78oC8Y0N6WxPfYS9aqe4sytyIK8WhuexcFF4wOU0CnIAriBHcIrvFgM531IuYoSjkhCSaN+fsCOmqY5mf7gAMDhi5XvAVaQcoIJGqE1KQ=]]></acast:settings>
			<itunes:subtitle>The Gateway Hypothesis of Addiction</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[The National Institutes of Health recently published a statement requiring sex as a biological variable in studies. This is in part simply because it's good science, and in part to correct for decades in which both animal and human studies were largely conducted with male subjects. In their review paper responding to this statement, Dr. Tracy Bale and Dr. Neill Epperson discuss how sex has a direct impact on brain development, and how it results in a sexually dimorphic brain: meaning there are physical differences between males and females. Listen to the latest BrainPod, Neuropsychopharmacology's official podcast, to hear Dr. Bale and Dr. Epperson discuss this topic!<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/ZNa9WJU0KN0" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[The National Institutes of Health recently published a statement requiring sex as a biological variable in studies. This is in part simply because it's good science, and in part to correct for decades in which both animal and human studies were largely conducted with male subjects. In their review paper responding to this statement, Dr. Tracy Bale and Dr. Neill Epperson discuss how sex has a direct impact on brain development, and how it results in a sexually dimorphic brain: meaning there are physical differences between males and females. Listen to the latest BrainPod, Neuropsychopharmacology's official podcast, to hear Dr. Bale and Dr. Epperson discuss this topic!<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/ZNa9WJU0KN0" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Sex as a Biological Variable: Who, What, When, Why, and How</title>
			<itunes:title>Sex as a Biological Variable: Who, What, When, Why, and How</itunes:title>
			<pubDate>Thu, 12 Jan 2017 14:11:28 GMT</pubDate>
			<itunes:duration>9:41</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/sexasabiologicalvariable-who-what-when-why-andhow/media.mp3" length="7284389" type="audio/mpeg"/>
			<guid isPermaLink="false">29D48D10-64CD-4613-81E6-551D39200565</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/sexasabiologicalvariable-who-what-when-why-andhow</link>
			<acast:episodeId>d2192062-beac-4f89-b3ce-aef53805f9a7</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>sexasabiologicalvariable-who-what-when-why-andhow</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCqVi/n1wkWqoBOIPcAJ4zckrKR65QRk5gPj643Ve6ugLuOdN+Xg9bMnqIihHfpYWPwPqgoo25lDUfSzYtLzveYE0PtLfI0uf0hZBR0xaXPyOCxCBQPBuwM/nOeKnsiWijv1VR1lPUUX7kRGReGAUaF2OB8g3NFv4M8M9dtlGrezJ/dAjeeFP+M0/v7nkObjd0Kay/3W9YWYp8ol61Uh2Cn+MRhrEW6uHynjNtjY9cM5U=]]></acast:settings>
			<itunes:subtitle>Sex as a Biological Variable: Who, What, When, Why, and How</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[The National Institutes of Health recently published a statement requiring sex as a biological variable in studies. This is in part simply because it's good science, and in part to correct for decades in which both animal and human studies were largely conducted with male subjects. In their review paper responding to this statement, Dr. Tracy Bale and Dr. Neill Epperson discuss how sex has a direct impact on brain development, and how it results in a sexually dimorphic brain: meaning there are physical differences between males and females. Listen to the latest BrainPod, Neuropsychopharmacology's official podcast, to hear Dr. Bale and Dr. Epperson discuss this topic!<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/TbdZ-sRfBjI" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[The National Institutes of Health recently published a statement requiring sex as a biological variable in studies. This is in part simply because it's good science, and in part to correct for decades in which both animal and human studies were largely conducted with male subjects. In their review paper responding to this statement, Dr. Tracy Bale and Dr. Neill Epperson discuss how sex has a direct impact on brain development, and how it results in a sexually dimorphic brain: meaning there are physical differences between males and females. Listen to the latest BrainPod, Neuropsychopharmacology's official podcast, to hear Dr. Bale and Dr. Epperson discuss this topic!<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/TbdZ-sRfBjI" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Neuropsychopharmacology Reviews: The Immunology of Behavior - Exploring the Role of the Immune System in Brain Health and Illness</title>
			<itunes:title>Neuropsychopharmacology Reviews: The Immunology of Behavior - Exploring the Role of the Immune System in Brain Health and Illness</itunes:title>
			<pubDate>Fri, 02 Dec 2016 14:07:48 GMT</pubDate>
			<itunes:duration>9:47</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/neuropsychopharmacologyreviews-theimmunologyofbehavior-exploringtheroleoftheimmunesysteminbrainhealthandillness/media.mp3" length="7357308" type="audio/mpeg"/>
			<guid isPermaLink="false">AAEF5BE7-E5D3-4B38-8CA8-07C7429E6D67</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/neuropsychopharmacologyreviews-theimmunologyofbehavior-exploringtheroleoftheimmunesysteminbrainhealthandillness</link>
			<acast:episodeId>d93edd9e-89dc-4833-85cc-b16d410d6930</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>neuropsychopharmacologyreviews-theimmunologyofbehavior-exploringtheroleoftheimmunesysteminbrainhealthandillness</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCcB5eU9uoxwNhkc9X5XBaxZnmJOqOoCZCs5p2HRaWu649D4uE4Fyf3Nmsp73wRcrPd6pbr67BX50GECWJJbw+hPsG7e3QeYCt1QDJJziE6zotg/WjaNskWcgPMReQiGpcjRD6xWyVgyapvXZpGnWwYkJt+Swkdkqc+0lnckje1G9G2G28H6cydjoVMONKiduaM=]]></acast:settings>
			<itunes:subtitle>Neuropsychopharmacology Reviews: The Immunology of Behavior - Exploring the Role of the Immune System in Brain Health and Illness</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[The 2017 issue of Neuropsychopharmacology Reviews, "The Immunology of Behavior focuses on the growing appreciation of the immune system in understanding brain and health illness.This podcast synthesizes this year's issue, which showcases a wide range of reviews about the relationship between immunology and brain and health illness, demonstrating how advances in our understanding of immunology have led to novel insights into psychiatric illnesses and their treatment. Hear more from Andrew H Miller, Ebrahim Haroon, and Jennifer C Felger, the editors of this NPPR issue!<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/Gagk8lM8Okg" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[The 2017 issue of Neuropsychopharmacology Reviews, "The Immunology of Behavior focuses on the growing appreciation of the immune system in understanding brain and health illness.This podcast synthesizes this year's issue, which showcases a wide range of reviews about the relationship between immunology and brain and health illness, demonstrating how advances in our understanding of immunology have led to novel insights into psychiatric illnesses and their treatment. Hear more from Andrew H Miller, Ebrahim Haroon, and Jennifer C Felger, the editors of this NPPR issue!<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/Gagk8lM8Okg" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>LSD Acutely Impairs Fear Recognition and Enhances Emotional Empathy and Sociality</title>
			<itunes:title>LSD Acutely Impairs Fear Recognition and Enhances Emotional Empathy and Sociality</itunes:title>
			<pubDate>Fri, 07 Oct 2016 18:00:00 GMT</pubDate>
			<itunes:duration>9:58</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/lsdacutelyimpairsfearrecognitionandenhancesemotionalempathyandsociality/media.mp3" length="7184969" type="audio/mpeg"/>
			<guid isPermaLink="false">17DC7C30-365E-4CB6-9B14-E84931C07543</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/lsdacutelyimpairsfearrecognitionandenhancesemotionalempathyandsociality</link>
			<acast:episodeId>e544ebaf-c2f4-44a5-841c-fe874191886f</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>lsdacutelyimpairsfearrecognitionandenhancesemotionalempathyandsociality</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCPASE1x50olkvVnKgV9O0tDIjFRofEh2mr5maQxLznKUyIihgGX0/Ng2IFeawCY1R76DTjoP0k83VqbWxLGuWceglEtV01RC9kVon85KJMnNZu8ekfXTubKkh9z7zLzHfhgpnGVmdla3Yq5KUp1PqrAWidc4ZDw3Brj6238G4HceZrgmVlDo+4XVOBF/4pZkK4rbtAvWGxidTyyjTxAjjS+EZ6sSmMszCJ47d58Flfg4=]]></acast:settings>
			<itunes:subtitle>LSD Acutely Impairs Fear Recognition and Enhances Emotional Empathy and Sociality</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[LSD is not only a well-known psychedelic drug, but it was also studied extensively for its potential in psychotherapy in the early days of its use, about fifty years ago. Those early studies didn't necessarily meet today's standards for clinical trials, and previous research ended in the 1970s, due to changing regulations and a prohibition against LSD. Today, LSD is once again being studied for its therapeutic use, this time in a carefully controlled clinical setting. In a recent study, a team of researchers investigated LSD's effects on fear recognition, emotional empathy, and sociality. Listen to the latest BrainPod, Neuropsychopharmacology's official podcast, to hear Dr. Matthias Liechti discuss this study!<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/K3Lw_ou59EM" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[LSD is not only a well-known psychedelic drug, but it was also studied extensively for its potential in psychotherapy in the early days of its use, about fifty years ago. Those early studies didn't necessarily meet today's standards for clinical trials, and previous research ended in the 1970s, due to changing regulations and a prohibition against LSD. Today, LSD is once again being studied for its therapeutic use, this time in a carefully controlled clinical setting. In a recent study, a team of researchers investigated LSD's effects on fear recognition, emotional empathy, and sociality. Listen to the latest BrainPod, Neuropsychopharmacology's official podcast, to hear Dr. Matthias Liechti discuss this study!<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/K3Lw_ou59EM" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Harnessing Smartphone-Based Digital Phenotyping to Enhance Behavioral and Mental Health</title>
			<itunes:title>Harnessing Smartphone-Based Digital Phenotyping to Enhance Behavioral and Mental Health</itunes:title>
			<pubDate>Thu, 12 May 2016 15:00:00 GMT</pubDate>
			<itunes:duration>9:01</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/harnessingsmartphone-baseddigitalphenotypingtoenhancebehavioralandmentalhealth/media.mp3" length="6809729" type="audio/mpeg"/>
			<guid isPermaLink="false">E6DDF030-8ED9-4EA2-A45F-59E3F3D5B60B</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/harnessingsmartphone-baseddigitalphenotypingtoenhancebehavioralandmentalhealth</link>
			<acast:episodeId>b5d8978b-48c0-4e5e-9c2d-bb08f1513161</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>harnessingsmartphone-baseddigitalphenotypingtoenhancebehavioralandmentalhealth</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCN4/HhOae/gFxpvt/x8gkgPndqtXp1bP6IynvNcG07v0EMdEddceYpvAtzf09wj6VevP0BgF8ZWU+7JRE5UjtAB2H1wvba+ycipiEb9lLoflTlp+7QsSJqyOsZXLyb25tNBMsJyOO6Y59t2pEM1Wwjzj5lP20W2rBjhHhCXdYD0Hs12myI9H7yX8r7O8AL7XqOiDXo6eTuicD/fD6u/IKeJVITo32J9CdlVHJFW4qdSw=]]></acast:settings>
			<itunes:subtitle>Harnessing Smartphone-Based Digital Phenotyping to Enhance Behavioral and Mental Health</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[Smartphones have become nearly ubiquitous in the United States. These mini-computers that we carry around in our bags or pockets have the potential to dramatically influence the practice of medicine, including psychiatry. A team of researchers is currently investigating the use of smartphones for what's known as digital phenotyping, or the continuous monitoring of someone's status via a personal digital device, to enhance behavioral and mental health. Listen to this month's BrainPod to hear Dr. JP Onnela discuss how digital phenotyping is crucial for studying mental health disorders.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/M63p_I6SZTU" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[Smartphones have become nearly ubiquitous in the United States. These mini-computers that we carry around in our bags or pockets have the potential to dramatically influence the practice of medicine, including psychiatry. A team of researchers is currently investigating the use of smartphones for what's known as digital phenotyping, or the continuous monitoring of someone's status via a personal digital device, to enhance behavioral and mental health. Listen to this month's BrainPod to hear Dr. JP Onnela discuss how digital phenotyping is crucial for studying mental health disorders.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/M63p_I6SZTU" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Women at the Podium: ACNP Strives to Reach Speaker Gender Equality at the Annual Meeting</title>
			<itunes:title>Women at the Podium: ACNP Strives to Reach Speaker Gender Equality at the Annual Meeting</itunes:title>
			<pubDate>Mon, 21 Mar 2016 14:47:36 GMT</pubDate>
			<itunes:duration>9:34</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/womenatthepodium-acnpstrivestoreachspeakergenderequalityattheannualmeeting/media.mp3" length="13785373" type="audio/mpeg"/>
			<guid isPermaLink="false">1ED59A5B-86F2-479D-BA1A-B8454E4D4F0F</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/womenatthepodium-acnpstrivestoreachspeakergenderequalityattheannualmeeting</link>
			<acast:episodeId>3c44e0b2-e8d9-470f-94fe-c54134e798db</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>womenatthepodium-acnpstrivestoreachspeakergenderequalityattheannualmeeting</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCcYzJKsr3XnzLE1lNZV04EabAfb5giydZdqI6utpVB6nEhsXbybJVCeObu6kdSsUV2g68ymzthd6s+mEbFCuMoU3Kg2j1qtibj6HvB/uBKToX7fubrqcV662ZB8IA33lBhoevNv2YuA26ON8kfWlIHb+5NxkU7chaE71cq7fUdgRCKEqRoWgFQMnjzE5SoqAwU=]]></acast:settings>
			<itunes:subtitle>Women at the Podium: ACNP Strives to Reach Speaker Gender Equality at the Annual Meeting</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[Lately, scientists have begun to pay closer attention to the numbers of men and women who present at scientific meetings. Even in those fields where women are a majority, men dominate speaking roles; in 2011, a group of leaders in neuroscience fields decided to remedy this situation. By the 2015 annual meeting of the American College of Neuropsychopharmacology, women made up 70% of the plenary speaking roles. Listen to this month's Brainpod to hear Dr. Bita Moghaddam and Dr. Raquel Gur discuss the importance of women at the podium, how their approach was successful, and what challenges still remain.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/tv6Oa1YqqeE" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[Lately, scientists have begun to pay closer attention to the numbers of men and women who present at scientific meetings. Even in those fields where women are a majority, men dominate speaking roles; in 2011, a group of leaders in neuroscience fields decided to remedy this situation. By the 2015 annual meeting of the American College of Neuropsychopharmacology, women made up 70% of the plenary speaking roles. Listen to this month's Brainpod to hear Dr. Bita Moghaddam and Dr. Raquel Gur discuss the importance of women at the podium, how their approach was successful, and what challenges still remain.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/tv6Oa1YqqeE" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Abuse of New Psychoactive Substances: Threats and Solutions</title>
			<itunes:title>Abuse of New Psychoactive Substances: Threats and Solutions</itunes:title>
			<pubDate>Tue, 09 Feb 2016 15:31:31 GMT</pubDate>
			<itunes:duration>10:21</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/abuseofnewpsychoactivesubstances-threatsandsolutions/media.mp3" length="7485470" type="audio/mpeg"/>
			<guid isPermaLink="false">E253CB1D-CAC2-4FC1-B1C6-8E315906BD84</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/abuseofnewpsychoactivesubstances-threatsandsolutions</link>
			<acast:episodeId>edde7fe7-25d8-4d39-a873-03f91b4b01f9</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>abuseofnewpsychoactivesubstances-threatsandsolutions</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCclNQUcUys+x70ZzSW+NqhRDGs6Gv7vFQ691k8mw4ab7/r2CxPsJ7nM0wqpatB94iMPJfZxaJB0B0QRIL6piXZW0x8TDLNhBU0vhIQtWscfTehe58iAo1zdE6/he45z95qcs7y/S8FgX12BG0m2F6t1i0UNV28o9MD7DqrKdC2dEFLL2zvfxFMGYkiXoTuR/ho=]]></acast:settings>
			<itunes:subtitle>Abuse of New Psychoactive Substances: Threats and Solutions</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[There has been a recent and notable increase in the non-medical use of new psychoactive substances (NPS), or "designer drugs." Unlike classic drugs of abuse, many NPS were initially developed for research purposes. In this podcast, Drs. Michael Baumann and Nora Volkow discuss the complexities of working with these substances and how, given their genesis, research with NPS could be considered "dual use;" or, potentially utilized for both beneficial and malicious purposes.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/jly1zpzVMyM" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[There has been a recent and notable increase in the non-medical use of new psychoactive substances (NPS), or "designer drugs." Unlike classic drugs of abuse, many NPS were initially developed for research purposes. In this podcast, Drs. Michael Baumann and Nora Volkow discuss the complexities of working with these substances and how, given their genesis, research with NPS could be considered "dual use;" or, potentially utilized for both beneficial and malicious purposes.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/jly1zpzVMyM" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Does Cannabis Cause, Exacerbate or Ameliorate Psychiatric Disorders? An Oversimplified Debate Discussed</title>
			<itunes:title>Does Cannabis Cause, Exacerbate or Ameliorate Psychiatric Disorders? An Oversimplified Debate Discussed</itunes:title>
			<pubDate>Tue, 12 Jan 2016 15:00:18 GMT</pubDate>
			<itunes:duration>10:21</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/doescannabiscause-exacerbateoramelioratepsychiatricdisorders-anoversimplifieddebatediscussed/media.mp3" length="7482789" type="audio/mpeg"/>
			<guid isPermaLink="false">384F69EF-CA28-4834-95E6-762102631AE2</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/doescannabiscause-exacerbateoramelioratepsychiatricdisorders-anoversimplifieddebatediscussed</link>
			<acast:episodeId>e1d0f9af-2355-4223-878e-2cac87451832</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>doescannabiscause-exacerbateoramelioratepsychiatricdisorders-anoversimplifieddebatediscussed</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCdW/cFXIo/GY+ecL5zJHXGcX7/jktz33mpsXdZKocaJFxxvyJFudLhbJs2wdPUChLgBH80LI6e6LCJA/1htF8cyU1knrN+v6ZokjmXwW8J1p+LQ5GXOZB6NmX6GT0VimbwdZJr5qK/rP9tocYoIQOugTrwIMpnhkkFiCEhRZrqp1CjVb4hJhvK+fteDMKA6ygU=]]></acast:settings>
			<itunes:subtitle>Does Cannabis Cause, Exacerbate or Ameliorate Psychiatric Disorders? An Oversimplified Debate Discussed</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[Marijuana use for medical purposes is becoming increasingly common in the U.S., and doctors prescribe it for ills ranging from headaches to insomnia. And yet, there is little scientific data supporting its medical use. In this podcast, Drs. Margaret Haney and Eden Evins discuss the relationship between cannabis use and two psychiatric disorders: post-traumatic stress disorder and psychotic illnesses, particularly schizophrenia.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/t-Jri70kjkM" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[Marijuana use for medical purposes is becoming increasingly common in the U.S., and doctors prescribe it for ills ranging from headaches to insomnia. And yet, there is little scientific data supporting its medical use. In this podcast, Drs. Margaret Haney and Eden Evins discuss the relationship between cannabis use and two psychiatric disorders: post-traumatic stress disorder and psychotic illnesses, particularly schizophrenia.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/t-Jri70kjkM" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Neuropsychopharmacology Reviews: Impact of Stress on the Brain: Pathology, Treatment and Prevention</title>
			<itunes:title>Neuropsychopharmacology Reviews: Impact of Stress on the Brain: Pathology, Treatment and Prevention</itunes:title>
			<pubDate>Thu, 10 Dec 2015 15:29:31 GMT</pubDate>
			<itunes:duration>10:55</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/neuropsychopharmacologyreviews-impactofstressonthebrain-pathology-treatmentandprevention/media.mp3" length="8178042" type="audio/mpeg"/>
			<guid isPermaLink="false">F46B6166-B052-4855-8CCC-95517589EEB6</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/neuropsychopharmacologyreviews-impactofstressonthebrain-pathology-treatmentandprevention</link>
			<acast:episodeId>b5c5b7d4-6449-4955-82f8-6efcbe763693</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>neuropsychopharmacologyreviews-impactofstressonthebrain-pathology-treatmentandprevention</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCemo8iS6S+C4sW9YlZZx+K8eXXwgqPbJxx1ygAOWxQdFnKVgRa7bOOL6dUId8ElXUaClZlIURHXLmYA/sC2lvN5GRTxBoVs2stuoTyju+F0XwMVLSlT1oGkfWBqCBGYAXH2q9l9MsYv05gTN7tH0UYds5+8oq01fR+nmwl6kHXRlDKIqNdIGA6BJ6Uy+cC6mwI=]]></acast:settings>
			<itunes:subtitle>Neuropsychopharmacology Reviews: Impact of Stress on the Brain: Pathology, Treatment and Prevention</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA["Impact of Stress on the Brain: Pathology, Treatment and Prevention," the 2016 issue of Neuropsychopharmacology Reviews, focuses on advances in our understanding of the impact of stress on the brain: From pathology to circuits, treatment to prevention. Emerging data from genetics, epigenetics, neural circuit and intergenerational models, animal models, and neuroimaging all suggest that stress affects the brain in a variety of dynamic and often long-lasting ways. The effects of these processes on developmental risk for pathology are particularly notable.Produced by Nature Publishing Group and featuring Kerry J. Ressler, MD, PhD and Jordan W. Smoller, MD, ScD, this podcast synthesizes a broad array of neuroscience perspectives and approaches, demonstrating with fascinating clarity how the brain, when homeostasis / allostasis is dysregulated through the process of stress (whether external or internal), can lead to emotional dysregulation and behavioral difficulties.Neuropsychopharmacology Reviews: http://www.nature.com/nppr/index.html<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/8C-8G2PSinI" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA["Impact of Stress on the Brain: Pathology, Treatment and Prevention," the 2016 issue of Neuropsychopharmacology Reviews, focuses on advances in our understanding of the impact of stress on the brain: From pathology to circuits, treatment to prevention. Emerging data from genetics, epigenetics, neural circuit and intergenerational models, animal models, and neuroimaging all suggest that stress affects the brain in a variety of dynamic and often long-lasting ways. The effects of these processes on developmental risk for pathology are particularly notable.Produced by Nature Publishing Group and featuring Kerry J. Ressler, MD, PhD and Jordan W. Smoller, MD, ScD, this podcast synthesizes a broad array of neuroscience perspectives and approaches, demonstrating with fascinating clarity how the brain, when homeostasis / allostasis is dysregulated through the process of stress (whether external or internal), can lead to emotional dysregulation and behavioral difficulties.Neuropsychopharmacology Reviews: http://www.nature.com/nppr/index.html<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/8C-8G2PSinI" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Neuropsychopharmacology Reviews: Neurodevelopment and the Origins of Brain Disorders</title>
			<itunes:title>Neuropsychopharmacology Reviews: Neurodevelopment and the Origins of Brain Disorders</itunes:title>
			<pubDate>Mon, 08 Dec 2014 15:30:00 GMT</pubDate>
			<itunes:duration>10:03</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/neuropsychopharmacologyreviews-neurodevelopmentandtheoriginsofbraindisorders/media.mp3" length="7242139" type="audio/mpeg"/>
			<guid isPermaLink="false">E45EB9C4-CD4F-4DD6-88FA-33F1CD29AA05</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/neuropsychopharmacologyreviews-neurodevelopmentandtheoriginsofbraindisorders</link>
			<acast:episodeId>d1b1176b-7c94-43cc-9fac-3f7660160287</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>neuropsychopharmacologyreviews-neurodevelopmentandtheoriginsofbraindisorders</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCcGTNstiwrfXUMV36ZJaGiV2ZQlVCEyLcUV/WJTe2L69IX5RkW7qBjeb57sXMNW1zNZ2QE+gC2vHEwTEkH2iAgO+/VEzhrshAG4rnk7lQPSTWplsiiI857LQ6BULw+WU0x//MgCzucfH58/sqnQgwWsDUfXWcjlXgcGs7WWhpN2Jpa4gNkW+fJmjKLfOwSfKQskZexKFogZSRYV7ZxlHI/A]]></acast:settings>
			<itunes:subtitle>Neuropsychopharmacology Reviews: Neurodevelopment and the Origins of Brain Disorders</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[In this issue of <i>Neuropsychopharmacology Reviews</i>, entitled <i>Neurodevelopment and the Origins of Brain Disorders</i>, subject discipline experts provide both experimental highlights and perspectives on the current understanding of basic mechanisms of neurodevelopment, the influence of developmental disruptions on childhood and adult-onset brain and behavioral disorders, and the emerging promise of translation into treatments.<br /><br />In this podcast, the editors of this year's volume, Pat Levitt (Simms/Mann Chair in Development Neurogenetics, Children's Hospital Los Angeles) and Jeremy Veenstra-VanderWeele (Mortimer D Sackler Associate Professor of Psychiatry, Columbia University/New York State Psychiatric Institute), discuss the recent research and its future applications.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/kg7QNGN8L0E" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[In this issue of <i>Neuropsychopharmacology Reviews</i>, entitled <i>Neurodevelopment and the Origins of Brain Disorders</i>, subject discipline experts provide both experimental highlights and perspectives on the current understanding of basic mechanisms of neurodevelopment, the influence of developmental disruptions on childhood and adult-onset brain and behavioral disorders, and the emerging promise of translation into treatments.<br /><br />In this podcast, the editors of this year's volume, Pat Levitt (Simms/Mann Chair in Development Neurogenetics, Children's Hospital Los Angeles) and Jeremy Veenstra-VanderWeele (Mortimer D Sackler Associate Professor of Psychiatry, Columbia University/New York State Psychiatric Institute), discuss the recent research and its future applications.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/kg7QNGN8L0E" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Caffeine consumption in adolescents</title>
			<itunes:title>Caffeine consumption in adolescents</itunes:title>
			<pubDate>Mon, 08 Dec 2014 15:30:00 GMT</pubDate>
			<itunes:duration>6:39</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/caffeineconsumptioninadolescents/media.mp3" length="15971200" type="audio/mpeg"/>
			<guid isPermaLink="false">B951A266-EF5E-4EE4-B373-4539070203DF</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/caffeineconsumptioninadolescents</link>
			<acast:episodeId>05d7d020-6eec-4af8-b10e-38b22ff20144</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>caffeineconsumptioninadolescents</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCcsw+AlfoCPNyI7CRG9QyW8f8sKKLg/Q7NtovjAyIVrIV9Wcmo2c96MxLWCAWS+K1/Y9dIzVXclJKdEr/oTW+uvBVSEvRvQ27TmrbFVOwcewf3Be+OZPe833JJcQtxr94XXiwPwWfbV/d0AP0yCvhISCUBJ3Zaf3oOmwrYhIc48xoMAKuJbadR5qWBwCj9e6Ao=]]></acast:settings>
			<itunes:subtitle>Caffeine consumption in adolescents</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[Adolescent consumption of caffeine, the most commonly used psychoactive stimulant in the world, has increased strikingly in recent years. Caffeine use has been associated with illicit drug use and risky behaviors, but whether consumption of caffeine during adolescence has effects on the mature brain is controversial. In this podcast, author Ryan Bachtell discusses his recent study, which found that consumption of caffeine by male adolescent rats results in enduring neurobiological effects in a key reward area in the brain and an increased sensitivity to cocaine in adulthood.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/1hJTpfEGiFk" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[Adolescent consumption of caffeine, the most commonly used psychoactive stimulant in the world, has increased strikingly in recent years. Caffeine use has been associated with illicit drug use and risky behaviors, but whether consumption of caffeine during adolescence has effects on the mature brain is controversial. In this podcast, author Ryan Bachtell discusses his recent study, which found that consumption of caffeine by male adolescent rats results in enduring neurobiological effects in a key reward area in the brain and an increased sensitivity to cocaine in adulthood.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/1hJTpfEGiFk" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>The value of alcohol</title>
			<itunes:title>The value of alcohol</itunes:title>
			<pubDate>Mon, 03 Mar 2014 15:00:00 GMT</pubDate>
			<itunes:duration>26:51</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/thevalueofalcohol/media.mp3" length="11299237" type="audio/mpeg"/>
			<guid isPermaLink="false">24E2BB9E-5F5B-4505-A846-B0E5DB50AA59</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/thevalueofalcohol</link>
			<acast:episodeId>90b84bf7-027b-40d4-8295-cfd8cb87a1fc</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>thevalueofalcohol</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCCU4p14UkPm177ZYCiPe8g/DcKgGClqWyffqYZq1dkydNC9uQ6LiRbZMfFWYe9s/zvJ0pFW3Sgc78BxfYPecyOlOEOsrwjSmjTZaNpFb1+BWaaUtvcrTOiGsnqbdWVQVFltBl6YPIFL2PA5TYvnYj+vSYaQJ60MwJkUciiUVaMz2yrf/385mJxwUVNmShog3pcz4B4oczcKrCkgoxyZWPJTNssIzUK+rRodzuEDVZOIPuVWg8q29aIJzfLJArT1f0ioiDHklyM9+776e97OX9UQ==]]></acast:settings>
			<itunes:subtitle>The value of alcohol</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[The relative value of alcohol may be encoded by discrete regions of the brain, according to a study published in Neuropsychopharmacology. Using functional magnetic resonance imaging (fMRI), Dr. James MacKillop and colleagues examined brain activity in 24 male volunteers, who were heavy drinkers, while they were deciding whether or not to drink alcohol priced at various levels. Their findings identify unique motifs of brain activity that may contribute to the pathologically increased value that addicted individuals place on alcohol.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/RAqAtvdSo14" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[The relative value of alcohol may be encoded by discrete regions of the brain, according to a study published in Neuropsychopharmacology. Using functional magnetic resonance imaging (fMRI), Dr. James MacKillop and colleagues examined brain activity in 24 male volunteers, who were heavy drinkers, while they were deciding whether or not to drink alcohol priced at various levels. Their findings identify unique motifs of brain activity that may contribute to the pathologically increased value that addicted individuals place on alcohol.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/RAqAtvdSo14" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Brain changes in young smokers</title>
			<itunes:title>Brain changes in young smokers</itunes:title>
			<pubDate>Mon, 03 Mar 2014 15:00:00 GMT</pubDate>
			<itunes:duration>26:51</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/brainchangesinyoungsmokers/media.mp3" length="11299237" type="audio/mpeg"/>
			<guid isPermaLink="false">24E2BB9E-5F5B-4505-A846-B0E5DB50AA59</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/brainchangesinyoungsmokers</link>
			<acast:episodeId>a58e2cbe-e47e-4b78-af99-c155712c274c</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>brainchangesinyoungsmokers</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCfe4xFzkTRMgUs7VV/ako1s1fen1KrF39GdT8tnGeoGnDIw6oirJ82cTnt1Jn9avJOg/lsnAkU4tScFAAxGxQTcW04Sb/Nri+7aa5Y2tMAOmrZ181qMsk5QsO/oVnJfY0fk739zDxZYu5fWTzmVi6ItXAmAXlNNO5JnYjP4EMr+CCP+/38aBkcCFkuIrAvezyv+OmlZ6JU2mSSp0b0r/Asszuvx3KISjfegkvUZlbfktA==]]></acast:settings>
			<itunes:subtitle>Brain changes in young smokers</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[Young adult smokers may experience alterations in brain structure related to cigarette exposure, dependence, and craving. The brain structure of adults has been shown to vary with smoking status, particularly in the insula—a part of the cerebral cortex involved in monitoring internal states and decision-making. In a study published in <i>Neuropsychopharmacology</i>, Dr. Edythe London and colleagues took smoking histories, assessed cigarette craving and dependence, and examined the insula using magnetic resonance imaging (MRI) in 16-22-year-old participants. The results suggest that participants with greater smoking exposure had more severe nicotine dependence, more cigarette craving, and less insular thickness than those with less exposure.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/io7ywh7niQ0" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[Young adult smokers may experience alterations in brain structure related to cigarette exposure, dependence, and craving. The brain structure of adults has been shown to vary with smoking status, particularly in the insula—a part of the cerebral cortex involved in monitoring internal states and decision-making. In a study published in <i>Neuropsychopharmacology</i>, Dr. Edythe London and colleagues took smoking histories, assessed cigarette craving and dependence, and examined the insula using magnetic resonance imaging (MRI) in 16-22-year-old participants. The results suggest that participants with greater smoking exposure had more severe nicotine dependence, more cigarette craving, and less insular thickness than those with less exposure.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/io7ywh7niQ0" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Neuropsychopharmacology Reviews: Biomolecular Discovery: Mechanisms, Therapeutics, and Biomarkers in Neural Disorders</title>
			<itunes:title>Neuropsychopharmacology Reviews: Biomolecular Discovery: Mechanisms, Therapeutics, and Biomarkers in Neural Disorders</itunes:title>
			<pubDate>Mon, 09 Dec 2013 15:00:00 GMT</pubDate>
			<itunes:duration>26:51</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/neuropsychopharmacologyreviews-biomoleculardiscovery-mechanisms-therapeutics-andbiomarkersinneuraldisorders/media.mp3" length="11299237" type="audio/mpeg"/>
			<guid isPermaLink="false">24E2BB9E-5F5B-4505-A846-B0E5DB50AA59</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/neuropsychopharmacologyreviews-biomoleculardiscovery-mechanisms-therapeutics-andbiomarkersinneuraldisorders</link>
			<acast:episodeId>ffa00b2c-83a0-4da5-b39d-b63440a4039d</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>neuropsychopharmacologyreviews-biomoleculardiscovery-mechanisms-therapeutics-andbiomarkersinneuraldisorders</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCCU4p14UkPm177ZYCiPe8g/DcKgGClqWyffqYZq1dkydNC9uQ6LiRbZMfFWYe9s/zvJ0pFW3Sgc78BxfYPecyOlOEOsrwjSmjTZaNpFb1+BWaaUtvcrTOiGsnqbdWVQVFltBl6YPIFL2PA5TYvnYj+vSYaQJ60MwJkUciiUVaMz2yrf/385mJxwUVNmShog3pcz4B4oczcKrCkgoxyZWPJTNssIzUK+rRodzuEDVZOIPuVWg8q29aIJzfLJArT1f0AVF9XMcf4/Z5wTuqTglwUQ==]]></acast:settings>
			<itunes:subtitle>Neuropsychopharmacology Reviews: Biomolecular Discovery: Mechanisms, Therapeutics, and Biomarkers in Neural Disorders</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[The 2014 issue of Neuropsychopharmacology Reviews is entitled Biomolecular Discovery: Mechanisms, Therapeutics, and Biomarkers in Neural Disorders. The articles in this issue focus on recent advances in the detection, subtyping and monitoring of complex neural disease progression, the definition of new molecular targets for therapeutic intervention and biomarkers, with an emphasis on the use of genome-wide analytical technologies.In this podcast, the editors of this year's volume, Carol Nilsson and Kathryn Cunningham, provide an overview of the topic.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/BjzP3RogtGw" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[The 2014 issue of Neuropsychopharmacology Reviews is entitled Biomolecular Discovery: Mechanisms, Therapeutics, and Biomarkers in Neural Disorders. The articles in this issue focus on recent advances in the detection, subtyping and monitoring of complex neural disease progression, the definition of new molecular targets for therapeutic intervention and biomarkers, with an emphasis on the use of genome-wide analytical technologies.In this podcast, the editors of this year's volume, Carol Nilsson and Kathryn Cunningham, provide an overview of the topic.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/BjzP3RogtGw" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Smoking throughout pregnancy may contribute to emotional problems in children</title>
			<itunes:title>Smoking throughout pregnancy may contribute to emotional problems in children</itunes:title>
			<pubDate>Mon, 07 Oct 2013 15:00:00 GMT</pubDate>
			<itunes:duration>26:51</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/smokingthroughoutpregnancymaycontributetoemotionalproblemsinchildren/media.mp3" length="11299237" type="audio/mpeg"/>
			<guid isPermaLink="false">24E2BB9E-5F5B-4505-A846-B0E5DB50AA59</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/smokingthroughoutpregnancymaycontributetoemotionalproblemsinchildren</link>
			<acast:episodeId>ff31a6d6-9e93-4f22-a8a2-a68e26e36c24</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>smokingthroughoutpregnancymaycontributetoemotionalproblemsinchildren</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCfe4xFzkTRMgUs7VV/ako1s1fen1KrF39GdT8tnGeoGnDIw6oirJ82cTnt1Jn9avJOg/lsnAkU4tScFAAxGxQTcW04Sb/Nri+7aa5Y2tMAOmrZ181qMsk5QsO/oVnJfY0fk739zDxZYu5fWTzmVi6ItXAmAXlNNO5JnYjP4EMr+CCP+/38aBkcCFkuIrAvezyv+OmlZ6JU2mSSp0b0r/AssK3fTK4QMyO2UY9L89sEXWw==]]></acast:settings>
			<itunes:subtitle>Smoking throughout pregnancy may contribute to emotional problems in children</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[Up to 25% of women in the U.S., Denmark and Sweden report smoking during pregnancy, despite associations of prenatal tobacco exposure with negative behavioral and cognitive outcomes. Hanan El Marroun and colleagues assessed brain morphology along with behavioral and emotional functioning of children whose mothers reported smoking in a range from one cigarette a day to more than 9 cigarettes per day during pregnancy. The results suggest that children whose mothers continued smoking have smaller total brain volumes, with smaller cortical gray and white matter volumes in particular, and exhibit more emotional problems, such as depressive symptoms and anxiety.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/KCCWf3NDPWo" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[Up to 25% of women in the U.S., Denmark and Sweden report smoking during pregnancy, despite associations of prenatal tobacco exposure with negative behavioral and cognitive outcomes. Hanan El Marroun and colleagues assessed brain morphology along with behavioral and emotional functioning of children whose mothers reported smoking in a range from one cigarette a day to more than 9 cigarettes per day during pregnancy. The results suggest that children whose mothers continued smoking have smaller total brain volumes, with smaller cortical gray and white matter volumes in particular, and exhibit more emotional problems, such as depressive symptoms and anxiety.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/KCCWf3NDPWo" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>HIV infection may raise risk of cocaine abuse</title>
			<itunes:title>HIV infection may raise risk of cocaine abuse</itunes:title>
			<pubDate>Thu, 15 Aug 2013 15:00:00 GMT</pubDate>
			<itunes:duration>26:51</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/hivinfectionmayraiseriskofcocaineabuse/media.mp3" length="11299237" type="audio/mpeg"/>
			<guid isPermaLink="false">24E2BB9E-5F5B-4505-A846-B0E5DB50AA59</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/hivinfectionmayraiseriskofcocaineabuse</link>
			<acast:episodeId>0a3f6d7f-c943-41b5-ac9d-36e6302958b1</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>hivinfectionmayraiseriskofcocaineabuse</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCCU4p14UkPm177ZYCiPe8g/DcKgGClqWyffqYZq1dkyf3ZXrFQX8WdxRyOq5k2Eq2/GCU0Rq/uw4RHOlvZitFjehUZ0MaaQqVJEqCWODt464hozF1KeOdi5z2d6Zt+Ws4Ey9uTD+a3tpCB3nC4rOuub7KbR8ongIqQSbrwRZTgnGfXajXselDH4dz2gqANCi0hcjTF4CglfXyDCXoMHyMxosL7neCEqxNI8sPlG9vRv8aYox9im3Mj5fTLcAtPKpq0t8JHbToPsBgVfAI4k/K3kQQbjFgOQI8yAdus4dj2Bk=]]></acast:settings>
			<itunes:subtitle>HIV infection may raise risk of cocaine abuse</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[Although psychostimulant abusers comprise one of the fastest growing populations of HIV-infected patients, relatively little is known about how HIV may impact the rewarding effects of abused drugs. Dr. Jay P. McLaughlin discusses how a protein associated with HIV infection, called HIV-1 Tat, may increase vulnerability for drug addiction. His research shows that mice who express HIV-1 Tat display an enhanced sensitivity to the rewarding properties of cocaine. The results suggest that just as addiction raises the risk of HIV, HIV may raise the risk of addiction.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/bCZtXyfX6Qc" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[Although psychostimulant abusers comprise one of the fastest growing populations of HIV-infected patients, relatively little is known about how HIV may impact the rewarding effects of abused drugs. Dr. Jay P. McLaughlin discusses how a protein associated with HIV infection, called HIV-1 Tat, may increase vulnerability for drug addiction. His research shows that mice who express HIV-1 Tat display an enhanced sensitivity to the rewarding properties of cocaine. The results suggest that just as addiction raises the risk of HIV, HIV may raise the risk of addiction.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/bCZtXyfX6Qc" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>A taste of alcohol</title>
			<itunes:title>A taste of alcohol</itunes:title>
			<pubDate>Mon, 20 May 2013 15:00:00 GMT</pubDate>
			<itunes:duration>26:51</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/atasteofalcohol/media.mp3" length="11299237" type="audio/mpeg"/>
			<guid isPermaLink="false">24E2BB9E-5F5B-4505-A846-B0E5DB50AA59</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/atasteofalcohol</link>
			<acast:episodeId>5500bbbd-bd23-4b7f-813e-4dbfa0a185e1</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>atasteofalcohol</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCKLPjEYLpGj+NMVKa+5C8pL4u/EOj1Vw4h5MMJYp0lCfe4xFzkTRMgUs7VV/ako1s1fen1KrF39GdT8tnGeoGnDIw6oirJ82cTnt1Jn9avJOg/lsnAkU4tScFAAxGxQTcW04Sb/Nri+7aa5Y2tMAOmrZ181qMsk5QsO/oVnJfY0fk739zDxZYu5fWTzmVi6ItXAmAXlNNO5JnYjP4EMr+CCP+/38aBkcCFkuIrAvezyv+OmlZ6JU2mSSp0b0r/AsssmRX5wDi5NKgwxpza3jK0A==]]></acast:settings>
			<itunes:subtitle>A taste of alcohol</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[Dr. David Kareken discusses how the urge to drink can be triggered by sensory cues alone. His latest research showed that a dopamine reaction took place in the brain when men were given a small amount of alcohol - enough to taste, but not enough to become intoxicated. The reaction was stronger in those with a genetic predisposition to alcoholism. This suggests that dopamine is involved in the desire to use a drug, even before the effects of the drug are felt, and that drug-seeking behavior can be triggered by a related environment.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/cme8x2JvQMM" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[Dr. David Kareken discusses how the urge to drink can be triggered by sensory cues alone. His latest research showed that a dopamine reaction took place in the brain when men were given a small amount of alcohol - enough to taste, but not enough to become intoxicated. The reaction was stronger in those with a genetic predisposition to alcoholism. This suggests that dopamine is involved in the desire to use a drug, even before the effects of the drug are felt, and that drug-seeking behavior can be triggered by a related environment.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/cme8x2JvQMM" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Neuropsychopharmacology Reviews: Epigenetics</title>
			<itunes:title>Neuropsychopharmacology Reviews: Epigenetics</itunes:title>
			<pubDate>Fri, 30 Nov 2012 15:00:00 GMT</pubDate>
			<itunes:duration>26:51</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/neuropsychopharmacologyreviews-epigenetics/media.mp3" length="11299237" type="audio/mpeg"/>
			<guid isPermaLink="false">24E2BB9E-5F5B-4505-A846-B0E5DB50AA59</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/neuropsychopharmacologyreviews-epigenetics</link>
			<acast:episodeId>645811d5-3790-4b3a-891b-d17061788e40</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>neuropsychopharmacologyreviews-epigenetics</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCb3QHWH/bWCmqC4Sh+iIOKTa9Ou6yq3vUqmEtPH0BOJJz36ALN9jkBB9c5zF9+33ge2kWOrvkPGd2aYZKkLvHv7sI43/Y/24xZi88JrPEc7+nZS70H4fPFu3scN0pYC95lYs4yR2iyXKdWEAZGDvYQ4R9qHoBOo9jac1AE6+DRug/nUPsHwUWeP51VV9wY77rFmqN0fjQYafutw8i5P3zrJssN9yr04bpFneZgdhqWZVXewt8LjcZzXK3YLxyF6OTmmpevPoPR8JaFCh6xBZUQQ==]]></acast:settings>
			<itunes:subtitle>Neuropsychopharmacology Reviews: Epigenetics</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[Epigenetics is the modification of genetic expression without changing the underlying DNA, or how environment affects genetic potential. It is highly involved in learning and memory, as well as maladaptations caused by stress or drug abuse. Dr. Eric Nestler, one of the editors of this year's Neuropsychopharmacology Reviews, provides an overview of the topic here, including the somewhat controversial theory of epigenetic heritability.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/3UN9z6XQuds" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[Epigenetics is the modification of genetic expression without changing the underlying DNA, or how environment affects genetic potential. It is highly involved in learning and memory, as well as maladaptations caused by stress or drug abuse. Dr. Eric Nestler, one of the editors of this year's Neuropsychopharmacology Reviews, provides an overview of the topic here, including the somewhat controversial theory of epigenetic heritability.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/3UN9z6XQuds" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Bath salts</title>
			<itunes:title>Bath salts</itunes:title>
			<pubDate>Fri, 21 Sep 2012 15:00:00 GMT</pubDate>
			<itunes:duration>26:51</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/bathsalts/media.mp3" length="11299237" type="audio/mpeg"/>
			<guid isPermaLink="false">24E2BB9E-5F5B-4505-A846-B0E5DB50AA59</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/bathsalts</link>
			<acast:episodeId>4cec4337-4a7c-4c1e-b2ab-d4bd6a099875</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>bathsalts</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCCU4p14UkPm177ZYCiPe8g/DcKgGClqWyffqYZq1dkydNC9uQ6LiRbZMfFWYe9s/zvJ0pFW3Sgc78BxfYPecyOlOEOsrwjSmjTZaNpFb1+BWaaUtvcrTOiGsnqbdWVQVFltBl6YPIFL2PA5TYvnYj+vSYaQJ60MwJkUciiUVaMz2yrf/385mJxwUVNmShog3pcz4B4oczcKrCkgoxyZWPJTNssIzUK+rRodzuEDVZOIPuVWg8q29aIJzfLJArT1f04TNBcSrL0kYp3Es7HAw17w==]]></acast:settings>
			<itunes:subtitle>Bath salts</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[Mephedrone and methylone are types of synthetic stimulant drugs that have been sold legally under names such as "bath salts" or "plant food". They can have a number of dangerous side effects, such as agitation, combativeness, and hallucinations. A recent court ruling has made many of these synthetic drugs illegal, but new variations continue to be available. In this latest podcast, Dr. Michael Baumann discusses the mechanism of action of "bath salts", their chemical similarity to MDMA, and the dangers of their use.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/scgebsTcnuM" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[Mephedrone and methylone are types of synthetic stimulant drugs that have been sold legally under names such as "bath salts" or "plant food". They can have a number of dangerous side effects, such as agitation, combativeness, and hallucinations. A recent court ruling has made many of these synthetic drugs illegal, but new variations continue to be available. In this latest podcast, Dr. Michael Baumann discusses the mechanism of action of "bath salts", their chemical similarity to MDMA, and the dangers of their use.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/scgebsTcnuM" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
		<item>
			<title>Neuropsychopharmacology Reviews: Neurotherapeutics</title>
			<itunes:title>Neuropsychopharmacology Reviews: Neurotherapeutics</itunes:title>
			<pubDate>Wed, 18 Jan 2012 15:00:00 GMT</pubDate>
			<itunes:duration>26:51</itunes:duration>
			<enclosure url="https://sphinx.acast.com/neuropsychopharmacologypodcast/neuropsychopharmacologyreviews-neurotherapeutics/media.mp3" length="11299237" type="audio/mpeg"/>
			<guid isPermaLink="false">24E2BB9E-5F5B-4505-A846-B0E5DB50AA59</guid>
			<itunes:explicit>false</itunes:explicit>
			<link>https://play.acast.com/s/neuropsychopharmacologypodcast/neuropsychopharmacologyreviews-neurotherapeutics</link>
			<acast:episodeId>6d8bd9c4-9730-42dc-8cf9-67ccba5e29f6</acast:episodeId>
			<acast:showId>1b454f3a-002e-540e-82a0-3e5bcb0b5da9</acast:showId>
			<acast:episodeUrl>neuropsychopharmacologyreviews-neurotherapeutics</acast:episodeUrl>
			<acast:settings><![CDATA[FYjHyZbXWHZ7gmX8Pp1rmbKbhgrQiwYShz70Q9/ffXZMTtedvdcRQbP4eiLMjXzCCU4p14UkPm177ZYCiPe8g/DcKgGClqWyffqYZq1dkyfk25a/7/uJaFpe7YZnDaarBn/RVJZfQz1hF4YoGzKFTdBy0W4L9dU4trn2C4L0Ltgv16LFvHjkIgBp1AXByNXZQJ4fq7SlF4rX9OwDKXN8OZfroR7AgrqdVHtposjb/cFbay6JneA4iYCLCa5qU7szp/4wrrT6HZNnoIZuyTECwSYb5N0NwnisszzNlN0brnrr2z7fJPDmik3NWJpk/BadCIKOpqDrXsvzU7qQZaWTx4VHg6szX00m0EV2moaCdGQ=]]></acast:settings>
			<itunes:subtitle>Neuropsychopharmacology Reviews: Neurotherapeutics</itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
			<itunes:image href="https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg"/>
			<description><![CDATA[The brain is a daunting therapeutic challenge. This year's edition of Neuropsychopharmacology Reviews provides an update on treatments for brain disorders ranging from schizophrenia to neurodegeneration. Join Kerri Smith as she talks to Gwenn Smith, editor of this year's volume, about current therapies such as drugs, electrical stimulation and cognitive therapies, and the future of neurotherapeutics in an era of uncertain funding.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/52ps7f0fMbg" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></description>
			<itunes:summary><![CDATA[The brain is a daunting therapeutic challenge. This year's edition of Neuropsychopharmacology Reviews provides an update on treatments for brain disorders ranging from schizophrenia to neurodegeneration. Join Kerri Smith as she talks to Gwenn Smith, editor of this year's volume, about current therapies such as drugs, electrical stimulation and cognitive therapies, and the future of neurotherapeutics in an era of uncertain funding.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/52ps7f0fMbg" height="1" width="1" alt=""/><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>]]></itunes:summary>
		</item>
    	<itunes:category text="Science"/>
    </channel>
</rss>
